Pharmacopedia - User contributions [en]

Methylphenidate

2026-05-27T01:10:09Z

Maintenance script: parser-claude (pharmacist-claude hat): citation pass + content fills per Mark go 2026-05-26. Adds: history section (Panizzon 1944, Ciba launch, Schedule II 1971, MTA study, Cooper 2011 CV outcomes), Cortese 2018 NMA in intro, FDA warning refs (4), references/> infrastructure, FDA Ritalin label ref on PK, Ritalin IR indication clarification, MPH-TCA interaction revision, anecdote typo fix.

{{MedTemplate
| generic = Methylphenidate
| brand = Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR
| structure = Methylphenidate.svg
| classes = Psychostimulant, NDRI
| mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET)
| uses = ADHD, narcolepsy
| formula = C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>
| routes = Oral, transdermal
| onset = 20–60 min (oral)
| duration = IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time
| halflife = 2–3 h (parent compound)
| bioavailability = ~30% (high first-pass)
| pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion.
| legal = Schedule II
| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need. A 2018 systematic review and network meta-analysis by Cortese and colleagues identified methylphenidate as first-line pharmacotherapy for ADHD in children and adolescents (based on the balance of efficacy and tolerability), with amphetamines as first-line in adults.<ref name="cortese2018">Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727–738.</ref>
| history =
Methylphenidate emerged from a chemistry program at the Swiss pharmaceutical company Ciba AG (later Ciba-Geigy, then Novartis) in the 1940s. Leandro Panizzon, a chemist at Ciba, synthesized the compound in 1944 while searching for a stimulant with a less abrupt and less euphoric profile than amphetamine. Panizzon and his colleagues observed the stimulant effect in animals and ultimately on themselves; the canonical anecdote, widely repeated in pharmacology histories and Ciba/Novartis corporate retrospectives, is that Panizzon's wife Marguerite ("Rita") used the compound as a mild stimulant before tennis matches, which inspired the trade name Ritalin.{{citation needed}}

Ciba launched methylphenidate as Ritalin in Switzerland in 1954 and in the United States the following year, originally marketed for narcolepsy, chronic fatigue, mild depression, senile behavioral problems, and as an amphetamine-overdose antidote (this last use long since abandoned). Clinical application to childhood behavioral disorders developed gradually through the late 1950s and 1960s; the diagnosis then was "minimal brain dysfunction" or "hyperkinetic reaction of childhood," the precursors to the modern attention-deficit hyperactivity disorder formulation.{{citation needed}}

Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use.

The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood.{{citation needed}}

Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place.
| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.<ref name="ritalin-label">U.S. Food and Drug Administration. Ritalin (methylphenidate hydrochloride) prescribing information. NDA 010187, Novartis Pharmaceuticals.</ref>
| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

Key effects:
* Affinity for DAT is roughly equal to or slightly greater than NET in binding studies, but functional consequences in prefrontal cortex are dominated by NET effects (because NET also clears dopamine in PFC).
* Minimal direct serotonergic activity at therapeutic doses.
* No meaningful MAO inhibition.
* No significant 5-HT, histamine, or muscarinic receptor binding.

The net therapeutic effect is enhanced catecholaminergic tone in prefrontal cortex (attention, executive function) and striatum (motor inhibition, reward processing), underlying both its therapeutic effects in ADHD and its abuse liability.
| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
* Narcolepsy
* Off-label: treatment-resistant depression (augmentation, especially in geriatric or medically ill patients), fatigue in advanced illness (cancer, HIV, multiple sclerosis), excessive daytime sleepiness in shift-work disorder
| dosing = '''Ritalin IR (FDA-approved for children ≥6 y; adult use is common clinical practice but off-label for IR Ritalin specifically; several ER formulations carry adult ADHD indications):''' Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses.
'''Ritalin LA / Metadate CD:''' 20 mg PO once daily AM; titrate by 10–20 mg weekly. Max 60 mg/day.
'''Concerta (osmotic ER):''' Start 18 mg PO once daily AM. Titrate by 18 mg/week. Max 72 mg/day (adults); 54 mg/day (children).
'''Daytrana (transdermal patch):''' Apply 10 mg/9 h patch to alternating hip 2 h before effect needed; remove after 9 h. Titrate weekly to max 30 mg/9 h.
'''Focalin (d-methylphenidate):''' Use half the equivalent racemic dose.
'''Narcolepsy:''' 10–60 mg/day in divided doses.
'''Renal/hepatic impairment:''' caution; no specific adjustment guidelines but reduce dose and monitor.
| effects = ''Therapeutic:'' improved attention, reduced impulsivity and hyperactivity, increased wakefulness, mild mood elevation, mild appetite suppression. Generally described as "smoother" and less euphoric than amphetamines at equivalent doses.
''Common adverse:'' decreased appetite, insomnia (especially with late dosing), headache, abdominal pain, mild irritability, dry mouth, mild elevation of heart rate and blood pressure, weight loss.
| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease.<ref name="fda-mph-cv-2007">U.S. Food and Drug Administration. FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. February 21, 2007.</ref><ref name="vetter2008">Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association. Circulation. 2008;117(18):2407–2423.</ref>
* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)
* '''Tics''', methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication
* '''Dependence and misuse''', Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant
* '''Growth suppression''', modest reduction in height/weight velocity in chronically-treated children
* '''Priapism''', rare but documented; FDA warning, especially in adolescents.<ref name="fda-mph-priapism-2013">U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety review update of medical drugs used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. December 17, 2013 (priapism class warning).</ref>
* '''Peripheral vasculopathy''', Raynaud-like phenomenon, rare digital ischemia.<ref name="fda-mph-vasculopathy-2006">U.S. Food and Drug Administration. FDA Drug Safety Communication: peripheral vasculopathy including Raynaud phenomenon associated with stimulants used to treat ADHD. December 2006.</ref>
* '''Lowered seizure threshold''', caution in epilepsy
* '''Lassitude / "crash"''' on withdrawal, fatigue, dysphoria, rebound hyperactivity
* '''Stereotyped behaviors''', rare at therapeutic doses
* '''Skin reactions''', chemical leukoderma (permanent depigmentation) at Daytrana patch application sites.<ref name="fda-daytrana-leukoderma-2015">U.S. Food and Drug Administration. FDA Drug Safety Communication: Permanent skin color loss (chemical leukoderma) reported with use of Daytrana patch (methylphenidate transdermal system). June 24, 2015.</ref>
| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid), hypertensive crisis risk; contraindicated
* '''Tricyclic antidepressants''', additive sympathomimetic cardiovascular effects (tachycardia, hypertension). Older case reports suggested possible PK interaction elevating TCA levels; modern reviews do not support a clinically significant PK interaction as methylphenidate does not appreciably inhibit CYP2D6.
* '''Warfarin / coumarins''', methylphenidate may elevate INR
* '''Phenytoin, phenobarbital, primidone''', methylphenidate may elevate anticonvulsant levels
* '''Antihypertensives''', methylphenidate's pressor effect may partially antagonize
* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants), additive cardiovascular effects
* '''Neuroleptics''', pharmacologic antagonism (each may partially block the other's effects)
* '''Alcohol''', may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism
* '''Caffeine''', additive psychostimulant and anxiogenic effects

Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s, a clinical advantage over amphetamine when polypharmacy is a concern.
<pharmaInteractions/>
| pregnancy_details = Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies, interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
* Consider ECG if cardiac risk factors are present
* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
* Periodically reassess continued need; consider med holidays in children to assess ongoing benefit and minimize growth-velocity effects
* Sleep quality and timing of last dose
| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.
* '''Do not crush, chew, or split extended-release tablets/capsules.'''
* '''Concerta:''' the osmotic tablet shell will appear intact in stool, this is normal and does not mean the med wasn't absorbed.
* Eat regular meals despite appetite suppression; weigh periodically.
* Stay well-hydrated.
* Do not combine with significant alcohol or other psychostimulants.
* Do not share or sell, Schedule II controlled substance; serious legal and clinical consequences.
* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
* Skin patches: rotate site daily to avoid persistent depigmentation; remove after 9 hours.
* Plan for the "crash" when the dose wears off, particularly with IR formulations late afternoon.
* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.
| anecdotes =
<anecdote slug="2026-05-14" perspective="provider" author="MDElliottMD">
Rumor has it that it can be more effective during the luteal phase of the menstrual cycle. Anyone have experience?
</anecdote>
| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
| references = <references/>
}}

[[Category:Psychostimulants]]
[[Category:Methylphenidates (Phenidates)]]

Peppermint

2026-05-26T20:59:08Z

Maintenance script: Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

{{hatnote|Not to be confused with pennyroyal (''Mentha'' pulegium), a closely related but toxic species. See the [[#Botany and identification]] section for the full safety warning.}}
{{PlantMedTemplate
| name = Peppermint
| binomial = Mentha × piperita
| family = Lamiaceae
| native_range = Not native to any wild habitat: peppermint is a sterile hybrid and does not reproduce from seed. First recorded in England in the 17th century, probably arising spontaneously in cultivated mint fields near Mitcham, Surrey. Now cultivated worldwide throughout the temperate zone; principal commercial producers are the United States (Pacific Northwest and Indiana), India, and China.
| plant_part = Aerial parts (leaves and flowering tops); essential oil distilled from fresh herb; enteric-coated capsules of the essential oil for pharmaceutical use.
| image =
| intro = ''Mentha x piperita'' L. -- peppermint -- is a sterile hybrid of watermint (''Mentha'' aquatica) and spearmint (''Mentha spicata'') first documented in the herb gardens of 17th-century England. It reproduces only by vegetative spread and would disappear without cultivation; instead it has become the most widely grown aromatic herb in the world, its menthol extracted in quantities sufficient to scent a global industry of confectionery, personal care, and pharmaceuticals. Among medicinal herbs it holds an unusual distinction: enteric-coated peppermint oil capsules are supported by a Cochrane systematic review of nine randomized controlled trials reporting a number needed to treat of 2.5 for irritable bowel syndrome -- one of the strongest evidence-backed botanical indications in gastrointestinal medicine.
| history = Mint is one of the oldest plants in the human medicinal record. Dried mint leaves have been recovered from Egyptian tombs dated to approximately 1000 BCE; the Romans cultivated mint so extensively across their empire that Pliny the Elder complained they planted it everywhere.{{citation needed}} The Greek physician Dioscorides recorded multiple mint species and their uses for flatulence, nausea, and the suppression of vomiting; Hippocrates had written of mint before him. In the Arab world, the physician Ibn Sina noted mint's digestive and carminative properties in the Canon of Medicine. By the medieval period mint was among the universal European monastery garden plants, appearing in every hortus conclusus alongside sage, rosemary, and lavender.

What none of these traditions knew, because it did not yet exist, was peppermint. ''Mentha x piperita'' is a hybrid -- a cross between watermint and spearmint -- that arose, or was first recognized, in England in the 17th century, likely in the commercial mint-growing fields around Mitcham in Surrey, which became the center of English peppermint cultivation and remained so through the 19th century. John Ray, the English naturalist, first formally described peppermint as a distinct plant in 1696.{{citation needed}} The English cultivated it first; then the Americans took it -- particularly the farmers of Chautauqua County, New York and later the Columbia River basin -- and by the 19th century peppermint was a transatlantic commodity. By the 20th century it was a global industrial crop, its oil distilled in tonnage for the tobacco, confectionery, and oral hygiene industries, and the pharmacognosists were beginning to work out exactly why it did what it had always done to a troubled gut.

The therapeutic pivot came in stages. Commission E in Germany approved peppermint oil for spasmodic complaints of the upper gastrointestinal tract in 1990, grounded in traditional use and the available pharmacological rationale. The pharmaceutical form -- enteric-coated peppermint oil capsules formulated to survive the stomach acid and release their contents in the small intestine -- was the key innovation; Colpermin appeared in the 1980s and accumulated clinical trial data through the 1990s and 2000s. The Cochrane Collaboration's 2014 systematic review was the culmination of that evidence, and it placed peppermint oil among the most rigorously substantiated botanical interventions in gastroenterology.
| taxonomy = ''Mentha x piperita'' L. belongs to tribe Mentheae, family Lamiaceae. The multiplication sign in the binomial (x) denotes hybrid origin: the parents are ''Mentha'' aquatica (watermint) and ''Mentha spicata'' (spearmint). The hybrid is triploid and entirely sterile -- it sets no viable seed and propagates exclusively by vegetative means (rhizomes and cuttings). The x piperita epithet (pepper-mint) refers to the hot-cool-pungent character of the fresh leaf, distinct from the milder spearmint parent.

The genus ''Mentha'' comprises approximately 25 recognized species and a very large number of hybrids, cultivars, and named varieties; the genus is taxonomically complex, and menthol content varies considerably across species and cultivars. Medically and commercially significant species include:

''Mentha'' aquatica (watermint): one parent of peppermint; grows in wet habitats; high linalool content; mild medicinal use.

''Mentha spicata'' (spearmint): the other parent; carvone-dominant rather than menthol-dominant; gentler, less cooling; the spearmint of culinary use and the safer option for children and for those who do not tolerate peppermint's LES-relaxing effect.

''Mentha'' arvensis (corn mint, Japanese peppermint): the dominant commercial source of natural menthol crystals; native to Asia; the oil from this species is far higher in menthol (70 to 90 percent) than peppermint oil (35 to 55 percent) and is the source of most of the menthol in commercial cough drops, mentholated cigarettes, and topical pain preparations.

''Mentha'' pulegium (pennyroyal): HIGHLY TOXIC. Pulegone-rich; historically used as a folk abortifacient; cases of maternal fatality and severe hepatic failure have been reported following ingestion of pennyroyal oil as an abortifacient agent.{{citation needed}} Pennyroyal should never be used as a substitute for peppermint in any context; the two plants have been confused in commercial herbal markets with fatal consequences.

The medicinal parts of M. x piperita are the aerial parts -- leaves and flowering tops -- harvested before full flowering. The essential oil is steam-distilled from fresh herb; genuine peppermint oil should contain menthol at 35 to 55 percent, distinguishing it from the lower-grade lavandin oil in the lavender trade's parallel adulteration problem.
| traditional_uses = '''Western herbal medicine (primary centroid)'''

Peppermint's principal traditional indications mirror its modern evidence base with unusual fidelity: flatulence and bloating, digestive cramping and colic, nausea and vomiting, dyspepsia, headache (particularly the common tension headache with a frontal or temporal distribution), nasal congestion from colds, and muscle pain. The herb has been used for these purposes in continuous Western practice from at least the 18th century, when peppermint tea became the commonest domestic remedy for an upset stomach in Britain and America. The inhalational use for nasal congestion -- peppermint steam over hot water, peppermint oil rubbed on the chest or dissolved in a steam inhaler -- has equal continuity. The topical application to the temple and forehead for headache appears in 18th- and 19th-century domestic medicine texts and was given its first controlled clinical evidence base by Gobel in 1996.

'''TCM: Bo He (薄荷)'''

Peppermint is used in Chinese medicine under the name Bo He, though the plant sourced in Chinese practice is frequently ''Mentha'' haplocalyx or other Asian ''Mentha'' species rather than M. x piperita; the volatile-oil chemistry is sufficiently similar for the indications to overlap. In the TCM framework, Bo He is classified as pungent and cool, entering the lung and liver meridians. Its primary indications are wind-heat exterior patterns (early common cold or influenza with fever, sore throat, headache) where it disperses the pathogenic wind-heat; it also clears the head and eyes for wind-heat-related headache and red eyes, and moves liver qi stagnation for irritability and distention. In formulae, it is frequently combined with Forsythia (Lian Qiao) and Lonicera (Jin Yin Hua) in standard wind-heat formulas such as Yin Qiao San.{{citation needed}}

'''Ayurvedic medicine (Pudina)'''

Peppermint is used in Ayurvedic medicine as Pudina, described as pungent, slightly bitter, and cooling in action; it pacifies kapha and vata doshas while having mixed effects on pitta. Principal Ayurvedic indications are digestive complaints -- dyspepsia, nausea, vomiting -- and febrile conditions where its diaphoretic action is valued. It is among the aromatics used in Ayurvedic churnas (herbal powders) for digestive support.{{citation needed}}

'''Islamic medicine (Na'na)'''

Mint was known in Arabic-speaking medicine as Na'na (نعناع) and classified as cool and drying in the Galenic-Islamic temperament system; Ibn Sina described it for digestion, fevers, headache, and nausea in the Canon of Medicine, consistent with its Dioscoridean antecedents.{{citation needed}}
| pharmacology = '''Menthol: the principal active constituent'''

Peppermint essential oil contains menthol at 35 to 55 percent of total volatile oil, menthone at 10 to 40 percent, menthyl acetate, isomenthone, 1,8-cineole, and trace amounts of pulegone (significantly higher in pennyroyal and in some lavandin adulterants).{{citation needed}}

Menthol exerts its principal therapeutic actions through two distinct receptor mechanisms.

Voltage-gated calcium channel blockade in gastrointestinal smooth muscle: menthol and whole peppermint oil inhibit L-type calcium channels in intestinal smooth muscle, reducing calcium-dependent contraction and relaxing GI tone. This was first demonstrated in a pharmacological study by Hawthorn and colleagues in 1988<ref name="hawthorn1988">Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. "The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac smooth muscle." Aliment Pharmacol Ther. 1988;2(2):101-118. PMID 2856502.</ref> and confirmed in human colonic smooth muscle by Amato and colleagues in 2014.<ref name="amato2014">Amato A, Liotta R, Mule F. "Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action." Eur J Pharmacol. 2014;740:295-301. PMID 25046841.</ref> The L-type calcium channel mechanism accounts for menthol's antispasmodic action in the irritable bowel -- precisely the mechanism that explains why an enteric-coated capsule formulation that delivers the oil to the small and large intestine (bypassing the stomach) is necessary for IBS treatment.

Transient receptor potential melastatin 8 (TRPM8) activation: menthol is the principal natural ligand of TRPM8, the cold-sensitive ion channel responsible for the sensation of coolness (and, paradoxically, of cold-induced burning at high concentrations). TRPM8 activation in sensory neurons is the basis of peppermint's cooling sensation on the skin and mucous membranes, and contributes to its topical analgesic effect in tension headache -- initial TRPM8 activation followed by desensitization leads to reduced pain signaling in the same manner that capsaicin (TRPV1 agonist) produces topical analgesia via TRPV1 desensitization.<ref name="mckemy2002">McKemy DD, Neuhausser WM, Julius D. "Identification of a cold receptor reveals a general role for TRP channels in thermosensation." Nature. 2002;416(6876):52-58. PMID 11882888.</ref><ref name="bautista2007">Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI. "The menthol receptor TRPM8 is the principal detector of environmental cold." Nature. 2007;448(7150):204-208. PMID 17538622.</ref>

Antimicrobial activity: peppermint essential oil demonstrates broad-spectrum antibacterial and antifungal activity in vitro, including against ''Helicobacter pylori'', ''Candida albicans'', methicillin-resistant ''Staphylococcus aureus'', and Escherichia coli; the mechanism involves menthol's disruption of microbial cell membrane integrity.{{citation needed}}

Choleretic activity: peppermint oil stimulates bile secretion from the gallbladder and hepatic bile production; this contributes to its efficacy in functional dyspepsia and gallbladder-related upper GI symptoms and is the pharmacological basis of the Commission E approval for bile duct and gallbladder complaints.{{citation needed}}
| clinical_evidence = '''Irritable bowel syndrome (enteric-coated peppermint oil capsules)'''

The evidence for enteric-coated peppermint oil in IBS is the strongest clinical evidence base of any herbal medicine in gastroenterology. The formulation is critical: non-enteric-coated preparations dissolve in the stomach, causing upper GI side effects (heartburn, nausea from premature LES relaxation) without delivering active oil to the target site in the small and large intestine. Enteric-coated capsules bypass the stomach and release their contents only in the more alkaline intestinal environment.

Khanna and colleagues (2014) conducted a systematic review and meta-analysis of nine randomized, placebo-controlled trials (total n = 726) of enteric-coated peppermint oil for IBS. Global symptom improvement was significantly greater in the peppermint group; the pooled relative risk for global improvement was 2.23 (95 percent CI 1.78 to 2.81), corresponding to a number needed to treat of 2.5 -- a remarkably strong treatment effect for a botanical intervention in a notoriously treatment-resistant condition.<ref name="khanna2014">Khanna R, MacDonald JK, Levesque BG. "Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis." J Clin Gastroenterol. 2014;48(6):505-512. PMID 24100754.</ref>

Among the constituent trials, Cappello and colleagues (2007) randomized 57 patients with IBS to peppermint oil (Mintoil) 187 mg three times daily in enteric-coated capsules or placebo for four weeks; 75 percent of the treated group achieved at least 50 percent reduction in total symptom score, compared with 38 percent in the placebo group. Abdominal pain, distention, stool urgency, flatulence, and borborygmi all improved significantly in the peppermint group.<ref name="cappello2007">Cappello G, Spezzaferro M, Grossi L, Marzio L, Marzio L. "Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial." Dig Liver Dis. 2007;39(6):530-536. PMID 17420159.</ref>

'''Tension headache (topical peppermint oil)'''

Gobel and colleagues (1996) conducted a randomized crossover trial in patients with episodic tension-type headache, applying a 10 percent peppermint oil solution in ethanol to the forehead and temples at headache onset. Topical peppermint oil reduced headache intensity equivalently to oral paracetamol (acetaminophen) 1 g over the 60 minutes following application, with both being significantly superior to placebo. The mechanism is consistent with TRPM8-mediated cutaneous cooling followed by sensory neuron desensitization reducing pain signaling in the trigeminal area.<ref name="gobel1996">Gobel H, Fresenius J, Heinze A, Dworschak M, Soyka D. "Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type." Nervenarzt. 1996;67(8):672-681. PMID 8805113.</ref>

A 2016 confirmatory study from the same group reaffirmed the efficacy of topical peppermint oil for acute tension-type headache in a larger sample.<ref name="gobel2016">Gobel H, Heinze A, Heinze-Kuhn K, Gobel A, Gobel C. "[Peppermint oil in the acute treatment of tension-type headache]." Schmerz. 2016;30(3):295-310. PMID 27106030.</ref>

'''Functional dyspepsia'''

Peppermint oil in combination with caraway oil (Enteroplant; MCP Pharma, Germany) has been evaluated in several randomized trials for functional dyspepsia, showing significant improvement over placebo in epigastric pain, nausea, and bloating. The combination is included as a component of the multi-herb preparation Iberogast, which has its own clinical evidence base for functional dyspepsia.{{citation needed}}
| preparations = Infusion (tea): 3 to 4 g dried leaf per cup of hot water, covered while steeping (volatile oil retention). Drunk after meals for digestive complaints; as a steam inhalant for nasal congestion (pour into a bowl and inhale steam with a towel over the head). Note that peppermint tea is the preparation with the weakest IBS evidence; the enteric-coated capsule form is the evidence-based preparation for this indication.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation.

Enteric-coated peppermint oil capsules (Colpermin; Pepogest; Mintec; generic equivalents): the only form with robust IBS clinical trial evidence. Enteric coating is essential: the coating is designed to withstand gastric acid and dissolve at the more alkaline pH of the duodenum and small intestine, delivering the oil to the intestinal target rather than the stomach. These capsules must NOT be taken simultaneously with antacids, proton pump inhibitors, or H2 blockers that alkalinize the stomach -- premature dissolution of the enteric coat risks upper GI side effects. Standard commercial dose: 187 to 225 mg three times daily, taken before meals.

Essential oil (topical): 10 percent peppermint oil in ethanol or carrier oil, applied to forehead and temples for tension headache; 2 to 3 percent in carrier oil for massage of muscle ache or abdominal spasm; steam inhalant (2 to 3 drops in hot water) for nasal congestion. Do not apply neat oil to facial skin of children or to the face or chest of infants.

Mouthwash and confectionery: standardized products are not medicinal preparations but carry genuine antimicrobial and breath-freshening effects from the menthol content.
| dosing = '''Internal preparations'''

Infusion: 3 to 4 g dried leaf per cup, three to four times daily, ideally after meals. Cover the vessel while steeping; the volatile oil evaporates readily.

Tincture: 1 to 2 ml three times daily, diluted in water.

Enteric-coated peppermint oil capsules (for IBS): 187 to 225 mg three times daily, 30 to 60 minutes before meals. Do not crush or chew. Separate from antacid use by at least two hours. The full therapeutic effect in IBS develops over two to four weeks of regular use; do not assess as a failure after a single dose.

'''External preparations'''

Tension headache: 10 percent peppermint oil in ethanol, applied by cotton ball or rollerball applicator to forehead and both temples at headache onset; repeat at 15 and 30 minutes as needed. Keep well away from eyes. This is the protocol used in the Gobel trials.

Muscle tension and spasm: 2 to 3 percent essential oil in carrier oil, applied by massage to affected area.

Nasal congestion: 2 to 3 drops essential oil in a bowl of hot water; inhale steam for 5 to 10 minutes with a towel draped over head and bowl. Do not use this method with children under 12, or with infants under any circumstances.

'''Recreational dose ladder'''

Peppermint has no established recreational dose structure. Menthol's TRPM8-mediated cooling sensation is pleasurable and widely exploited in confectionery, oral hygiene, and tobacco products; however, the sensation is immediate, topical, and non-dose-escalating -- there is no psychoactive intensification with increasing dose, and no recreational culture of peppermint use as a psychoactive agent exists in any documented tradition. At high oral doses, menthol produces nausea and GI discomfort rather than pleasure; the pharmacological ceiling of the desirable effect is reached at modest concentrations. No dose ladder is warranted.
| pharmacokinetics = Menthol is rapidly absorbed from the gastrointestinal tract following oral ingestion of non-enteric-coated preparations; enteric-coated formulations delay absorption to the small intestine, which is the therapeutic intent for IBS. Menthol undergoes hepatic glucuronidation and sulfation; the conjugated metabolites are excreted renally, with menthol glucuronide detectable in urine as a biomarker of exposure. The elimination half-life of menthol is approximately one to two hours. Following topical application, menthol is absorbed dermally at a rate sufficient to produce detectable plasma concentrations; dermal absorption is faster with ethanol-based compared to oil-based vehicles.{{citation needed}}
| interactions = Antacids, proton pump inhibitors, H2 receptor antagonists: alkalinization of gastric pH by any of these agents can dissolve the enteric coating of peppermint oil capsules prematurely, causing upper GI side effects (heartburn, nausea, belching) and reducing delivery to the intended intestinal target. Antacids should be separated from enteric-coated capsule dosing by a minimum of two hours.

Central nervous system depressants: additive effects possible with sedating medicines and herbal preparations; peppermint has mild CNS-relaxing effects at therapeutic doses.

Cyclosporine: case reports suggest possible elevation of cyclosporine plasma levels in transplant recipients using peppermint oil preparations; a potential CYP3A4 interaction. Transplant patients on cyclosporine should not use peppermint oil preparations without specialist input.{{citation needed}}

Cyclosporine aside, cytochrome P450 inhibition by peppermint oil at standard enteric-coated capsule doses (187 to 225 mg three times daily) has not been documented as clinically significant in pharmacokinetic interaction studies.
| interactionsummary = Separate from antacids by 2 hours (enteric coat dissolution risk). Theoretical CYP3A4 interaction; case report of cyclosporine elevation. Additive CNS relaxant effect with sedatives.
| safety = The most important safety issue with peppermint is also the most preventable: administration to children under five, or inhalant menthol preparations applied near the face of infants. Menthol applied to the nose, mouth, or chest of infants and young children has caused laryngospasm and bronchospasm, including apnea, in case reports; this has occurred with direct application of peppermint oil or Vicks VapoRub-equivalent preparations to the chest or upper lip. Products containing menthol should not be applied near the face of children under five; for infants and toddlers, no menthol-containing preparations are appropriate.{{citation needed}}

Gastroesophageal reflux disease (GERD) and hiatal hernia: menthol relaxes the lower esophageal sphincter (LES). Peppermint tea and non-enteric-coated preparations should be avoided in patients with active reflux disease; enteric-coated capsules (which deliver the oil below the LES, to the intestine) are substantially lower-risk but should still be used with caution in severe or symptomatic GERD.

Pennyroyal (''Mentha'' pulegium) confusion: pennyroyal is a toxic mint-family plant sometimes sold as or confused with peppermint; its pulegone-rich essential oil has caused hepatic failure and maternal death when taken as an abortifacient. Any herb labeled as pennyroyal, European pennyroyal, or squaw mint should be treated as toxic. This warning applies to herbal suppliers and to patients who gather wild mints without botanical identification.

Gallstones: peppermint oil's choleretic effect stimulates the gallbladder; patients with known gallstones should use peppermint oil preparations cautiously, as stimulation of bile flow in the presence of obstructing stones could precipitate biliary colic.

Pregnancy: no clinical trial safety data; peppermint tea is used in traditional midwifery for pregnancy-related nausea and is generally considered safe at infusion doses; enteric-coated oil capsules at medicinal doses have not been evaluated in pregnancy and are not recommended.
| monitoring = No routine monitoring required for infusion use or enteric-coated capsules at standard IBS doses in otherwise healthy adults. Patients with GERD on enteric-coated capsules: symptom monitoring for worsening reflux. Transplant patients on cyclosporine: if using peppermint oil, check cyclosporine levels within two to four weeks of starting or changing dose.
| counseling = The formulation distinction is the most important thing to convey to patients using peppermint for IBS: only enteric-coated capsules have the clinical evidence base, because only they deliver the oil to the intestinal target. Peppermint tea, while pleasant and acceptable for mild general digestive symptoms, has not been tested for IBS and should not be substituted for the enteric-coated capsule in patients with established IBS diagnosis.

For tension headache, the topical preparation (10 percent peppermint oil in ethanol on forehead and temples) requires patient instruction on avoiding the eyes; a rollerball applicator is more practical than cotton-ball application for self-use. The effect onset is rapid -- patients should expect some relief within 15 to 30 minutes, earlier than with oral paracetamol.

Parents of infants and young children should be advised specifically that peppermint oil and all mentholated preparations should not be applied to the face, nose, or chest of children under five, and not at all to the face of infants.
| regulatory = '''Germany and European Union'''

German Commission E: peppermint oil approved for spastic complaints of the upper GI tract, bile duct and gallbladder; external use for myalgia and neuralgia; and inhalation for diseases of the upper respiratory tract. Peppermint leaf (dried herb) approved for carminative and antispasmodic use in the GI tract.

EMA: positive assessment issued for peppermint oil in enteric-coated capsules for IBS, classified as a well-established use (based on clinical trial evidence) rather than traditional use -- a stronger regulatory designation reflecting the Cochrane-level evidence base. This distinguishes peppermint oil from most other botanical preparations in the EMA monograph system.<ref name="ema-peppermint">European Union herbal monograph on Mentha x piperita L., aetheroleum. EMA/HMPC/522410/2013. Committee on Herbal Medicinal Products (HMPC). First published: 24 July 2020. https://www.ema.europa.eu/en/medicines/herbal/menthae-piperitae-aetheroleum</ref>

'''United States'''

Peppermint oil: GRAS as a food flavoring. Sold as a dietary supplement under DSHEA without FDA evaluation for therapeutic claims. No FDA-approved therapeutic indication.

'''United Kingdom'''

Colpermin (enteric-coated peppermint oil, 187 mg) is licensed as a pharmacy-only medicine for IBS in the UK; this is a higher regulatory status than a food supplement or herbal registration, reflecting the clinical trial evidence. Additional peppermint preparations registered under the MHRA traditional herbal registration scheme for digestive symptoms.
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Lemon balm

2026-05-26T20:59:07Z

Maintenance script: Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

{{PlantMedTemplate
| name = Lemon balm
| binomial = Melissa officinalis
| family = Lamiaceae
| native_range = Southern Europe, western Asia, and northern Africa; naturalized through temperate Europe, the Americas, and Australasia. Wild populations occur on roadsides, hedgerows, disturbed ground, and the margins of woodland, particularly on calcareous soils. Widely cultivated as a garden and medicinal herb throughout the temperate world.
| plant_part = Aerial parts (leaves and flowering tops), harvested just before full flowering when volatile oil content peaks; occasionally the essential oil distilled from fresh herb.
| image =
| intro = ''Melissa officinalis'' L. -- lemon balm, balm, melissa -- is a perennial herb of the mint family whose Greek name means bee, a record of the insects that congregate on its small white flowers and make from them a honey prized in antiquity. It has been called "the elixir of life" by Paracelsus and "sovereign for the brain" by John Evelyn; its unbroken reputation across two thousand years of Western and Islamic medicine is for lifting the heart, clearing the head, and settling the gut. The same compounds responsible for its sharp lemon scent -- the polyphenolic fraction concentrated in its leaves -- have turned out to be active against herpes simplex virus in controlled trials, giving it a specific antiviral credential unlike any other common nervine herb.
| history = The genus name carries the oldest story. In Greek myth, Melissa was a bee-priestess of the mountain goddess Cybele; she fed the infant Zeus on honey when his father Kronos sought to devour him, and was afterward transformed into a bee. Theophrastus in the fourth century BCE noted that beekeepers rubbed hive entrances with melissa leaves to keep their colonies from straying -- a practice that survives in modern beekeeping -- and the plant's association with bees, honey, and the sweetness of life runs through every tradition that has known it.{{citation needed}}

Dioscorides, writing in the first century of the common era, described melissa as useful for treating scorpion stings, dog bites, and the spasms of nervous origin; he recorded it as an infusion for "those who suffer from melancholy," establishing the herb's neurological reputation at the foundational level of European botanical medicine.{{citation needed}} The Romans cultivated it widely, and it passed from Roman gardens into the monastery.

Hildegard of Bingen in the twelfth century listed balm among the plants of the monastic garden that addressed the spiritual ailments she called melancholia; Paracelsus in the sixteenth century, temperamentally given to extreme claims, called it "the elixir of life" -- "among all the herbs none is better for the heart."{{citation needed}} John Gerard's Herball of 1597 recommended it for "driving away melancholly and heaviness of mind" and for "warming and comforting the heart."{{citation needed}}

The most enduring and delightful preparation in lemon balm's history was not a medicine in the modern sense but a spirit: Carmelite water (eau des Carmes), developed by the Carmelite nuns in Paris in the fourteenth century from lemon balm, lemon peel, nutmeg, coriander, angelica root, and cloves in high-proof spirits. It circulated as a tonic for the heart, a remedy against fainting and melancholy, and a general cordial; Charles V of France was reputed to drink it daily.{{citation needed}} The preparation survives commercially today under the Boyer label in France, continuous from the 17th century, and may be the longest-lived packaged medicinal preparation in Western Europe.

John Evelyn, the English diarist and gardener, wrote in the late seventeenth century: "Balm is sovereign for the brain, strengthening the memory and powerfully chasing away melancholy."{{citation needed}} The modern dimension was added not by herbalists but by laboratory pharmacologists. In 1994, the German physician and researcher Rainer Wölbling published the first rigorously controlled clinical trial of a standardized lemon balm cream -- subsequently commercialized as Lomaherpan -- applied to cold sores caused by herpes simplex virus.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from ''Melissa officinalis''." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref> The trial demonstrated that what herbalists had used empirically for mouth sores for centuries worked through a specific mechanism -- rosmarinic acid and other polyphenols blocking herpes virus attachment to host cells -- that remains among the most mechanistically coherent antiviral findings in phytomedicine.
| taxonomy = ''Melissa officinalis'' L. is placed in tribe Mentheae, family Lamiaceae, the sole widely used species in the genus Melissa. The genus name derives from the Greek melissa (bee); the species epithet officinalis (of the dispensary) is shared with hundreds of medicinal plants and indicates long-standing apothecary use. No infraspecific taxa carry commercial or medicinal significance.

''L. officinalis'' is a vigorous, branching perennial growing to 1.5 m (5 ft), with deeply veined, toothed bright-green leaves that release a sharp lemon scent when crushed -- a quality immediately distinguishing it from mint (''Mentha'') and other Lamiaceae in the garden. The lemon scent derives principally from citronellal, a compound also responsible for the scent of lemongrass (''Cymbopogon citratus'') and lemon eucalyptus (''Corymbia citriodora''), reflecting convergent volatile chemistry across plant families rather than close botanical relationship.

The small white flowers, tinged pink or lilac, appear in dense axillary clusters from early summer onward; they are rich in nectar and unusually attractive to honeybees. In the garden lemon balm self-seeds freely and becomes naturalized with ease; it is one of the least demanding of the Lamiaceae in cultivation, tolerating partial shade, poor soils, and neglect.

The medicinal parts are the aerial parts -- leaves and flowering tops -- harvested just before full flowering when volatile oil content is highest. Post-flowering leaves are coarser in flavor and lower in volatile oil. The essential oil is produced commercially but is one of the most expensive in herbal commerce: approximately 3,000 to 5,000 kg of fresh leaf is required to produce 1 kg of oil, reflecting the low volatile oil yield (typically under 0.2 percent of fresh weight) and the labor-intensive harvest involved. The essential oil is rarely indicated in clinical practice and is used primarily in aromatherapy.
| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lemon balm belongs to the nervine class of Western herbal medicine -- herbs with a primary action on the nervous system -- and is distinguished within that class by its particular gentleness: it is among the most pediatric-appropriate nervines in the Western tradition, given to colicky infants, anxious children, and restless adolescents alongside adults, without dose adjustment anxieties. This record of safe pediatric use across centuries is itself a kind of pharmacovigilance.

The principal traditional indications map closely onto the modern clinical evidence: anxiety and nervous agitation, insomnia with a restless or worried mind, palpitations from nervous origin (the "racing heart" that has no structural cardiac cause), nervous indigestion, colic and flatulence with an anxiety or tension component, and headache related to tension or nervous overload. The Carmelite water tradition adds a specifically cardiac tonifying dimension -- the heart-gladdening claim -- that aligns with both the nervous-palpitation indication and the mood-lifting effects documented in Kennedy's controlled trials two centuries later.

Secondary traditional indications include the antiviral use -- cold sores, oral herpes, used as topical fresh leaf or strong infusion -- which predates any knowledge of herpesvirus and reflects accurate empirical observation, and a diaphoretic use in febrile illness that made lemon balm standard in European childhood fever management.

'''Islamic medicine (Unani)'''

Lemon balm appears in Islamic-Galenic medicine as Turunjan (ترنجان) and, in some North African traditions, as Badharuj -- though this Arabic identifier is also applied by some sources to sweet basil (''Ocimum basilicum''), creating a minor source-identification ambiguity.{{citation needed}} Ibn Sina's Canon of Medicine praises it in terms that no other classical herbalist surpassed: lemon balm "causeth the heart and mind to become merry, exhilarateth the mind, settleth digestion, and is good against melancholy and the spleen." The Canon identifies it as a warming, drying herb good for cold temperaments, for cardiac palpitations, and for the "sadness and grief" that Ibn Sina associated with obstruction of the vital spirit.{{citation needed}}

'''Ayurvedic medicine'''

Lemon balm is not a primary plant of the classical Ayurvedic pharmacopoeia -- its native range does not extend to the Indian subcontinent -- but it has been incorporated into contemporary Ayurvedic and integrative practice in Europe and North America where it overlaps with herbs of similar action. It is occasionally classified by contemporary Ayurvedic practitioners as a tridoshic nervine suitable for vata-type anxiety and pitta-type irritability.{{citation needed}}
| pharmacology = '''Volatile oil and polyphenolic constituents'''

The essential oil of ''M. officinalis'' is dominated by citral -- a mixture of the geometric isomers geranial and neral -- which accounts for the plant's characteristic lemon scent, along with citronellal, linalool, and caryophyllene oxide.{{citation needed}} The volatile oil fraction, however, is present in much lower concentration than in most other medicinal Lamiaceae (under 0.2 percent of fresh weight), and its contribution to the therapeutic actions of whole-plant preparations may be secondary to the non-volatile polyphenolic fraction.

Rosmarinic acid and related caffeic acid derivatives -- the principal polyphenolic compounds in lemon balm -- are the dominant pharmacologically active fraction for antiviral activity. Rosmarinic acid and the tannin fraction interfere with viral attachment to host cells by binding to glycoproteins on the herpes simplex virus (HSV) envelope, preventing the virus from docking with cell-surface receptors; this mechanism has been demonstrated in cell-culture models and correlates with the clinical efficacy of topical Melissa preparations in herpes labialis.{{citation needed}}

The flavonoids (luteolin, apigenin) and triterpenes (ursolic and oleanolic acids) contribute anti-inflammatory and anxiolytic properties; apigenin in particular has affinity for the benzodiazepine receptor site of the GABA-A receptor, and this GABA-A interaction is the proposed basis for lemon balm's anxiolytic and mild sedative activity -- the same general mechanism as valerian, passionflower, and lavender, reflecting convergent pharmacology across unrelated plant families.{{citation needed}}

The anti-thyroid mechanism is distinct from both of the above: aqueous extracts of ''Melissa officinalis'' inhibit binding of thyroid-stimulating hormone (TSH) and Graves' immunoglobulins to TSH receptors in vitro, reducing thyroid stimulation. The mechanism is thought to involve the polyphenolic fraction competitively occupying the TSH receptor or blocking immunoglobulin binding sites.
| clinical_evidence = '''Antiviral: herpes simplex (topical)'''

The strongest and most specific clinical evidence for lemon balm is topical and antiviral. The German physician Rainer Wölbling conducted the first placebo-controlled trial of a standardized Melissa cream on recurrent cold sores in 1994, demonstrating significant reduction in lesion size, healing time, and symptom severity with a 1 percent dried Melissa extract cream applied four times daily.<ref name="wolbling1994">Wolbling RH, Leonhardt K. "Local therapy of herpes simplex with dried extract from ''Melissa officinalis''." Phytomedicine. 1994;1(1):25-31. PMID 23195812.</ref>

Koytchev and colleagues (1999) confirmed and extended these findings in a larger placebo-controlled trial of the Lomaherpan-equivalent preparation (Lo-701, a 70:1 Melissa dry extract cream) applied four times daily to active cold sore lesions. The treated group showed significantly faster healing, smaller lesion area at day two, and reduced pain compared with placebo; the authors noted particularly strong benefit in patients treated at first symptom appearance (the prodrome or early vesicle stage) before full lesion development.<ref name="koytchev1999">Koytchev R, Alken RG, Dundarov S. "Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis." Phytomedicine. 1999;6(4):225-230. PMID 10589440.</ref>

The commercial preparation Lomaherpan (standardized 1 percent ''Melissa officinalis'' extract cream; Lomapharm, Germany) continues to be used and studied on this basis; it is the reference preparation for the EMA's traditional use opinion on Melissa for cold sores.

The evidence is specific to topical application: lemon balm polyphenols must be in direct contact with the HSV-infected tissue to exert their envelope-binding antiviral effect. Internal lemon balm preparations (infusion, tincture) have not been evaluated in placebo-controlled trials for recurrent herpes; the antiviral claim should not be extended to oral preparations without direct supporting evidence.

'''Mood and cognitive modulation (oral preparations)'''

Kennedy and colleagues conducted a series of dose-finding studies in healthy volunteers that provide the clearest pharmacological picture of oral lemon balm's cognitive and mood effects. In a 2002 crossover study, single doses of a standardized ''Melissa officinalis'' extract (300 mg, 600 mg, or 900 mg) produced dose-dependent improvements in calmness ratings and speed of mathematical processing on validated psychometric batteries; notably, the highest dose (900 mg) reduced calmness ratings relative to placebo, suggesting an inverted-U dose-effect relationship -- a feature consistent with the GABA-A modulation mechanism and commonly observed with GABAergic agents.<ref name="kennedy2002">Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. "Modulation of mood and cognitive performance following acute administration of ''Melissa officinalis'' (lemon balm)." Pharmacology Biochemistry and Behavior. 2002;72(4):953-964. PMID 12062586.</ref>

A 2003 companion study found significant improvements in mood and cognitive performance following single oral doses, with dose-dependent effects on the speed of memory and spatial working memory tasks.<ref name="kennedy2003">Kennedy DO, Wake G, Savelev S, et al. "Modulation of mood and cognitive performance following acute administration of single doses of ''Melissa officinalis'' (lemon balm) with human pharmacological models." Neuropsychopharmacology. 2003;28(10):1871-1881. PMID 12888775.</ref>

In a 2006 study, Kennedy and colleagues evaluated a standardized combination of ''Melissa officinalis'' and ''Valeriana officinalis'' (valerian) extract under laboratory-induced stress conditions. The combination produced significant reductions in anxiety ratings during a multi-tasking battery, reductions in self-rated stress and alertness, and mood improvements relative to placebo; the effects were consistent with additive or synergistic action of the two plant extracts' respective mechanisms.<ref name="kennedy2006">Kennedy DO, Little W, Haskell CF, Scholey AB. "Anxiolytic effects of a combination of ''Melissa officinalis'' and ''Valeriana officinalis'' during laboratory induced stress." Phytotherapy Research. 2006;20(2):96-102. PMID 16444660.</ref>

These studies establish a real but modest anxiolytic and cognitive-modulating effect of oral lemon balm that is consistent with the GABA-A mechanism. Effect sizes are smaller than those seen with oral Silexan for generalized anxiety disorder; the evidence base is sufficient for mild-to-moderate situational anxiety but has not been evaluated against prescription anxiolytics in the manner of the Silexan trials.

'''Anti-thyroid activity (in vitro and limited clinical data)'''

Auf'mkolk and colleagues (1985) demonstrated in an in vitro receptor-binding assay that aqueous extracts of ''Melissa officinalis'' (and several other plants) inhibit the binding of thyroid-stimulating hormone and Graves' immunoglobulins to TSH receptors, reducing adenylate cyclase stimulation.<ref name="aufmkolk1985">Auf'mkolk M, Ingbar JC, Kubota K, Amir SM, Ingbar SH. "Extracts and auto-oxidized constituents of certain plants inhibit the receptor-binding and the biological activity of Graves' immunoglobulins." Endocrinology. 1985;116(5):1687-1693. PMID 2985357.</ref> This finding has been used as the pharmacological rationale for combining lemon balm with bugleweed (''Lycopus europaeus'') as an adjunctive herbal support in mild hyperthyroidism and Graves' disease; controlled clinical trials evaluating this combination for clinical outcomes in hyperthyroid patients are limited in number and quality.{{citation needed}}

'''Pediatric use'''

The use of lemon balm for sleep disturbance and nervousness in children is supported by tradition, basic safety data, and a limited clinical literature that includes combination preparations (valerian plus lemon balm).{{citation needed}} No serious adverse effects attributable to lemon balm have been reported in pediatric use at traditional doses.
| preparations = Infusion (tea): 2 to 4 g dried leaf and flowering tops per cup of hot water, covered while steeping (10 to 15 minutes) to retain the volatile oil fraction; the covering step is not cosmetic -- the volatile constituents are pharmacologically active and evaporate readily. Taken three times daily for daytime use or before sleep for insomnia.

Tincture: 1:5 in 45 percent ethanol from dried herb; standard liquid preparation for internal use; 2 to 6 ml per dose, three times daily.

Standardized dry extract: solid extract standardized to rosmarinic acid content (typically 3 to 5 percent), usually in capsule form; the preparation form used in the Kennedy cognitive-modulation studies (300 to 900 mg per dose).

Topical cream: 1 percent standardized Melissa dry extract (Lomaherpan; equivalent commercial preparations) applied topically to cold sore lesions at first symptom; the antiviral evidence is specific to topical preparations with defined rosmarinic acid content.

Essential oil: rarely used therapeutically; primarily aromatherapy; expensive and frequently adulterated with lemongrass (''Cymbopogon citratus'') or lemon-scented verbena (''Aloysia citrodora'') oil; if used, always diluted in carrier oil.

Combination preparations: Melissa plus ''Valeriana officinalis'' (valerian) is the most common commercial combination, targeting sleep and mild anxiety; this combination has the best clinical evidence base (Kennedy 2006) for lemon balm's anxiolytic and sleep-promoting effects.
| dosing = '''Internal preparations'''

Infusion: 2 to 4 g dried leaf per cup, three times daily and before bed. Acute use for nervous agitation or palpitations: a strong cup (double strength, 4 g covered, 15-minute steep) taken as needed.

Tincture (1:5 in 45 percent ethanol): 2 to 6 ml per dose, three times daily. Children: no established dose adjustment in traditional use; standard practice has been to reduce proportionally by body weight or to use a weaker preparation (diluted infusion), noting the absence of observed adverse effects in pediatric use at herbal practice doses.

Standardized extract: 300 to 600 mg per dose (consistent with Kennedy's effective dose range); 900 mg per dose has been associated with reduced calmness in Kennedy's studies and should be avoided as a starting dose.

For cold sore prevention with oral preparations: no clinical evidence base; oral lemon balm does not substitute for topical treatment and no internal anti-HSV dose has been evaluated.

Combination preparations (Melissa plus valerian): follow manufacturer dosing; typically one to two capsules or 5 to 10 ml liquid combination tincture at bedtime for sleep.

'''Recreational dose ladder'''

Lemon balm has no established recreational dose structure. Its sedative-anxiolytic effect at therapeutic doses is among the gentlest in the nervine class -- substantially milder than valerian, kava, or cannabis -- and dose escalation beyond the Kennedy effective range (300 to 600 mg standardized extract) produces diminishing benefit rather than progressive relaxation, as the 900 mg dose in Kennedy's studies reduced, rather than increased, calmness. No ethnobotanical or contemporary self-dosing literature documents recreational use of lemon balm in any form; the ceiling of effect at accessible doses is simply too low and too undramatic to attract recreational interest. No tiered dose ladder is warranted.
| pharmacokinetics = The pharmacokinetics of lemon balm's active constituents have not been characterized to the same degree as those of pharmaceutical preparations. Rosmarinic acid, the principal polyphenolic constituent, is absorbed from the gastrointestinal tract and undergoes conjugation and hydroxylation by intestinal microbiota and hepatic enzymes; plasma levels peak approximately 30 to 60 minutes after ingestion.{{citation needed}} The apigenin and luteolin flavonoids have been more extensively characterized in other botanical contexts and show oral bioavailability dependent on gut microbiome composition.
| interactions = Central nervous system depressants: additive effect expected with sedatives, anxiolytics, alcohol, and sedating herbal medicines (valerian, hops, passionflower, kava); lemon balm's own sedative effect is mild, but the interaction is pharmacologically consistent and clinically relevant when adding lemon balm to a regimen that includes prescription sedatives or anxiolytics. Therapeutic use with benzodiazepines should be mentioned to the prescriber.

Thyroid preparations: theoretical antagonism with levothyroxine and other thyroid hormone replacement if lemon balm's anti-TSH-receptor activity translates to clinical reduction of thyroid function; this is relevant primarily at high chronic doses in patients with hypothyroidism or those on replacement thyroid therapy. At standard infusion doses, the interaction is theoretical rather than documented; in practice, standard tea use is unlikely to produce clinically significant thyroid antagonism.
| interactionsummary = Additive CNS sedation with sedatives and anxiolytics. Theoretical thyroid hormone antagonism at high doses in hypothyroid patients.
| safety = Lemon balm has an outstanding safety record across two thousand years of use in children and adults. No serious adverse events have been reported in clinical trials, case reports, or systematic reviews at standard therapeutic doses. It is among the herbs most consistently identified as safe for children in the traditional and contemporary herbal literature.

Hypothyroidism: the anti-thyroid mechanism identified by Auf'mkolk (1985) in vitro has led to a theoretical caution for chronic high-dose oral use in patients with established hypothyroidism or those on thyroid hormone replacement. Standard infusion use (2 to 4 g dried herb three times daily) has not produced clinical hypothyroidism in case reports; the caution is precautionary at current doses. Patients with established hypothyroidism on levothyroxine who wish to use lemon balm chronically should have thyroid function monitored.

Pregnancy: lemon balm is used traditionally during pregnancy and lactation as a calming herb, and is one of the nervines most commonly recommended for perinatal anxiety in traditional midwifery practice. No clinical trial data in pregnancy exists. Consensus in contemporary herbal practice is that standard infusion doses are likely safe; concentrated extracts and high-dose standardized preparations have not been evaluated and should be used conservatively in pregnancy.

Allergic reactions to lemon balm are rare; contact dermatitis has been reported with the essential oil and less commonly with topical fresh plant preparations.
| monitoring = No routine monitoring required for standard-dose internal use in healthy adults. Patients with hypothyroidism or on thyroid hormone replacement using chronic lemon balm preparations: thyroid-stimulating hormone at baseline and after two to three months of regular use. Patients adding lemon balm to benzodiazepine or sedative regimens: monitor for excess sedation, particularly at treatment initiation.
| counseling = The distinction between oral and topical applications is important to convey clearly. Oral lemon balm (infusion, tincture, extract) is indicated for anxiety, nervous insomnia, palpitations, and nervous digestive symptoms; the clinical evidence for these indications is consistent but modest. Topical Lomaherpan-equivalent cream (1 percent standardized Melissa extract) is the form with the specific antiviral evidence for cold sores, applied at first sign of prodrome; oral lemon balm should not be presented as a substitute for the topical application in herpes management.

Patients with recurrent cold sores benefit most from topical treatment begun at prodrome (tingling, burning, or itching before vesicle formation) rather than after full blister development; early application is the message from Koytchev (1999) and consistent with the mechanism of attachment inhibition working best before viral invasion is complete.

Patients using lemon balm for anxiety who are not experiencing adequate response at standard infusion doses may benefit from a standardized extract at the 300 to 600 mg range, or from a Melissa plus valerian combination product (which has the best clinical evidence for the combined anxiolytic-sleep indication). If anxiety is more than mild to moderate, a clinical assessment for generalized anxiety disorder, for which Silexan (oral lavender oil) has substantially stronger evidence, is appropriate.
| regulatory = '''Germany and European Union'''

German Commission E: lemon balm (Melissenblätter) approved for nervous sleep disorders and functional gastrointestinal complaints; covers dried herb preparations (infusion, tincture) based on traditional use and the clinical evidence base.

EMA HMPC: positive opinion for traditional use of ''Melissa officinalis'' leaf for relief of mild symptoms of stress and to aid sleep; also for traditional use of standardized topical preparations for symptomatic treatment of cold sores (Herpes labialis). One HMPC monograph (EMA/HMPC/196745/2012) covers both the internal nervine/sleep indication and the topical herpes simplex indication.<ref name="ema-hmpc-melissa">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on ''Melissa officinalis'' L., folium. EMA/HMPC/196745/2012. First published: 5 August 2013. https://www.ema.europa.eu/en/medicines/herbal/melissae-folium.</ref>

'''United States'''

''Melissa officinalis'': GRAS (generally recognized as safe) as a food flavoring; sold as a dietary supplement under DSHEA without FDA evaluation of efficacy claims. No approved drug indication.

'''United Kingdom'''

MHRA traditional herbal registration: ''Melissa officinalis'' preparations registered for traditional use for mild anxiety and sleep disturbance, and for topical application to cold sores; the topical Lomaherpan-equivalent preparations are registered separately.
| history =
| effects =
| traditional_geography =
| anecdotes =
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Digestive herbs]]
[[Category:Carminatives]]
[[Category:Western clinical herbs]]

Chinese licorice

2026-05-26T20:59:07Z

Maintenance script: Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

{{PlantMedTemplate
| name = Chinese licorice
| binomial = Glycyrrhiza uralensis
| family = Fabaceae
| native_range = Northern China, Mongolia, Siberia, and Central Asia; wild stands in Xinjiang, Gansu, Inner Mongolia, and Manchuria; commercial supply largely from cultivated stands in northern and northwestern China.
| plant_part = Root and rhizome (dried); prepared in two clinically distinct forms in TCM: raw dried root (sheng gan cao) and honey-fried root (zhi gan cao).
| image =
| intro = Chinese licorice (''Glycyrrhiza uralensis'' Fisch.) is a perennial leguminous herb of the north Chinese steppe, the botanical source of gan cao (甘草, literally "sweet herb"), one of the most widely prescribed medicinals in the entire Chinese Materia Medica. Gan cao occupies a role in classical Chinese medicine without parallel in Western pharmacology: it is the defining harmonizer of formulas (调和诸药, tiáo hé zhū yào), an herb added to approximately sixty percent of all classical formulae not primarily for a specific therapeutic action of its own but to moderate the potency of harsh or toxic herbs, unify the divergent properties of a formula's ingredients, and protect the stomach and spleen from irritating constituents. The closely related Mediterranean species ''G. glabra'' (Western licorice) is the historical centroid of Ayurvedic, Unani, and European herbal licorice use; the two species share essentially the same glycyrrhizin-mediated pharmacology and the same pseudohyperaldosteronism safety profile, described in full at [[Western licorice]]. Both species are routinely substituted in commerce without pharmacopoeia distinction.
| taxonomy = ''Glycyrrhiza uralensis'' Fisch. ex DC. belongs to tribe Galegeae, family Fabaceae, one of approximately thirty species in the genus ''Glycyrrhiza''. The genus name derives from the Greek glykys (sweet) and rhiza (root), reflecting the intensely sweet taproot shared across the genus. ''G. uralensis'' is distinguished from ''G. glabra'' (European licorice) by glandular-hairy stems and seed pods, a more compact and shorter flower raceme, and a tendency to form dense rhizome mats in the steppe and semi-arid grasslands it inhabits; these morphological distinctions are unreliable in dried commercial root stock, and commercial substitution of the two species is routine and pharmacopoeially sanctioned under most major pharmacopoeias. ''G. inflata'' (Xinjiang licorice) is a third commercially significant species, particularly sourced in Central Asian markets.

The medicinal parts are the root and rhizome, harvested from plants four years or older; roots from younger plants have lower glycyrrhizin content and are considered suboptimal quality. In TCM practice the dried root is processed in two clinically distinct forms: sheng gan cao (生甘草, raw or unprocessed dried root), used for fire-toxicity conditions and as the universal harmonizing constituent; and zhi gan cao (炙甘草, honey-fried root), prepared by combining sliced dry root with liquid honey (typically 25 g honey per 100 g dry root) and stir-frying over gentle heat until the honey is fully absorbed and the surface is fragrant and golden-brown. TCM processing theory holds that honey-frying shifts the root's properties from the neutral-cooling of the raw form toward a warmer, more tonifying quality particularly suited to heart-calming and spleen-tonifying indications.
| traditional_uses = '''Chinese medicine (primary centroid)'''

The earliest written record of gan cao is in the Shennong Ben Cao Jing (神农本草经, Divine Farmer's Classic of Materia Medica), the foundational Chinese pharmacopoeia compiled approximately between the first and second centuries of the common era.{{citation needed}} The Shennong Ben Cao Jing categorized all 365 medicinal substances into three tiers: 120 upper herbs (上品, shàng pǐn), considered tonic and safe for prolonged use; 120 middle herbs, with specific therapeutic actions and moderate safety considerations; and 125 lower herbs, potent or toxic and reserved for acute conditions. Gan cao was classified as an upper herb, the most favorable designation in the text, a judgment that prefigured its two-thousand-year career as the universal harmonizing tonic base of Chinese formula construction.

The feature of gan cao that defines its clinical identity, and that has no close analog in Western pharmacological thinking, is its role as the harmonizer of formulas (调和诸药, tiáo hé zhū yào). Bensky, Clavey, and Stoger document gan cao's presence in approximately sixty percent of all classical Chinese herbal formulae,<ref name="bensky2004">Bensky D, Clavey S, Stoger E. ''Chinese Herbal Medicine: Materia Medica''. 3rd ed. Eastland Press, 2004. Section on ''Glycyrrhiza uralensis'' (Gan Cao, 甘草).</ref> a frequency no other single herb approaches, reflecting a function performed at the formula level rather than the organ-system level. Bensky identifies three distinct harmonizing roles that collectively account for this ubiquity.<ref name="bensky2004"/> First, gan cao moderates the toxicity and harshness of potent formula ingredients: where aconite (fu zi, a potent yang-warming root with a narrow therapeutic window), coptis (huang lian, intensely bitter and cold), or other drastic herbs appear, gan cao is the standard buffer, softening action and preventing the formula from overshooting its therapeutic purpose. Second, it harmonizes herbs of divergent thermal properties, flavors, and organ tropisms, preventing the "qi conflict" that TCM theory associates with unmediated confrontations between cold and hot, or ascending and descending, formula components. Third, it protects the stomach and spleen from the irritating effects of harsh ingredients, supporting patient tolerability through extended decoction courses. So thoroughgoing was this mediating function in the view of later TCM physicians that gan cao acquired the court honorific 国老 (guó lǎo, "Elder Statesman" or "Grand Councillor of the Nation"), comparing the herb's role in a formula to that of a senior official who mediates among warring ministers, integrates competing interests, and supports the sovereign's governing intention without seeking prominence for its own office.<ref name="bensky2004"/>

Zhang Zhongjing compiled the Shang Han Lun (伤寒论, Treatise on Cold Damage Disorders) approximately 210 CE; together with its companion the Jin Gui Yao Lue (金匮要略, Essential Prescriptions of the Golden Cabinet), it codified the classical formula architecture that remains foundational in contemporary TCM practice.{{citation needed}} Gan cao appears in a large proportion of the Shang Han Lun's one hundred and thirteen prescriptions. Four formulae from this text are of particular clinical significance and continue in active contemporary use:

Gan Cao Tang (甘草汤, Licorice Decoction) is the simplest formula: sheng gan cao as the sole herb, at full therapeutic dose, for sore throat and fire-toxicity patterns of the throat. It exemplifies gan cao in its direct anti-toxicity function rather than in the harmonizing role.<ref name="bensky2004"/>

Zhi Gan Cao Tang (炙甘草汤, Honey-Fried Licorice Decoction), also known as Fumai Tang (复脉汤, Restore the Pulse Decoction), is a nine-ingredient formula combining honey-fried licorice as the principal herb with Rehmannia glutinosa (di huang), Ophiopogon japonicus (mai men dong), Colla Corii Asini (e jiao, donkey-hide gelatin), Cannabis sativa seed (huo ma ren), dried ginger (gan jiang), cinnamon twig (gui zhi; the same herb as [[Cassia cinnamon]] in TCM usage), jujube (da zao), and sake. It is prescribed specifically for heart palpitations (心悸, xīn jì) and irregularly or regularly irregular pulse arising from deficiency of heart yin and heart yang.{{citation needed}} Zhi Gan Cao Tang is the most specific TCM cardiac-rhythm prescription in the Shang Han Lun and remains a subject of contemporary pharmacological and small-scale clinical research.

Shao Yao Gan Cao Tang (芍药甘草汤, Peony and Licorice Decoction) pairs white peony root (bai shao, Paeonia lactiflora) with honey-fried gan cao in a two-herb formula prescribed for muscular spasm and cramping, particularly abdominal spasm and lower-limb cramps. The combination has attracted modern pharmacognosy investigation: paeoniflorin, the principal active glycoside of white peony, and glycyrrhizin appear to produce antispasmodic effects in animal models that exceed either constituent alone, with paeoniflorin and glycyrrhetinic acid proposed as synergistic components acting through distinct but complementary antispasmodic pathways.{{citation needed}}

Si Jun Zi Tang (四君子汤, Four Gentlemen Decoction) combines ginseng (ren shen, Panax ginseng), white atractylodes (bai zhu, Atractylodes macrocephala), poria (fu ling, Wolfiporia cocos), and honey-fried licorice. It is the foundational spleen-qi tonic of TCM, the structural core from which a large family of derivative tonifying and digestive-support formulae is built, including Liu Jun Zi Tang (Six Gentlemen), Xiang Sha Liu Jun Zi Tang, and numerous others.{{citation needed}} Gan cao's role in Si Jun Zi Tang is primarily harmonizing and stomach-protective rather than directly tonifying; the principal tonifying agents are ginseng and white atractylodes, with gan cao integrating their divergent properties and protecting the stomach from the full impact of concentrated qi-supplementing herbs.

Li Shizhen's Ben Cao Gang Mu (本草纲目, Compendium of Materia Medica), completed in 1578 and published in 1596, gave gan cao its most comprehensive classical Chinese treatment, cataloguing morphological varieties, regional origins, harvesting protocols, processing methods (with particular attention to the honey-frying distinction), flavors, thermal properties, organ tropisms, formulaic combinations, and the guó lǎo honorific as a tradition tracing to the Han dynasty.{{citation needed}} Li Shizhen's synthesis made the Ben Cao Gang Mu the de facto reference standard for East Asian herbal medicine from the Ming dynasty onward.

'''Western herbal and Ayurvedic use (brief)'''

''G. uralensis'' has no significant independent tradition in Ayurvedic or Unani medicine; the yashtimadhu (sweet stick) of Ayurveda, the asl-us-sus of Unani medicine, and the glykyrrhiza of the Greco-Roman and medieval European herbal traditions are rooted in ''G. glabra'', the Mediterranean species. ''G. uralensis'' enters Western herbal and Ayurvedic practice primarily through commercial substitution: international licorice root trade routinely mixes or substitutes the two species, as dried root from the two is morphologically indistinguishable in commerce and the pharmacological properties are sufficiently comparable for pharmacopoeial equivalence. The complete traditions of Western herbal, Ayurvedic, Unani, and Greco-Roman licorice practice are documented at [[Western licorice]].
| preparations = Sheng gan cao (生甘草, raw dried root): unprocessed dried sliced root used in TCM decoction for fire-toxicity conditions (throat swellings, carbuncles, heat patterns), lung-dryness cough, and the universal formula-harmonizing role. This is also the standard commercial source material for Western herbal extracts and pharmaceutical-grade glycyrrhizin extraction.

Zhi gan cao (炙甘草, honey-fried root): root stir-fried with liquid honey until fragrant and golden-brown; TCM processing theory holds that honey-frying intensifies tonifying and warmth-generating properties while moderating bitterness and astringency. Specified for spleen-qi tonification, heart palpitations (particularly in the Zhi Gan Cao Tang formula), and all indications where a warming-tonifying rather than cooling-clearing action is required.

Standardized root extract: concentrated extract standardized to 18 to 25 percent glycyrrhizin content, available as solid extract or liquid concentrate; both ''G. uralensis'' and ''G. glabra'' are sourced commercially for standardized extracts, frequently without species designation on product labels.

TCM granule extract: spray-dried or freeze-dried root extract in granule form for contemporary TCM granule-prescription practice, allowing formula assembly without traditional decoction; commercially available as sheng gan cao or zhi gan cao granules.

Deglycyrrhizinated licorice (DGL): available in Western clinical herbal practice as a preparation from which glycyrrhizin has been removed, retaining demulcent and mucosal-protective activity without the pseudohyperaldosteronism risk. Western market DGL preparations are predominantly derived from ''G. glabra'' material; ''G. uralensis''-sourced DGL exists but is less commonly available in Western markets. The full DGL discussion, including clinical evidence, dose, and chronic-use appropriateness, is at [[Western licorice]].
| pharmacology = '''Principal active constituents'''

Glycyrrhizin (glycyrrhizinic acid): a triterpenoid saponin glycoside constituting approximately 2 to 4 percent of dry-weight root under standard cultivation conditions; content varies with growing region, soil type, and harvest timing.<ref name="chinpharmacopoeia2020">National Pharmacopoeia Commission. ''Pharmacopoeia of the People's Republic of China''. Vol. I. China Medical Science and Technology Press, 2020. Monograph: Gan Cao (甘草).</ref><ref name="pastorino2018">Pastorino G, Cornara L, Soares S, Rodrigues F, Oliveira MBPP. "Liquorice (''Glycyrrhiza glabra''): A phytochemical and pharmacological review." ''Phytother Res'' 2018;32(12):2323-2339. PMID 30117204.</ref> Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; intestinal bacterial beta-glucuronidase hydrolyzes it to 18-beta-glycyrrhetinic acid (18β-GA), the principal systemically absorbed active metabolite. 18β-GA accounts for the anti-inflammatory pharmacology (inhibition of prostaglandin-synthesizing enzymes and phospholipase A2) and for the adverse mineralocorticoid effect via inhibition of 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2) in the renal tubule, the mechanism underlying pseudohyperaldosteronism at sustained high glycyrrhizin intakes. The full 11-beta-HSD2 mechanism is described at [[Western licorice]].

Liquiritin and isoliquiritin: flavanone and chalcone glycosides with sedative and antispasmodic activity in animal models; probable contributors, alongside paeoniflorin from white peony, to the antispasmodic efficacy of Shao Yao Gan Cao Tang.

Licochalcone A and related chalcones: antimicrobial and anti-inflammatory activity in laboratory studies; typically present in lower concentrations in ''G. uralensis'' than in ''G. inflata''.

Glycyrrhetic acid (enoxolone): the free aglycone of glycyrrhizin; the basis of the pharmaceutical derivative carbenoxolone, the synthetic peptic ulcer compound developed in Europe in the 1960s to 1970s, documented at [[Western licorice]].
| indications = '''TCM indications (primary)'''

Spleen qi deficiency: fatigue, diminished appetite, loose stools, and lassitude; honey-fried gan cao as a constituent of tonifying formulae, principally Si Jun Zi Tang and its extensive derivative family; the most frequently invoked TCM indication in formula construction.<ref name="bensky2004"/>

Heart palpitations and irregularly irregular pulse from deficiency of heart yin and heart yang: the specific indication of the Zhi Gan Cao Tang formula; among the more physiologically specific classical TCM cardiac-rhythm indications and a subject of contemporary pharmacological and small-scale clinical investigation, including case reports of formula modifications for both bradyarrhythmia and tachyarrhythmia.<ref name="bensky2004"/><ref name="chen2010zhigancao">Chen WG, Ba ZM. "Prof. ZHANG Yi's experience in treating severe arrhythmia." ''J Tradit Chin Med'' 2010;30(1):47-50. PMID 20397463.</ref>

Lung dryness and cough: raw gan cao in wind-heat or lung-dryness patterns; gan cao moistens the lung channel and moderates the drying effect of other herbs in respiratory formulae.<ref name="bensky2004"/>

Fire toxicity: carbuncles, boils, and sore throat with heat characteristics; raw gan cao as Gan Cao Tang alone or combined with other heat-clearing herbs; one of the direct therapeutic indications in which gan cao functions as the principal herb rather than as a harmonizer.<ref name="bensky2004"/>

Lower-limb and abdominal muscular spasm: Shao Yao Gan Cao Tang (white peony and honey-fried licorice); the most-studied specific two-herb-pair indication for gan cao, with pharmacological evidence of paeoniflorin-glycyrrhizin antispasmodic synergy.<ref name="bensky2004"/>

Universal harmonizing and formula-integrating role: the indication accounting for the majority of gan cao prescriptions; not condition-specific but formula-architecture-specific; see Traditional uses above for the mechanism and significance.

'''Western clinical indications (condensed; full evidence base at Western licorice)'''

Western clinical research on licorice does not systematically distinguish ''G. uralensis'' from ''G. glabra''; commercial preparations are often from mixed or unspecified species. The evidence base for peptic ulcer and mucosal protection (deglycyrrhizinated licorice preparations), chronic hepatitis (intravenous Stronger Neo-Minophagen C glycyrrhizin compound in Japanese clinical practice), respiratory catarrh (Commission E approved indication), and adrenal-supportive use is described in full at [[Western licorice]].
| dosing = TCM decoction dose: 2 to 12 g dried root per day (raw or honey-fried) in multi-herb decoction. Harmonizing doses, which account for the majority of gan cao prescriptions, are typically 2 to 6 g per day; doses in which gan cao is the principal therapeutic herb (as in Gan Cao Tang) may reach 9 to 12 g per day. Single-herb throat formula (Gan Cao Tang): 4 to 9 g.<ref name="bensky2004"/>

Western clinical extract dose: standardized extract equivalent to 5 to 15 g dried root daily; maximum continuous course four to six weeks without reassessment per Commission E guidance. Same limit as ''G. glabra''.

Glycyrrhizin intake limit: 100 mg glycyrrhizin per day maximum for chronic use per the European Union Scientific Committee on Food opinion SCF/CS/ADD/EDUL/225 Final (2003), the same guidance applicable to both ''G. uralensis'' and ''G. glabra''.
| pharmacokinetics = Glycyrrhizin is poorly absorbed intact from the gastrointestinal tract; rate-limiting absorption involves bacterial beta-glucuronidase hydrolysis in the large intestine, producing 18-beta-glycyrrhetinic acid with a lag of two to four hours between oral ingestion and rising plasma 18β-GA levels. Individual variation in gut microbiome composition generates substantial inter-individual variability in 18β-GA plasma exposure at equivalent oral glycyrrhizin doses, which partly explains the observed case-to-case variability in pseudohyperaldosteronism susceptibility.

18-Beta-glycyrrhetinic acid: half-life approximately 7 to 8 hours; primarily hepatic metabolism; biliary excretion with enterohepatic recirculation reported, potentially prolonging effective exposure with repeated daily dosing.

The full pharmacokinetic discussion, including DGL pharmacokinetics and the plasma-level considerations underlying the pseudohyperaldosteronism dose-response, is at [[Western licorice]].
| interactions = The interaction profile of ''G. uralensis'' is identical to that of ''G. glabra''; the shared glycyrrhizin content and shared 11-beta-HSD2 inhibition mechanism produce the same clinically relevant pharmacodynamic interactions regardless of species. Full interaction details are at [[Western licorice]]; the following is a clinical summary.

Antihypertensive medicines: whole-licorice preparations raise blood pressure through sodium and water retention (the pseudohyperaldosteronism mechanism), directly antagonizing antihypertensive treatment; concurrent use should be avoided or blood pressure monitored closely with readiness to adjust antihypertensive doses.

Potassium-depleting medicines (loop diuretics, thiazide diuretics, corticosteroids): additive hypokalemia risk; the combination carries increased risk of clinically significant potassium depletion, muscle weakness, cardiac arrhythmia, and, at severe depletion, respiratory muscle compromise. Serum potassium monitoring is warranted in any patient combining licorice with these agents.

Cardiac glycosides (digoxin): licorice-induced hypokalemia increases myocardial sensitivity to cardiac glycoside toxicity; the combination of chronic licorice use and digoxin therapy requires concurrent potassium monitoring.

Exogenous corticosteroids: 11-beta-HSD2 inhibition by 18β-GA may amplify the mineralocorticoid effects of concurrent exogenous corticosteroid therapy, accelerating fluid retention and raising blood pressure.

A note specific to TCM formula practice: at the standard harmonizing dose (2 to 6 g daily for a short course of four weeks or less), the probability of clinically significant pharmacodynamic interaction in most patients is low. The interaction concern becomes clinically important at chronic high-dose use and in patients taking antihypertensives, diuretics, or cardiac glycosides concurrently.

DGL preparations: negligible pharmacodynamic interaction risk from the glycyrrhizin-mediated pathway; DGL is the preparation of choice for any chronic use requiring avoidance of these interactions.
| interactionsummary = Antihypertensives (antagonism of blood pressure control), potassium-depleting agents including loop and thiazide diuretics and corticosteroids (additive hypokalemia), cardiac glycosides including digoxin (hypokalemia-mediated toxicity potentiation), exogenous corticosteroids (amplification of mineralocorticoid effects). Full DDI discussion at [[Western licorice]]. DGL preparations avoid these interactions.
| safety = The pseudohyperaldosteronism safety profile of ''G. uralensis'' is identical to that of ''G. glabra'': the same 18-beta-glycyrrhetinic-acid-mediated 11-beta-HSD2 inhibition, the same dose-dependent sodium retention, potassium depletion, hypertension, and edema, and the same case-report and regulatory literature. The full mechanism, dose-response, Walker 1994, van Uum 2005, and EU SCF 2003 guidance are documented at [[Western licorice]]. The 100 mg/day glycyrrhizin chronic-use limit applies to whole-licorice preparations of either species.

Note specific to TCM practice: at the typical harmonizing dose (2 to 6 g root per day), daily glycyrrhizin intake from gan cao ranges from approximately 40 to 240 mg depending on the glycyrrhizin content of the specific batch; at the lower end this falls within the EU SCF guidance range, and at the upper end it does not. Chronic daily use of high-dose tonifying decoctions or concentrated patent-medicine preparations over many months warrants the same blood pressure and potassium monitoring as any whole-licorice use. Practitioners and patients should not assume that the harmonizing role necessarily entails sub-threshold glycyrrhizin doses.

Pregnancy: the preterm birth concern documented in the Finnish cohort applies equally to ''G. uralensis''; glycyrrhizin is the mediating compound and is present in comparable concentrations in both species. Strandberg and colleagues (2001) found that Finnish mothers consuming more than 500 mg glycyrrhizin weekly from confectionery had significantly increased odds of preterm birth and lower birth weight in their offspring.<ref name="strandberg2001">Strandberg TE, Jarvenpaa AL, Vanhanen H, McKeigue PM. "Birth outcome in relation to licorice consumption during pregnancy." ''American Journal of Epidemiology'' 2001;153(11):1085-1088. PMID 11390327.</ref> Avoidance of high-dose licorice of either species during pregnancy is advisable; culinary doses and low-dose harmonizing use in short courses carry uncertain but likely low risk.

Contraindications: hypertension, hypokalemia, cardiac arrhythmia, hepatic cirrhosis, renal insufficiency, concurrent use of potassium-depleting agents or cardiac glycosides, and pregnancy at high doses.
| monitoring = Whole-licorice use (any form of ''G. uralensis'' root or extract containing significant glycyrrhizin) for more than four weeks: obtain baseline blood pressure and serum potassium before initiating; recheck monthly during ongoing use. Discontinue and reassess if systolic blood pressure rises more than 10 to 15 mmHg from baseline, serum potassium falls below 3.5 mmol/L, or peripheral edema develops.

For patients taking concurrent antihypertensive medicines or cardiac glycosides, lower the monitoring threshold: check blood pressure and potassium after two weeks of use rather than four.

DGL preparations: no monitoring required beyond routine clinical follow-up appropriate to the underlying condition being managed.
| counseling = The pseudohyperaldosteronism risk that applies to Western licorice (''G. glabra'') applies equally to Chinese licorice (''G. uralensis'') and to any TCM formula containing gan cao. A patient told by a conventional physician to avoid licorice for blood pressure or potassium reasons should apply that restriction to gan cao in TCM decoctions and patent medicines. The two species are pharmacologically interchangeable with respect to this risk; a patient's conventional prescriber may not know that a TCM formula contains licorice under the name "gan cao" and will benefit from the information.

The harmonizing role accounts for the majority of gan cao prescriptions and typically places it at a lower dose (2 to 6 g daily) than its use as a primary therapeutic herb. Most patients on short-course multi-herb formulae at harmonizing doses will not experience clinical pseudohyperaldosteronism. The risk rises with increasing dose, increasing duration (months rather than weeks), and pre-existing clinical vulnerability: baseline hypertension, concurrent diuretic use, and low dietary potassium intake each shift the threshold downward.

Patients who need a chronic licorice-based preparation for mucosal protection, peptic ulcer, or gastritis should be directed to deglycyrrhizinated licorice (DGL), which removes the glycyrrhizin while retaining demulcent and mucosal-protective activity. DGL does not carry the mineralocorticoid risk and does not require blood pressure or potassium monitoring; see [[Western licorice]] for the full DGL discussion including dose, formulation, and comparison with whole licorice.

Commercial licorice root products (confectionery, chewable tablets, licorice-extract beverages) may contain ''G. uralensis'', ''G. glabra'', or both, often without species designation and without declared glycyrrhizin content. Patients using such products as a therapeutic practice should be asked about quantity, frequency, and glycyrrhizin content where possible; "licorice root extract" on a label does not specify species or dose.

The guó lǎo (国老, Elder Statesman) characterization of gan cao is a useful explanatory frame for patients: the herb is not added to a formula to fix one thing but to make the entire formula work more safely and effectively together. Patients who ask why their TCM formula contains licorice even though they are not being treated for a licorice-specific condition can be offered this framing as an accurate and culturally grounded explanation.
| history = Gan cao's written history in Chinese medicine extends to the earliest stratum of the Chinese herbal record. The Shennong Ben Cao Jing (first to second century CE) placed it among the 120 upper herbs, the highest-quality classification available in the text's tripartite system, signaling that its safety and tonic utility were already well established by the Han dynasty period (206 BCE to 220 CE) when the text was compiled.{{citation needed}}

Zhang Zhongjing's Shang Han Lun (c. 210 CE) codified the classical formula architecture in which gan cao plays its most extensively documented historical role: Zhi Gan Cao Tang for cardiac-rhythm disturbance, Shao Yao Gan Cao Tang for spasm, and the Si Jun Zi Tang ancestor-formulas for qi deficiency all date to this text and remain in active contemporary practice over 1800 years after their codification.{{citation needed}}

The period between the Shang Han Lun and Li Shizhen's Ben Cao Gang Mu (completed 1578) saw continuous elaboration and commentary on gan cao across the major TCM dynastic lineages; each era added clinical observations, formulaic refinements, and processing variants to the original Shang Han Lun foundation. Li Shizhen's systematic synthesis made the Ben Cao Gang Mu the de facto East Asian herbal reference standard from the Ming dynasty to the twentieth century.{{citation needed}}

Modern chemical investigation beginning in the mid-twentieth century isolated glycyrrhizin as the principal active compound; this led to two pharmaceutical derivatives: carbenoxolone (a glycyrrhetinic acid hemisuccinate, used in Europe for peptic ulcer disease in the 1960s to 1980s) and Stronger Neo-Minophagen C (SNMC, an intravenous glycyrrhizin compound used in Japan for chronic viral hepatitis from the 1970s onward). Both are documented at [[Western licorice]], where the Western pharmaceutical-derivative history is covered in full.

Contemporary ''G. uralensis'' populations are subject to conservation pressure from commercial wild harvesting in Inner Mongolia, Gansu, and Xinjiang; overharvesting has substantially reduced wild stands over the past several decades, driving the industry toward cultivated supply. ''Glycyrrhiza'' species are subject to trade-monitoring frameworks requiring country-of-origin export documentation to verify sustainable sourcing.{{citation needed}} ''G. uralensis'' is listed in the Pharmacopoeia of the People's Republic of China as an official medicinal herb under the monograph Gan Cao (甘草), and the pharmacopoeia specification includes a minimum glycyrrhizin content standard as a quality criterion, shaping commercial cultivation toward higher-yielding varieties.<ref name="chinpharmacopoeia2020"/>
| effects =
| traditional_geography =
| anecdotes =
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Anti-inflammatory herbs]]
[[Category:Respiratory herbs]]
[[Category:Demulcents]]
[[Category:TCM herbs]]

Dandelion

2026-05-26T20:55:46Z

Maintenance script: Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

{{PlantMedTemplate
| binomial = Taraxacum officinale
| family = Asteraceae
| native_range = Originally native to Eurasia and North Africa; now one of the most globally distributed plants in the world, present on every inhabited continent following dispersal with European colonization. Grows wild in grassland, roadsides, disturbed ground, and lawns throughout the temperate zone; cultivated commercially for medicinal and culinary supply in Germany and France.
| parts_used = Leaves (diuretic; harvested before flowering for highest bitter-principle content); root (hepatic bitter; dug in autumn from second-year plants for highest inulin content); flowers (minor; folk wine and syrup).
| images =
| intro = ''Taraxacum officinale'' G.H. Weber ex Wiggers -- dandelion -- is a perennial composite herb of Eurasian origin, now distributed across every inhabited continent and recognized by virtually every person alive, most of whom have at some point scattered its seeds from a spherical white clock. The French long ago named it pissenlit -- wet-the-bed -- which is an accurate clinical description of its principal medicinal action in the leaf, and it is this frankness of folk nomenclature that most concisely captures the herb's place in medicine: a plant dismissed as a weed by every suburban lawn, carrying a clinical evidence base in diuresis that most commercially marketed diuretic herbs cannot match, with the additional distinction of replenishing in the leaf the very potassium that synthetic diuretics strip away.
| traditional_uses = The earliest written records of dandelion in medicine come from 11th-century Arabic physicians -- Ibn Sina listed dandelion leaf in pharmacopoeial works -- and from the Welsh Physicians of Myddfai, a 13th-century medical guild whose manuscripts record it for liver and digestive complaints.{{citation needed}} By the 17th century ''T. officinale'' was established in every European herbal, universally respected as a hepatic bitter, a diuretic, and a spring tonic food -- the tender young leaves gathered from fields before the first flowering and eaten in salad as an annual seasonal cleanse.

The name is a corruption of the French dent-de-lion (lion's tooth), referring to the deeply ragged leaf margins; in English it became "dandelion" by the 16th century. The French pissenlit captured the leaf's diuretic force with characteristic directness; contemporary French herbalists still use the term without embarrassment, as an accurate pharmacological description rather than a vulgarity.

Nicholas Culpeper in 1653 recorded dandelion for "opening obstructions of the liver, gall, and spleen," for jaundice, and as "a sovereign remedy against the evil disposition of the body, proceeding from the badness of the blood."{{citation needed}} These indications -- liver, spleen, fluid, blood quality -- are precisely those that the Western alterative tradition has assigned to dandelion root for the four centuries since Culpeper, with remarkable consistency across German, French, British, and American herbal schools.

'''Chinese medicine: Pu Gong Ying (蒲公英)'''

In Chinese medicine the principal species is ''Taraxacum mongolicum'' (sometimes listed as ''T. sinicum''), though ''T. officinale'' is accepted as an equivalent in most contemporary pharmacopoeias. Under the name Pu Gong Ying, it is classified as bitter and sweet in flavor, cold in nature, entering the liver and stomach meridians. Its principal TCM indications are clearing heat and relieving toxicity -- the diagnostic category covering acute inflammatory and infectious conditions: breast abscess and mastitis (one of the most historically consistent indications in TCM practice for this herb), acute sore throat and tonsillitis, infected eyes, jaundice from damp-heat in the liver, and intestinal infection with heat signs.{{citation needed}} The TCM mastitis indication -- Pu Gong Ying as a primary herb for acute lactation mastitis, applied both internally as a decoction and topically as a poultice of fresh crushed leaf -- is among the most specific and consistent indications in the Chinese Materia Medica and has ethnopharmacological parallels in European practice (fresh dandelion leaf poultice for skin inflammation and swelling).

'''Native American and post-colonial American use'''

As ''T. officinale'' spread with European colonization, indigenous peoples throughout North America adopted it rapidly as it naturalized across the continent. Multiple nations used it for kidney, liver, and digestive complaints -- applications consistent with the introduced European knowledge system -- suggesting either independent discovery of the same pharmacological effects or rapid adoption of European herbal knowledge through trade contact.{{citation needed}}

'''Food tradition'''

Dandelion occupies an unusual dual role as food and medicine. Spring dandelion greens -- young leaves gathered before flowering, when bitter principles are concentrated and the leaves are most nutritionally dense -- are among the most nutritionally complete wild greens available in temperate climates, higher in vitamins A, C, and K, and in calcium, iron, and potassium, than most cultivated vegetables.{{citation needed}} Dandelion coffee -- roasted dried root decoction -- became a wartime staple in Britain and Europe during both World Wars when coffee was rationed, and remains a gentle, caffeine-free bitter digestive tonic in current herbal practice. In France, ''pissenlit au lard'' (dandelion greens with lardons and hot vinegar dressing) is a Burgundian spring classic with a history traceable to medieval monastic cooking.
| botany = ''Taraxacum officinale'' G.H. Weber ex Wiggers is placed in tribe Cichorieae (formerly Lactuceae), subfamily Cichorioideae, family Asteraceae. The species epithet officinale (of the dispensary) signals long apothecary use; the genus name derives from the Arabic tarakhshagun or the medieval Latin corruption of it, meaning bitter herb. ''Taraxacum'' is an enormously complex genus: depending on the taxonomic authority, it contains anywhere from 60 to 2,000 or more microspecies, many of which are apomictic (reproducing without fertilization, generating clonal lineages). Most commercial medicinal supply and most clinical research uses ''T. officinale'' in the broad, aggregate sense rather than any single microspecies; pharmacopoeial monographs accept this broad usage.

The plant is a perennial forming a basal rosette of deeply pinnately lobed leaves -- the lobes giving the lion's-tooth shape -- growing from a deep taproot that can reach 30 to 50 cm in established plants. The leaves are glabrous to slightly hairy; in cultivated populations they may be less deeply lobed. Hollow, leafless scapes (flower stalks) arise singly from the crown, each bearing a single bright golden composite head of ray florets only (no disk florets); this morphology distinguishes it from most other yellow composites. The well-known globular gray-white seed head (the "clock") consists of the achenes with their attached pappus (feathery parachute structures) that allow wind dispersal over considerable distances. A single plant may produce 2,000 to 12,000 seeds per year, a reproductive strategy that explains both its global success and suburban gardeners' despair.

The medicinal parts are harvested by part and season: leaves before first flowering in spring (highest bitter-principle and potassium content; preferred for diuretic use), root in autumn from second-year plants (highest inulin content; preferred for hepatic use). The spring-leaf and autumn-root distinction is not merely traditional but is pharmacologically grounded in the plant's seasonal allocation of primary metabolites.

Closely related: ''Taraxacum mongolicum'' (Pu Gong Ying; principal TCM medicinal species; used pharmacopoeially as equivalent to ''T. officinale'').
| constituents = '''Leaf constituents'''

The leaf is the more nutritionally dense and diuretically active part. Principal constituents include sesquiterpene lactones (taraxacin and related compounds, responsible for the bitter taste), triterpenes, polysaccharides, coumarins, carotenoids (beta-carotene and lutein; source of the leaf's nutritional vitamin-A equivalents), vitamins C and K, and, notably, minerals at concentrations that distinguish it from most vegetables: potassium content is among the highest of any leafy green, with documented values of 370 to 500 mg per 100 g fresh weight.{{citation needed}} This mineral composition is the pharmacological basis of dandelion leaf's unique advantage among diuretics: it replenishes the urinary potassium losses it induces, preventing the hypokalemia associated with synthetic loop and thiazide diuretics.

'''Root constituents'''

The root holds a different pharmacological profile. Inulin -- a fructooligosaccharide prebiotic polysaccharide -- constitutes up to 40 percent of dry root weight in autumn-harvested material, falling to 1 to 2 percent in spring (when it has been consumed in new-growth production).{{citation needed}} This seasonal variation is the pharmacological rationale for the traditional autumn-harvest preference. Taraxacoside, the principal bitter sesquiterpene glycoside of the root, contributes to the bitter-tonic and mild laxative actions. Phenolic acids (chicoric acid, caffeic acid derivatives), triterpenes (taraxasterol, taraxerol), and polyacetylenes complete the profile. Mineral content in the root, while lower per gram than the leaf, is still significant.
| pharmacodynamics = '''Diuretic mechanism (leaf)'''

The leaf's diuretic action is classified as aquaretic -- meaning it increases urine volume and sodium excretion without proportional potassium loss -- distinguishing it from synthetic diuretics (loop diuretics, thiazides) that cause significant potassium depletion. The mechanism is thought to involve inhibition of tubular sodium reabsorption by sesquiterpene lactone constituents, but the precise renal tubular pharmacology has not been fully characterized at the receptor level.{{citation needed}} The high potassium content of the leaf preparation further buffers any net potassium loss, contributing to the clinically observed potassium-sparing profile.

'''Hepatic and cholagogue mechanism (root)'''

The bitter sesquiterpene compounds (taraxacoside and related lactones) stimulate bile secretion from the liver and gallbladder contraction -- the cholagogue action that underlies the hepatic-bitter tonic use. This mechanism is consistent with the pharmacology of other bitter Asteraceae (chicory, artichoke) and with the TCM clearing-heat-from-liver-channel framing of the same traditional indication. In animal models, dandelion root extracts have demonstrated hepatoprotective effects against carbon tetrachloride-induced hepatotoxicity and against acetaminophen toxicity, consistent with antioxidant and anti-inflammatory mechanisms.{{citation needed}}

'''Anti-inflammatory mechanism'''

Polyphenolic compounds in the leaf and root (including chicoric acid, caffeic acid derivatives, and flavonoids) inhibit pro-inflammatory signaling cascades in cell-culture models, including reduction of LPS-stimulated NF-kB activation and suppression of pro-inflammatory cytokine release.<ref name="jeon2017">Jeon D, Kim SJ, Kim HS. "Anti-inflammatory evaluation of the methanolic extract of ''Taraxacum officinale'' in LPS-stimulated human umbilical vein endothelial cells." BMC Complement Altern Med. 2017;17(1):508. PMID 29187173.</ref> Whether these in vitro effects translate to clinically meaningful anti-inflammatory activity in human tissue remains to be established in powered clinical trials.

'''Prebiotic mechanism (root inulin)'''

Inulin is a well-characterized prebiotic: it selectively promotes the growth of beneficial gut microbiota (principally ''Bifidobacterium'' and ''Lactobacillus'' species) by serving as a fermentable substrate for these organisms while being resistant to digestion by human gut enzymes. The effect is dose-dependent and well-established for inulin regardless of botanical source; dandelion root is one of the most concentrated natural sources of inulin outside chicory root (''Cichorium intybus'') and Jerusalem artichoke (''Helianthus tuberosus'').{{citation needed}}
| indications = '''Diuretic activity: human clinical evidence'''

Clare, Conroy, and Spelman (2009) conducted a single-day human clinical study in 17 healthy volunteers, administering an extract of ''Taraxacum officinale'' leaf (8 ml per dose from a 1:5 infusion) three times over seven hours. Urine volume and urinary frequency increased significantly between the first and second doses and between the second and third doses relative to pre-treatment baseline, demonstrating acute diuretic activity in humans. Urinary excretion of potassium was not significantly depleted, consistent with the leaf's high potassium content counterbalancing urinary losses.<ref name="clare2009">Clare BA, Conroy RS, Spelman K. "The diuretic effect in human subjects of an extract of ''Taraxacum officinale'' folium over a single day." J Altern Complement Med. 2009;15(8):929-934. PMID 19678785.</ref><ref name="raczkotilla1974">Racz-Kotilla E, Racz G, Solomon A. "The action of ''Taraxacum officinale'' extracts on the body weight and diuresis of laboratory animals." Planta Med. 1974;26(3):212-217. PMID 4427955.</ref> This study is single-day and uncontrolled (no parallel placebo arm); it establishes acute diuretic activity but does not address long-term efficacy or comparative effectiveness against synthetic diuretics.

No large-scale randomized controlled trials of dandelion leaf for clinical edema, hypertension, or fluid retention have been published. The clinical evidence base for the diuretic indication is consistent but limited in scale and rigor relative to conventional diuretics.

'''Hepatic and alterative uses: traditional and preclinical evidence only'''

The hepatic-tonic, alterative, and liver-cleansing indications that constitute the principal traditional use of dandelion root do not have a randomized clinical trial evidence base in humans. Animal models show hepatoprotective effects against chemical hepatotoxins; the bitter-tonic mechanism is pharmacologically well-grounded; the cholagogue action is consistent with the class pharmacology of sesquiterpene bitters. The absence of clinical trial data reflects the general underfunding of hepatic herbal medicine research rather than any evidence of inefficacy, but the distinction between traditional use supported by preclinical data and use supported by clinical trials should be maintained in patient-facing communication.

'''Anticancer activity: in vitro studies only'''

Ovadje and colleagues have published a series of in vitro studies demonstrating that aqueous dandelion root extract selectively induces apoptosis in human leukemia cell lines through both intrinsic and extrinsic pathways, without significant toxicity to normal peripheral blood mononuclear cells.<ref name="ovadje2011">Ovadje P, Chatterjee S, Griffin C, Tran C, Hamm C, Pandey S. "Selective induction of apoptosis through activation of caspase-8 in human leukemia cells (Jurkat) by dandelion root extract." J Ethnopharmacol. 2011;133(1):86-91. PMID 20849941.</ref><ref name="ovadje2012">Ovadje P, Hamm C, Pandey S. "Efficient induction of extrinsic cell death by dandelion root extract in human chronic myelomonocytic leukemia (CMML)." PLoS One. 2012;7(2):e30604. PMID 22363452.</ref> These are laboratory findings in cell lines; they do not constitute clinical evidence of anticancer efficacy in humans. No clinical trials of dandelion root extract for cancer treatment have been completed or published. These findings are scientifically interesting and warrant further investigation but should not be represented as clinical evidence of therapeutic effect.
| preparations = Leaf infusion (tea): 4 to 8 g fresh or dried leaves per cup of hot water, steeped covered (volatile constituents are modest; the cover prevents steam loss rather than oil loss). Taken 2 to 3 times daily for diuretic and tonic use; or fresh leaves as salad greens (the traditional spring tonic form, maximally nutritious and minimally processed).

Root decoction: 5 to 10 g dried root in 500 ml water, simmered covered for 15 to 20 minutes; strained and drunk in 2 to 3 portions through the day. The preferred preparation for hepatic-bitter and cholagogue use; suited to the autumn-harvested root with its peak inulin content.

Root tincture: 1:5 in 40 to 45 percent ethanol from dried root; 2 to 5 ml three times daily.

Roasted root "coffee": dried root roasted until dark brown (approximately 200 degrees Celsius, 30 minutes); ground and prepared by decoction or percolation as a coffee substitute. The roasting converts much of the inulin to simpler fructose units and develops the characteristic dark, slightly bitter flavor; the hepatic bitter action is retained at reduced intensity. A gentle daily liver tonic and caffeine-free coffee alternative with a continuous history from World War II rationing.

Root powder: 2 to 4 g per day in capsule or tablet form; convenient standardized option.
| dosing = '''Leaf (diuretic, tonic)'''

Infusion: 4 to 8 g dried leaf per cup, 2 to 3 times daily. Fresh leaf as salad: no formal dose ceiling; traditional seasonal use is ad libitum.

Tincture (1:5 in 40 percent ethanol): 2 to 5 ml three times daily.

'''Root (hepatic-bitter, cholagogue, prebiotic)'''

Decoction: 5 to 10 g dried root per day in divided doses. Tincture (1:5): 2 to 5 ml three times daily. Powder: 2 to 4 g per day.

The traditional distinction between spring-leaf use (diuretic, nutritive tonic) and autumn-root use (hepatic-bitter, prebiotic) reflects genuine pharmacological differences in the plant across seasons and should be preserved in practice where possible.

'''Recreational dose ladder'''

Dandelion has no recreational or psychoactive profile in any documented tradition. Neither the leaf nor the root produces altered consciousness, euphoria, sedation, or any psychoactive effect at any accessible dose. The bitter taste at higher leaf or root doses is limiting; above 10 to 15 g of dried root per day, mild nausea and diarrhea occur as the dose-limiting gastrointestinal effects. No dose ladder is warranted.
| pharmacokinetics = The pharmacokinetics of ''T. officinale'' constituents have not been well characterized. Taraxacoside and related sesquiterpene lactones are likely absorbed from the gastrointestinal tract and undergo hepatic metabolism; the kinetics are not documented to the same standard as pharmaceutical preparations. Inulin from the root is not absorbed -- it passes undigested to the large intestine where it is fermented by colonic microbiota; this is entirely the intended pharmacological mechanism for its prebiotic action rather than a bioavailability problem. Polyphenolic compounds (chicoric acid, caffeic acid derivatives) are absorbed in part from the small intestine and undergo conjugation and methylation by gut enzymes and hepatic CYP enzymes.{{citation needed}}
| interactions = Lithium: dandelion leaf's diuretic action reduces renal lithium clearance (as does any diuretic); this can elevate lithium plasma levels into the toxic range. Patients taking lithium should not use dandelion leaf preparations without medical supervision and lithium-level monitoring.{{citation needed}}

Potassium-sparing diuretics and ACE inhibitors: dandelion leaf's potassium-retaining character combined with potassium-sparing agents (spironolactone, eplerenone) or ACE inhibitors (which reduce urinary potassium excretion) could theoretically produce hyperkalemia in vulnerable patients. The risk is low at typical leaf-infusion doses but warrants monitoring in patients with renal impairment or on potassium-sparing regimens.

Antidiabetic medicines: dandelion has mild blood-glucose-lowering properties in animal models; additive hypoglycemic effect is possible with insulin and oral antidiabetic agents. Monitor blood glucose in diabetic patients who begin regular dandelion use.

Anticoagulants (warfarin): dandelion leaves are very high in vitamin K. Patients on warfarin anticoagulation whose vitamin K intake changes significantly (including by adding large quantities of dandelion leaf to the diet) may experience INR instability. Consistency of intake is more important than avoidance.
| interactionsummary = Lithium: diuresis raises lithium levels (monitor). High vitamin K in leaf: INR variability with warfarin. Additive hypoglycemia possible with antidiabetic medicines.
| counseling = The distinction between leaf and root preparations should be communicated clearly: the diuretic action resides principally in the leaf, and the hepatic-bitter and prebiotic actions in the root. A patient seeking fluid-retention relief should use the leaf infusion; a patient seeking liver support, digestive bitters, or prebiotic gut support should use the root decoction or roasted root.

The potassium-sparing quality of the dandelion leaf diuresis is genuinely clinically relevant and worth explaining to patients who have previously been told to avoid diuretics because of potassium concerns: dandelion leaf does not cause the potassium depletion associated with furosemide or hydrochlorothiazide. This distinction is well-grounded pharmacologically, though the clinical trial evidence is limited in scale.

The anticancer cell-line findings should not be communicated to patients as evidence of clinical efficacy. The in vitro data are preliminary and interesting; no clinical benefit in cancer treatment has been established. Patients with cancer who are interested in dandelion root for general liver support or digestive use (reasonable traditional indications) should be informed of this distinction.

===Safety===

Dandelion is among the safest herbs in the Western pharmacopoeia for adults, children, and in pregnancy. Serious adverse events are not documented in the clinical or case-report literature at standard dietary or medicinal doses.

Gallstones: the root's cholagogue (gallbladder-stimulating) action is the principal safety concern. In patients with known gallstones, particularly large stones or any degree of bile duct obstruction, stimulating gallbladder contraction can precipitate biliary colic. Dandelion root preparations should be used with caution in patients with known cholelithiasis and are contraindicated in patients with obstructive jaundice or bile duct obstruction.

Asteraceae allergy: dandelion is in the same plant family as ragweed (''Ambrosia'' spp.), chamomile, and chrysanthemum. Patients with documented Asteraceae contact or inhalant allergy may have cross-reactive responses to dandelion; this is most relevant for topical use of fresh plant material. Oral ingestion of dandelion in Asteraceae-allergic individuals is generally well-tolerated but warrants initial caution.

Pregnancy and lactation: dandelion leaf and root are used as food and tonic herbs in traditional midwifery without reported harm; the plant is among the herbs most consistently classified as safe in pregnancy at dietary doses. Large-dose medicinal preparations have not been formally evaluated in pregnancy trials.

===Regulatory===

'''Germany'''

German Commission E: dandelion root with herb (Taraxaci radix cum herba) approved for disturbances of bile flow, stimulation of diuresis, loss of appetite, and dyspepsia.

'''European Union'''

EMA HMPC: positive assessment for traditional use of dandelion root and herb for symptomatic treatment of minor digestive disorders (dyspepsia, bloating, flatulence) and as adjuvant for increased urinary output in minor urinary complaints. Traditional use listing under the EU Traditional Herbal Medicinal Products Directive.<ref name=ema-taraxacum>European Union herbal monograph on ''Taraxacum officinale'' F.H. Wigg., radix. EMA/HMPC/475726/2020. Committee on Herbal Medicinal Products (HMPC). https://www.ema.europa.eu/en/medicines/herbal/taraxaci-officinalis-radix</ref>

'''United States'''

Dandelion root and leaf: GRAS (generally recognized as safe) as food; sold as a dietary supplement under DSHEA without FDA evaluation of therapeutic claims.

'''United Kingdom'''

MHRA traditional herbal registration: dandelion root preparations registered for traditional use for relief of minor digestive and urinary complaints.
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Digestive herbs]]
[[Category:Hepatoprotective herbs]]
[[Category:Urological herbs]]
[[Category:Diuretic herbs]]
[[Category:Western clinical herbs]]
[[Category:TCM herbs]]

Lavender

2026-05-26T20:55:20Z

Maintenance script: Move references inside PlantMedTemplate call (fix phantom leading paragraphs)

{{PlantMedTemplate
| name = Lavender
| binomial = Lavandula angustifolia
| family = Lamiaceae
| native_range = Dry calcareous hillsides of the western Mediterranean: Provence (southern France), Spain, northern Italy, Croatia, and Greece; wild populations typically occur at 600 to 1,400 m elevation on exposed limestone garrigue and maquis. Widely cultivated throughout temperate Europe, North America, and Australia; Provence remains the global center of commercial cultivation.
| plant_part = Dried flower (inflorescence); essential oil distilled from fresh flowers.
| image =
| intro = ''Lavandula angustifolia'' Mill. -- true lavender, English lavender -- is a perennial aromatic shrub of the western Mediterranean garrigue, whose name descends from the Latin lavare, to wash, a record of the centuries it spent in the Roman bathhouse before it entered the clinic. Among aromatic herbs it holds a singular evidence record: a standardized oral preparation of its essential oil is the only essential-oil plant medicine to have been evaluated against a prescription anxiolytic in a randomized controlled trial and found non-inferior. Between the Roman bath and that trial stretches two thousand years of uninterrupted medicinal use for the same cluster of indications: anxiety, sleeplessness, and pain of the head.
| history = The name came first. Pliny the Elder in the first century of the common era recorded the use of nardus gallicus -- a lavender relative -- as a bath additive throughout the Roman world, and later writers formalized the association with lavare.{{citation needed}} The Greco-Roman medicinal plant was not ''L. angustifolia'' but its cousin ''Lavandula stoechas'' -- the French or Spanish lavender, high in camphor and pharmacologically distinct -- which Dioscorides in his De Materia Medica (1st century CE) recorded for headache, nausea, and disorders of the lung.{{citation needed}} ''L. angustifolia'' entered European medicine through the medieval monastic garden, where Benedictine and Cistercian communities cultivated it as a strewing herb, a wash for wounds, and a remedy for the head -- the "vapours" of nervous complaint that would occupy it for centuries thereafter.

John Parkinson, the apothecary who served James I, wrote in his Theatrum Botanicum of 1640 that lavender was of "especiall good use for all griefes and paines of the head and brain."{{citation needed}} Tudor England had already made lavender domestic property: lavender water was among the standard preparations of every gentlewoman's stillroom, the dried flowers were stuffed into pillows against insomnia, and bundles were laid between linens to discourage moths -- a use continuous from Roman times. Queen Elizabeth I reportedly consumed lavender conserve daily as a remedy for her migraines.{{citation needed}}

The most consequential accident in the history of aromatherapy occurred in a perfumery laboratory in Lyon, France, around 1910. Rene-Maurice Gattefosse -- a French chemist working in his family's perfume business -- burned his hand severely in a laboratory explosion and plunged it without premeditation into a vessel of lavender oil. The burn, he later wrote, healed with unexpected rapidity and without infection or scarring; the experience convinced him that essential oils deserved systematic clinical study.{{citation needed}} His 1937 monograph Aromatherapie gave the practice its name and established lavender as its founding plant. Robert Tisserand carried Gattefosse's work into the English-speaking world in the 1970s and 1980s, and the aromatherapy tradition -- lavender as wound healer, nerve calmer, sleep inducer -- entered consumer culture on a scale that no other essential oil has matched.{{citation needed}}

The German Commission E formally approved lavender flower for mood disturbances, restlessness, and insomnia in 1990, giving it a regulatory foundation in Germany at a time when most European herbal preparations lacked one. That approval rested on traditional use rather than clinical trial evidence; the trial evidence came later. Schwabe Pharmaceuticals developed Silexan -- a standardized pharmaceutical-grade oral lavender oil capsule -- in the 2000s and conducted a series of randomized controlled trials that collectively produced the most rigorous clinical evidence base of any aromatic herb medicine. The transition from bathhouse plant to evidence-based anxiolytic took roughly two thousand years and one burned hand.
| taxonomy = ''Lavandula angustifolia'' Mill. (synonyms: ''L. officinalis'' Chaix, ''L. vera'' DC.) belongs to tribe Ocimeae, family Lamiaceae, one of approximately 40 species in the genus ''Lavandula''. The genus name derives from lavare (to wash); the species epithet angustifolia (narrow-leaved) distinguishes it from broader-leaved relatives. Four species and one hybrid group carry the majority of commercial and medicinal significance.

''L. angustifolia'', true lavender or English lavender, produces the finest-quality essential oil -- highest in linalool and linalyl acetate, lowest in camphor -- and is the medicinal and perfumery standard against which other species are measured. It is the species from which Silexan is produced.

''L. latifolia'', spike lavender, yields a higher volume of oil per plant but of coarser character: camphor and 1,8-cineole content are markedly higher, linalyl acetate lower; the oil is sharper and used in industrial applications, cheaper perfumery, and traditional preparations distinct from those of angustifolia.

L. x intermedia, lavandin, is a sterile hybrid of angustifolia and latifolia that dominates commercial Provence cultivation today; it produces the greatest oil yield per hectare, and its oil is the principal ingredient in most mass-market lavender products. Lavandin oil is not equivalent to true lavender oil for medicinal purposes: camphor content is substantially higher, and linalyl acetate lower.

''L. stoechas'', French or Spanish lavender, is visually distinguished by its butterfly-wing bracts atop the flower spike; its chemistry diverges considerably from ''L. angustifolia'', being rich in camphor and fenchone. It was the medicinal lavender of Greco-Roman antiquity but is not the species behind modern anxiolytic research or the Western clinical herbal tradition.

The medicinal parts of ''L. angustifolia'' are the dried flower (inflorescence, harvested before full opening to maximize volatile oil content) and the essential oil steam-distilled from fresh flowers. The Pharmacopoeia Europaea monograph ''Lavandula''e flos specifies a minimum essential oil content in the dried inflorescence.{{citation needed}}

Wild ''L. angustifolia'' populations occur on exposed limestone hillsides in Provence, the Apennines, the Dalmatian coast, and the mountains of Spain and Greece. The English Pilgrims transported lavender to New England in 1620; it has naturalized in temperate climates worldwide without becoming invasive.{{citation needed}}
| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lavender occupies the nervine class of Western herbal medicine -- herbs with an affinity for the nervous system -- and has been applied to the same cluster of indications across European herbal traditions for at least several hundred years: anxiety and nervous agitation, insomnia rooted in a restless mind, headache and migraine (particularly those with an anxiety or tension component), nervous indigestion and colic, neuralgia, and the diffuse condition the English herbalists called the "vapours" -- a category of nervous debility and emotional distress that has no exact modern diagnostic equivalent but maps substantially onto generalized anxiety disorder.

The traditional preparation for internal use was an infusion of dried flowers, drunk warm before sleep or during episodes of nervous distress. Lavender water -- a distillate of flowers in water or diluted alcohol -- was applied to the head and temples for headache. The tincture in 40-proof spirit was the apothecary preparation for internal use. The oil, expressed or steam-distilled from flowers, was rubbed onto the temples for headache, onto the chest for nervous respiratory complaints, and onto affected areas for neuralgia and joint pain. Lavender sachets placed in the bed or under the pillow were the traditional sleep aid; clothes stored with dried lavender sprigs were protected from moths. Every one of these forms is continuous in the Western herbal tradition from at least the 16th century.

'''Islamic medicine (Unani)'''

Lavender was known in Arabic-speaking medical traditions under the name Khuzami (Arabic: khuzama) and appears in the Unani materia medica as a cephalic (head-acting) herb, indicated for headache, epilepsy, and melancholy. Ibn Sina (Avicenna), writing in the early 11th century in the Canon of Medicine, recorded lavender for nervous headache and for strengthening the brain.{{citation needed}}

'''Aromatherapy tradition (20th century)'''

Following Gattefosse's 1937 monograph, lavender essential oil became the foundational plant of the French aromatherapy tradition -- used topically and by inhalation for wound healing, burns, antisepsis, anxiety, and sleep. This tradition makes claims for lavender oil that overlap substantially with the traditional Western herbal tradition while adding an emphasis on topical wound-healing that traces directly to Gattefosse's burn. The distinction between aromatherapy (inhalational or topical use of essential oil) and the oral preparations studied in clinical trials is pharmacologically important and is addressed in the Clinical evidence section.
| pharmacology = '''Volatile oil constituents and mechanism'''

The essential oil of ''L. angustifolia'' consists primarily of linalool (25 to 45 percent), a monoterpene alcohol, and linalyl acetate (25 to 45 percent), its acetic acid ester.{{citation needed}} These two compounds account for the characteristic lavender fragrance and are the principal pharmacologically active constituents in oral Silexan. Camphor and 1,8-cineole -- constituents responsible for the sharper character of inferior species and for adulteration of true lavender oil with cheaper lavandin -- are present at less than one and less than two percent respectively in genuine ''L. angustifolia'' oil, and their presence in high concentration is a marker of species substitution or adulteration.

At the receptor level, two principal mechanisms have been characterized for the oral route.

GABA-A positive allosteric modulation: linalool and linalyl acetate act as positive allosteric modulators at the GABA-A receptor in a manner broadly analogous to benzodiazepines -- increasing chloride conductance and reducing neuronal excitability -- but at a binding site distinct from the classical benzodiazepine site.{{citation needed}}

Voltage-gated calcium channel inhibition: linalool inhibits voltage-gated calcium channels (VGCCs) in hippocampal neurons, reducing presynaptic calcium influx and the release of excitatory neurotransmitters; this mechanism is distinct from and additive with the GABA-A effect and may account for some specificity of anxiolytic action without the full benzodiazepine-receptor pharmacology.{{citation needed}}

The dual GABA-A and VGCC mechanism explains a feature of Silexan's clinical profile that distinguishes it from classical benzodiazepines: no confirmed abuse potential, no withdrawal syndrome on discontinuation, and no evidence of tolerance in studies up to ten weeks.

Inhalation delivers linalool and linalyl acetate via the olfactory mucosa and pulmonary absorption, with systemic concentrations substantially lower than oral administration; this accounts for the smaller effect sizes in aromatherapy trials relative to oral Silexan studies. The two routes are pharmacologically comparable in target but not in pharmacokinetic exposure.

Topically, lavender essential oil has demonstrated broad-spectrum antibacterial and antifungal activity in vitro, including against methicillin-resistant ''Staphylococcus aureus'' (MRSA) and ''Candida albicans'', via disruption of microbial cell membrane integrity; wound-healing acceleration has been shown in animal models.{{citation needed}}
| clinical_evidence = The clinical evidence base for lavender divides sharply along route of administration. Oral Silexan (standardized lavender oil, 80 mg/day) has been evaluated in a series of double-blind randomized controlled trials; inhalation aromatherapy has been evaluated in a larger number of smaller trials with more modest and more variable effect sizes. The two evidence bodies should not be conflated.

'''Oral Silexan: randomized controlled trials'''

The Woelk and Schlaefke (2010) trial was the first to compare Silexan directly with a prescription anxiolytic. Patients with mixed anxiety and restlessness were randomized to Silexan 80 mg/day or lorazepam 0.5 mg/day for ten weeks; the primary outcome was reduction in Hamilton Anxiety Scale (HAM-A) total score. Silexan was non-inferior to lorazepam: HAM-A total score fell by 45 percent from baseline in the Silexan group and 46 percent in the lorazepam group, a difference that was not statistically significant. Silexan patients reported no withdrawal symptoms or signs of dependence on discontinuation.<ref name="woelk2010">Woelk H, Schlaefke S. "A multi-centre, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder." Phytomedicine. 2010;17(2):94-99. PMID 19962288.</ref>

Kasper and colleagues (2010) evaluated Silexan 80 mg/day against placebo in patients with subthreshold anxiety disorder -- a category of clinically significant anxiety not meeting full diagnostic criteria for generalized anxiety disorder -- over ten weeks. Silexan produced significant reductions in HAM-A total score, HAM-A psychic anxiety subscale, and Pittsburgh Sleep Quality Index compared with placebo; the effect was apparent by week two and maintained through week ten.<ref name="kasper2010">Kasper S, Gastpar M, Muller WE, et al. "Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder: evidence from clinical trials." Wien Med Wochenschr. 2010;160(21-22):547-556. PMID 21170695.</ref>

The most definitive comparative trial came in 2014. Kasper and colleagues randomized 539 patients with generalized anxiety disorder to Silexan 80 mg/day or paroxetine 20 mg/day for ten weeks. On HAM-A total score reduction, Silexan was non-inferior to paroxetine; secondary outcomes including the Beck Anxiety Inventory and clinical global assessment showed comparable improvement. Silexan's tolerability profile was markedly more favorable: the paroxetine arm showed higher rates of sexual dysfunction and nausea.<ref name="kasper2014">Kasper S, Gastpar M, Muller WE, et al. "Lavender oil preparation Silexan is effective in generalized anxiety disorder -- a randomized, double-blind comparison to placebo and paroxetine." Int J Neuropsychopharmacol. 2014;17(6):859-869. PMID 24456909.</ref>

A 2023 meta-analysis pooled data from randomized placebo-controlled trials of Silexan across anxiety disorder categories and found consistent, statistically significant superiority over placebo on standardized anxiety measures, with a standardized mean difference of clinically meaningful magnitude.<ref name="meta2023">Kasper S, et al. "Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials." Eur Neuropsychopharmacol. 2023;66:71-82. PMID 36717399.</ref>

A 2021 double-blind crossover trial in healthy recreational polydrug users found no evidence of abuse potential for Silexan at 80 mg or 160 mg -- no drug-liking, no euphoria, no psychomotor impairment, and no craving on discontinuation -- establishing Silexan's anxiolytic effect as non-addictive and distinguishing it from benzodiazepines at a pharmacological and behavioral level.<ref name="abuse2021">Schlaefke S, et al. "No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial." J Psychopharmacol. 2021. PMID 33300578.</ref>

'''Inhalation aromatherapy: smaller and more varied evidence'''

A body of smaller randomized trials -- in postoperative patients, dental-procedure anxiety, neonatal intensive care, and sleep quality in elderly populations -- has found statistically significant but modest anxiolytic and sleep-promoting effects from lavender inhalation or topical application in carrier oil. Effect sizes in aromatherapy trials are generally smaller than in the oral Silexan trials, study populations are more heterogeneous, and blinding is inherently imperfect given lavender's recognizable odor. The evidence supports lavender aromatherapy as an adjunct for mild situational anxiety and sleep disturbance; it does not support it as a primary treatment for generalized anxiety disorder at the level established for oral Silexan.{{citation needed}}

One small randomized trial evaluated lavender essential oil inhalation at the onset of acute migraine headache and found statistically significant reduction in headache severity compared with a placebo inhalation control; sample sizes were insufficient for definitive conclusions and the study has not been replicated at scale.<ref name="sasannejad2012">Sasannejad P, Saeedi M, Shoeibi A, Gorji A. "Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial." Eur Neurol. 2012;67(5):288-291. PMID 22517298.</ref>

The antimicrobial activity documented in vitro -- including activity against MRSA -- has not been translated into powered clinical trials. The topical wound-healing tradition has animal-model support but no placebo-controlled clinical trial data in humans.
| preparations = Dried flower (inflorescence): harvested before full bloom, dried at low temperature to preserve volatile oil; used for infusion, sachets, and as the starting material for tincture and essential oil production. Genuine lavender flower carries an immediately recognizable sweet-floral fragrance without camphor sharpness; camphoraceous character indicates ''L. latifolia'' or lavandin substitution.

Essential oil: steam-distilled from fresh flowers; genuine ''L. angustifolia'' oil contains 25 to 45 percent linalool and 25 to 45 percent linalyl acetate, with camphor below 1 percent; these parameters distinguish true lavender from adulterated or substitute species. For topical use, always dilute in carrier oil (2 to 5 percent); neat application to intact skin carries some allergy risk even with true lavender oil, and dilution is the standard of practice.

Silexan (brand name Lasea; Schwabe Pharmaceuticals): a standardized pharmaceutical-grade oral lavender oil capsule formulated for gastrointestinal absorption; manufactured at pharmaceutical quality standards with defined linalool and linalyl acetate content. This preparation is not equivalent to and should not be substituted by tipping commercial essential oil into food or capsules: solubility, concentration, solvent matrix, and quality standards differ fundamentally. Silexan is a prescription medicinal product in Germany.

Tincture: 1:5 in 40 percent ethanol from dried flowers; the traditional apothecary form for internal use.

Hydrosol (lavender water): the aqueous condensate separated from essential oil during steam distillation; contains trace quantities of volatile oil in aqueous suspension; used topically in cosmetics and as a facial toner; not concentrated enough for pharmacological effects of the essential oil.

Dried sachet: flowers loosely packed in muslin or linen, placed in drawers, linen closets, or under pillows; a traditional and household preparation continuous in use for sleep and moth-repellent purposes from at least the medieval period.
| dosing = '''Internal preparations'''

Infusion (dried flower): 1 to 2 g dried flowers per cup of hot water, steeped 10 to 15 minutes; taken 2 to 3 times daily and at bedtime for sleep. Traditional dose with no robust clinical trial evidence for this form; the Commission E approval covers this preparation based on traditional use.

Tincture (1:5 in 40 percent ethanol): 0.5 to 1 teaspoon (2.5 to 5 ml) diluted in a small amount of water, taken 2 to 3 times daily. Traditional dose with no clinical trial evidence independent of the Silexan data.

Silexan oral capsule: 80 mg once daily, the dose used in all published RCTs; some protocols have used 160 mg/day for more severe anxiety without identified additional harm. Take with food. Clinical benefit in GAD trials was apparent by week two and fully established by week four to six.

'''External preparations'''

Essential oil topical: 5 to 10 drops (0.25 to 0.5 ml) diluted in 1 tablespoon (15 ml) carrier oil (yielding approximately 2 to 3 percent); applied by massage to affected area. Aromatherapy diffusion: 3 to 5 drops in 15 ml water in a cold-air diffuser in the bedroom at night. Traditional sleep preparation: 3 to 5 drops essential oil on a cotton ball placed on the pillow, or a dried lavender sachet under the pillow.

'''Recreational dose ladder'''

Lavender carries no established recreational dose structure in the ethnopharmacological or self-dosing literature. The anxiolytic and sedative ceiling at therapeutic doses is modest: Silexan at 80 mg/day produces an effect non-inferior to lorazepam 0.5 mg/day but does not produce sedation sufficient to impair cognition or function in the RCT population. Dose escalation beyond 160 mg/day oral (twice the standard dose) has not been systematically studied and produces no documented psychoactive intensification; the pharmacology -- GABA-A allosteric modulation and VGCC inhibition without direct GABA-A agonism -- predicts a dose-effect plateau rather than progressive deepening of central depression. No recreational culture of lavender use analogous to kava, valerian, or cannabis has been documented in any ethnobotanical or contemporary context. The essential oil used as an inhalant produces transient relaxation but no psychoactive profile warranting a tiered dose ladder.
| pharmacokinetics = Linalool and linalyl acetate in Silexan are absorbed from the gastrointestinal tract following oral administration; linalyl acetate undergoes hydrolysis to linalool in the gut and by plasma esterases, such that linalool is the principal circulating species. Peak plasma concentrations are reached approximately 30 to 90 minutes after oral dosing.{{citation needed}} Linalool undergoes hepatic metabolism via cytochrome P450-mediated hydroxylation and glucuronidation; the metabolites are excreted renally. No significant accumulation has been reported at 80 mg/day dosing.

Following inhalation, linalool is absorbed via the pulmonary mucosa and by olfactory epithelium; plasma concentrations are substantially lower than after oral administration of an equivalent linalool dose, consistent with the smaller effect sizes observed in aromatherapy relative to oral-Silexan trials.
| interactions = Central nervous system depressants: theoretical additive sedation with benzodiazepines, alcohol, opioid analgesics, barbiturates, antihistamines, and sedating herbal medicines including valerian (''Valeriana officinalis''), kava (''Piper methysticum''), hops (''Humulus lupulus''), and passionflower (''Passiflora incarnata''). The clinical significance of this interaction at Silexan's standard 80 mg/day dose has not been formally evaluated; caution is appropriate when combining Silexan with benzodiazepines in patients transitioning from one agent to the other. The Woelk and Schlaefke (2010) trial documented successful lorazepam discontinuation in patients switched to Silexan,<ref name="woelk2010"/> suggesting that substitution is clinically feasible, but cross-tapering should be supervised.

Cytochrome P450: in vitro data at suprapharmacological concentrations suggest possible inhibition of CYP2C9 and CYP3A4 by lavender oil constituents. No pharmacokinetic interaction has been documented in clinical trials at 80 mg/day; the relevance of in vitro findings to standard clinical dosing is uncertain. No dose adjustment of co-administered medicines is presently supported by clinical evidence.
| interactionsummary = Additive CNS depression with sedatives, anxiolytics, alcohol, and sedating herbal medicines. No confirmed cytochrome P450 interaction at therapeutic dose.
| safety = Silexan at 80 mg/day has been well tolerated in all published RCTs, with no serious adverse events attributed to the study medicine. The most commonly reported adverse effects have been mild gastrointestinal symptoms (nausea, belching with lavender odor) and headache, each occurring at low incidence and resolving without intervention.

Prepubertal gynecomastia: Henley, Lipson, and Korach (2007) reported three cases of prepubertal boys who developed gynecomastia while using topical products containing lavender oil and tea tree oil; gynecomastia resolved in each case on discontinuation of the products. In vitro experiments demonstrated estrogenic and anti-androgenic activity of both lavender oil and tea tree oil at the tested concentrations.<ref name="henley2007">Henley DV, Lipson N, Korach KS, Bloch CA. "Prepubertal gynecomastia linked to lavender and tea tree oils." N Engl J Med. 2007;356(5):479-485. PMID 17267908.</ref> Subsequent epidemiological study has not confirmed a population-level signal; the three case reports represent a potential association rather than an established causal relationship. Conservative practice: avoid heavy chronic daily application of lavender oil-containing products to the skin of prepubertal boys.

Allergic contact dermatitis: linalool undergoes autooxidation in stored, poorly sealed, or heat-exposed essential oil, generating linalool hydroperoxide and other sensitizing oxidation products. Sensitization acquired through repeated exposure to oxidized lavender oil is permanent and subsequent exposures produce contact dermatitis. Properly stored, freshly purchased true lavender oil from a reputable supplier has low sensitization risk. This concern is among the more clinically relevant safety issues with topical lavender use; lavender is among the more common causes of fragrance-related contact sensitization in Europe.{{citation needed}}

Essential oil ingestion (non-Silexan): tipping lavender essential oil from a commercial aromatherapy bottle into food or beverages or swallowing it directly is not equivalent to Silexan and is not recommended. Case reports of oral essential oil ingestion -- in children accessing essential oil bottles -- have documented CNS depression and respiratory distress. Silexan is a specifically formulated pharmaceutical-grade oral preparation; the distinction between this and ad hoc oral consumption of essential oil is not cosmetic.

Pregnancy: Silexan trials have excluded pregnant participants; safety data for oral lavender oil preparations in pregnancy are absent. Ordinary aromatherapy use (inhalation at ambient concentrations, topical application in diluted carrier oil) is generally considered low risk but is not supported by trial data. High-dose oral preparations should be avoided in pregnancy in the absence of safety information.
| monitoring = No specific monitoring required for lavender flower infusion or tincture at traditional doses. Patients beginning Silexan 80 mg/day for generalized anxiety disorder: clinical assessment at two to four weeks to establish early response; continue through six weeks before assessing non-response. Patients with benzodiazepine dependence who are transitioning to Silexan should be supervised: cross-tapering under medical guidance is appropriate given the theoretical additive sedation risk during any overlap period.
| counseling = Patients beginning Silexan should understand that it is derived from lavender essential oil but is not equivalent to lavender aromatherapy: the clinical evidence for anxiety comes specifically from the oral capsule formulation at 80 mg/day, not from diffusers, massage oils, or pillow sprays. Benefit may take two to four weeks to become fully apparent; onset latency resembles that of SSRIs more closely than the immediate sedation of benzodiazepines.

The absence of dependence potential and withdrawal symptoms distinguishes Silexan from benzodiazepines. Patients anxious about benzodiazepine dependence or who have not tolerated them may find this distinction meaningful.

Patients using lavender essential oil products topically should use oils that are fresh, correctly stored (sealed, cool, and dark), and diluted in carrier oil for skin application; undiluted application to large skin areas over prolonged periods carries higher sensitization risk. Old or discolored essential oil should be discarded.

The prepubertal gynecomastia concern is worth mentioning to parents of boys who ask about lavender products; the evidence is from case reports rather than epidemiological studies, and the risk is not quantified, but the in vitro endocrine activity establishes a biologically plausible mechanism.
| regulatory = '''Germany and European Union'''

German Commission E (1990): lavender flower approved for mood disturbances with restlessness and sleep disturbances, and nervous stomach conditions; covers traditional oral preparations (infusion, tincture) based on traditional use rather than clinical trial evidence.

EMA HMPC: positive assessment of lavender flower as a traditional herbal medicinal product for mild anxiety and sleep disturbance; traditional use listing under the EU Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC). The EMA HMPC opinion does not cover Silexan, which was developed and approved as a distinct pharmaceutical medicinal product under a separate regulatory pathway.<ref name="ema-hmpc-lavender">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on ''Lavandula angustifolia'' P. Mill., flos. EMA/HMPC/734125/2010. First published: 13 June 2012. https://www.ema.europa.eu/en/medicines/herbal/lavandulae-flos.</ref>

Silexan (Lasea; Schwabe Pharmaceuticals): approved as a prescription medicinal product (not a traditional herbal product) in Germany and some other EU member states specifically for the treatment of generalized anxiety disorder, based on the RCT program described above. This is the most stringent regulatory status achieved by any essential-oil preparation in the EU regulatory framework.

'''United States'''

Lavender oil: GRAS (generally recognized as safe) status with the US FDA as a food flavoring additive; no approved therapeutic indication. Sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) without FDA evaluation of efficacy claims.

'''United Kingdom'''

MHRA traditional herbal registration: lavender preparations registered for traditional use for mild anxiety and sleep disturbance under the Traditional Herbal Registration scheme.
| history =
| effects =
| traditional_geography =
| anecdotes =
| references = <references/>
}}

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Lavender

2026-05-26T18:01:55Z

Maintenance script: parser-claude: REVERT accidental blanking from prior null-edit attempt; restoring rev 7054 (last MDElliottMD edit). Apologies.

{{PlantMedTemplate
| name = Lavender
| binomial = Lavandula angustifolia
| family = Lamiaceae
| native_range = Dry calcareous hillsides of the western Mediterranean: Provence (southern France), Spain, northern Italy, Croatia, and Greece; wild populations typically occur at 600 to 1,400 m elevation on exposed limestone garrigue and maquis. Widely cultivated throughout temperate Europe, North America, and Australia; Provence remains the global center of commercial cultivation.
| plant_part = Dried flower (inflorescence); essential oil distilled from fresh flowers.
| image =
| intro = Lavandula angustifolia Mill. -- true lavender, English lavender -- is a perennial aromatic shrub of the western Mediterranean garrigue, whose name descends from the Latin lavare, to wash, a record of the centuries it spent in the Roman bathhouse before it entered the clinic. Among aromatic herbs it holds a singular evidence record: a standardized oral preparation of its essential oil is the only essential-oil plant medicine to have been evaluated against a prescription anxiolytic in a randomized controlled trial and found non-inferior. Between the Roman bath and that trial stretches two thousand years of uninterrupted medicinal use for the same cluster of indications: anxiety, sleeplessness, and pain of the head.

| history = The name came first. Pliny the Elder in the first century of the common era recorded the use of nardus gallicus -- a lavender relative -- as a bath additive throughout the Roman world, and later writers formalized the association with lavare.{{citation needed}} The Greco-Roman medicinal plant was not L. angustifolia but its cousin Lavandula stoechas -- the French or Spanish lavender, high in camphor and pharmacologically distinct -- which Dioscorides in his De Materia Medica (1st century CE) recorded for headache, nausea, and disorders of the lung.{{citation needed}} L. angustifolia entered European medicine through the medieval monastic garden, where Benedictine and Cistercian communities cultivated it as a strewing herb, a wash for wounds, and a remedy for the head -- the "vapours" of nervous complaint that would occupy it for centuries thereafter.

John Parkinson, the apothecary who served James I, wrote in his Theatrum Botanicum of 1640 that lavender was of "especiall good use for all griefes and paines of the head and brain."{{citation needed}} Tudor England had already made lavender domestic property: lavender water was among the standard preparations of every gentlewoman's stillroom, the dried flowers were stuffed into pillows against insomnia, and bundles were laid between linens to discourage moths -- a use continuous from Roman times. Queen Elizabeth I reportedly consumed lavender conserve daily as a remedy for her migraines.{{citation needed}}

The most consequential accident in the history of aromatherapy occurred in a perfumery laboratory in Lyon, France, around 1910. Rene-Maurice Gattefosse -- a French chemist working in his family's perfume business -- burned his hand severely in a laboratory explosion and plunged it without premeditation into a vessel of lavender oil. The burn, he later wrote, healed with unexpected rapidity and without infection or scarring; the experience convinced him that essential oils deserved systematic clinical study.{{citation needed}} His 1937 monograph Aromatherapie gave the practice its name and established lavender as its founding plant. Robert Tisserand carried Gattefosse's work into the English-speaking world in the 1970s and 1980s, and the aromatherapy tradition -- lavender as wound healer, nerve calmer, sleep inducer -- entered consumer culture on a scale that no other essential oil has matched.{{citation needed}}

The German Commission E formally approved lavender flower for mood disturbances, restlessness, and insomnia in 1990, giving it a regulatory foundation in Germany at a time when most European herbal preparations lacked one. That approval rested on traditional use rather than clinical trial evidence; the trial evidence came later. Schwabe Pharmaceuticals developed Silexan -- a standardized pharmaceutical-grade oral lavender oil capsule -- in the 2000s and conducted a series of randomized controlled trials that collectively produced the most rigorous clinical evidence base of any aromatic herb medicine. The transition from bathhouse plant to evidence-based anxiolytic took roughly two thousand years and one burned hand.

| taxonomy = Lavandula angustifolia Mill. (synonyms: L. officinalis Chaix, L. vera DC.) belongs to tribe Ocimeae, family Lamiaceae, one of approximately 40 species in the genus Lavandula. The genus name derives from lavare (to wash); the species epithet angustifolia (narrow-leaved) distinguishes it from broader-leaved relatives. Four species and one hybrid group carry the majority of commercial and medicinal significance.

L. angustifolia, true lavender or English lavender, produces the finest-quality essential oil -- highest in linalool and linalyl acetate, lowest in camphor -- and is the medicinal and perfumery standard against which other species are measured. It is the species from which Silexan is produced.

L. latifolia, spike lavender, yields a higher volume of oil per plant but of coarser character: camphor and 1,8-cineole content are markedly higher, linalyl acetate lower; the oil is sharper and used in industrial applications, cheaper perfumery, and traditional preparations distinct from those of angustifolia.

L. x intermedia, lavandin, is a sterile hybrid of angustifolia and latifolia that dominates commercial Provence cultivation today; it produces the greatest oil yield per hectare, and its oil is the principal ingredient in most mass-market lavender products. Lavandin oil is not equivalent to true lavender oil for medicinal purposes: camphor content is substantially higher, and linalyl acetate lower.

L. stoechas, French or Spanish lavender, is visually distinguished by its butterfly-wing bracts atop the flower spike; its chemistry diverges considerably from L. angustifolia, being rich in camphor and fenchone. It was the medicinal lavender of Greco-Roman antiquity but is not the species behind modern anxiolytic research or the Western clinical herbal tradition.

The medicinal parts of L. angustifolia are the dried flower (inflorescence, harvested before full opening to maximize volatile oil content) and the essential oil steam-distilled from fresh flowers. The Pharmacopoeia Europaea monograph Lavandulae flos specifies a minimum essential oil content in the dried inflorescence.{{citation needed}}

Wild L. angustifolia populations occur on exposed limestone hillsides in Provence, the Apennines, the Dalmatian coast, and the mountains of Spain and Greece. The English Pilgrims transported lavender to New England in 1620; it has naturalized in temperate climates worldwide without becoming invasive.{{citation needed}}

| traditional_uses = '''Western herbal medicine (primary centroid)'''

Lavender occupies the nervine class of Western herbal medicine -- herbs with an affinity for the nervous system -- and has been applied to the same cluster of indications across European herbal traditions for at least several hundred years: anxiety and nervous agitation, insomnia rooted in a restless mind, headache and migraine (particularly those with an anxiety or tension component), nervous indigestion and colic, neuralgia, and the diffuse condition the English herbalists called the "vapours" -- a category of nervous debility and emotional distress that has no exact modern diagnostic equivalent but maps substantially onto generalized anxiety disorder.

The traditional preparation for internal use was an infusion of dried flowers, drunk warm before sleep or during episodes of nervous distress. Lavender water -- a distillate of flowers in water or diluted alcohol -- was applied to the head and temples for headache. The tincture in 40-proof spirit was the apothecary preparation for internal use. The oil, expressed or steam-distilled from flowers, was rubbed onto the temples for headache, onto the chest for nervous respiratory complaints, and onto affected areas for neuralgia and joint pain. Lavender sachets placed in the bed or under the pillow were the traditional sleep aid; clothes stored with dried lavender sprigs were protected from moths. Every one of these forms is continuous in the Western herbal tradition from at least the 16th century.

'''Islamic medicine (Unani)'''

Lavender was known in Arabic-speaking medical traditions under the name Khuzami (Arabic: khuzama) and appears in the Unani materia medica as a cephalic (head-acting) herb, indicated for headache, epilepsy, and melancholy. Ibn Sina (Avicenna), writing in the early 11th century in the Canon of Medicine, recorded lavender for nervous headache and for strengthening the brain.{{citation needed}}

'''Aromatherapy tradition (20th century)'''

Following Gattefosse's 1937 monograph, lavender essential oil became the foundational plant of the French aromatherapy tradition -- used topically and by inhalation for wound healing, burns, antisepsis, anxiety, and sleep. This tradition makes claims for lavender oil that overlap substantially with the traditional Western herbal tradition while adding an emphasis on topical wound-healing that traces directly to Gattefosse's burn. The distinction between aromatherapy (inhalational or topical use of essential oil) and the oral preparations studied in clinical trials is pharmacologically important and is addressed in the Clinical evidence section.

| pharmacology = '''Volatile oil constituents and mechanism'''

The essential oil of L. angustifolia consists primarily of linalool (25 to 45 percent), a monoterpene alcohol, and linalyl acetate (25 to 45 percent), its acetic acid ester.{{citation needed}} These two compounds account for the characteristic lavender fragrance and are the principal pharmacologically active constituents in oral Silexan. Camphor and 1,8-cineole -- constituents responsible for the sharper character of inferior species and for adulteration of true lavender oil with cheaper lavandin -- are present at less than one and less than two percent respectively in genuine L. angustifolia oil, and their presence in high concentration is a marker of species substitution or adulteration.

At the receptor level, two principal mechanisms have been characterized for the oral route.

GABA-A positive allosteric modulation: linalool and linalyl acetate act as positive allosteric modulators at the GABA-A receptor in a manner broadly analogous to benzodiazepines -- increasing chloride conductance and reducing neuronal excitability -- but at a binding site distinct from the classical benzodiazepine site.{{citation needed}}

Voltage-gated calcium channel inhibition: linalool inhibits voltage-gated calcium channels (VGCCs) in hippocampal neurons, reducing presynaptic calcium influx and the release of excitatory neurotransmitters; this mechanism is distinct from and additive with the GABA-A effect and may account for some specificity of anxiolytic action without the full benzodiazepine-receptor pharmacology.{{citation needed}}

The dual GABA-A and VGCC mechanism explains a feature of Silexan's clinical profile that distinguishes it from classical benzodiazepines: no confirmed abuse potential, no withdrawal syndrome on discontinuation, and no evidence of tolerance in studies up to ten weeks.

Inhalation delivers linalool and linalyl acetate via the olfactory mucosa and pulmonary absorption, with systemic concentrations substantially lower than oral administration; this accounts for the smaller effect sizes in aromatherapy trials relative to oral Silexan studies. The two routes are pharmacologically comparable in target but not in pharmacokinetic exposure.

Topically, lavender essential oil has demonstrated broad-spectrum antibacterial and antifungal activity in vitro, including against methicillin-resistant Staphylococcus aureus (MRSA) and Candida albicans, via disruption of microbial cell membrane integrity; wound-healing acceleration has been shown in animal models.{{citation needed}}

| clinical_evidence = The clinical evidence base for lavender divides sharply along route of administration. Oral Silexan (standardized lavender oil, 80 mg/day) has been evaluated in a series of double-blind randomized controlled trials; inhalation aromatherapy has been evaluated in a larger number of smaller trials with more modest and more variable effect sizes. The two evidence bodies should not be conflated.

'''Oral Silexan: randomized controlled trials'''

The Woelk and Schlaefke (2010) trial was the first to compare Silexan directly with a prescription anxiolytic. Patients with mixed anxiety and restlessness were randomized to Silexan 80 mg/day or lorazepam 0.5 mg/day for ten weeks; the primary outcome was reduction in Hamilton Anxiety Scale (HAM-A) total score. Silexan was non-inferior to lorazepam: HAM-A total score fell by 45 percent from baseline in the Silexan group and 46 percent in the lorazepam group, a difference that was not statistically significant. Silexan patients reported no withdrawal symptoms or signs of dependence on discontinuation.<ref name="woelk2010">Woelk H, Schlaefke S. "A multi-centre, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder." Phytomedicine. 2010;17(2):94-99. PMID 19962288.</ref>

Kasper and colleagues (2010) evaluated Silexan 80 mg/day against placebo in patients with subthreshold anxiety disorder -- a category of clinically significant anxiety not meeting full diagnostic criteria for generalized anxiety disorder -- over ten weeks. Silexan produced significant reductions in HAM-A total score, HAM-A psychic anxiety subscale, and Pittsburgh Sleep Quality Index compared with placebo; the effect was apparent by week two and maintained through week ten.<ref name="kasper2010">Kasper S, Gastpar M, Muller WE, et al. "Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder: evidence from clinical trials." Wien Med Wochenschr. 2010;160(21-22):547-556. PMID 21170695.</ref>

The most definitive comparative trial came in 2014. Kasper and colleagues randomized 539 patients with generalized anxiety disorder to Silexan 80 mg/day or paroxetine 20 mg/day for ten weeks. On HAM-A total score reduction, Silexan was non-inferior to paroxetine; secondary outcomes including the Beck Anxiety Inventory and clinical global assessment showed comparable improvement. Silexan's tolerability profile was markedly more favorable: the paroxetine arm showed higher rates of sexual dysfunction and nausea.<ref name="kasper2014">Kasper S, Gastpar M, Muller WE, et al. "Lavender oil preparation Silexan is effective in generalized anxiety disorder -- a randomized, double-blind comparison to placebo and paroxetine." Int J Neuropsychopharmacol. 2014;17(6):859-869. PMID 24456909.</ref>

A 2023 meta-analysis pooled data from randomized placebo-controlled trials of Silexan across anxiety disorder categories and found consistent, statistically significant superiority over placebo on standardized anxiety measures, with a standardized mean difference of clinically meaningful magnitude.<ref name="meta2023">Kasper S, et al. "Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials." Eur Neuropsychopharmacol. 2023;66:71-82. PMID 36717399.</ref>

A 2021 double-blind crossover trial in healthy recreational polydrug users found no evidence of abuse potential for Silexan at 80 mg or 160 mg -- no drug-liking, no euphoria, no psychomotor impairment, and no craving on discontinuation -- establishing Silexan's anxiolytic effect as non-addictive and distinguishing it from benzodiazepines at a pharmacological and behavioral level.<ref name="abuse2021">Schlaefke S, et al. "No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial." J Psychopharmacol. 2021. PMID 33300578.</ref>

'''Inhalation aromatherapy: smaller and more varied evidence'''

A body of smaller randomized trials -- in postoperative patients, dental-procedure anxiety, neonatal intensive care, and sleep quality in elderly populations -- has found statistically significant but modest anxiolytic and sleep-promoting effects from lavender inhalation or topical application in carrier oil. Effect sizes in aromatherapy trials are generally smaller than in the oral Silexan trials, study populations are more heterogeneous, and blinding is inherently imperfect given lavender's recognizable odor. The evidence supports lavender aromatherapy as an adjunct for mild situational anxiety and sleep disturbance; it does not support it as a primary treatment for generalized anxiety disorder at the level established for oral Silexan.{{citation needed}}

One small randomized trial evaluated lavender essential oil inhalation at the onset of acute migraine headache and found statistically significant reduction in headache severity compared with a placebo inhalation control; sample sizes were insufficient for definitive conclusions and the study has not been replicated at scale.<ref name="sasannejad2012">Sasannejad P, Saeedi M, Shoeibi A, Gorji A. "Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial." Eur Neurol. 2012;67(5):288-291. PMID 22517298.</ref>

The antimicrobial activity documented in vitro -- including activity against MRSA -- has not been translated into powered clinical trials. The topical wound-healing tradition has animal-model support but no placebo-controlled clinical trial data in humans.

| preparations = Dried flower (inflorescence): harvested before full bloom, dried at low temperature to preserve volatile oil; used for infusion, sachets, and as the starting material for tincture and essential oil production. Genuine lavender flower carries an immediately recognizable sweet-floral fragrance without camphor sharpness; camphoraceous character indicates L. latifolia or lavandin substitution.

Essential oil: steam-distilled from fresh flowers; genuine L. angustifolia oil contains 25 to 45 percent linalool and 25 to 45 percent linalyl acetate, with camphor below 1 percent; these parameters distinguish true lavender from adulterated or substitute species. For topical use, always dilute in carrier oil (2 to 5 percent); neat application to intact skin carries some allergy risk even with true lavender oil, and dilution is the standard of practice.

Silexan (brand name Lasea; Schwabe Pharmaceuticals): a standardized pharmaceutical-grade oral lavender oil capsule formulated for gastrointestinal absorption; manufactured at pharmaceutical quality standards with defined linalool and linalyl acetate content. This preparation is not equivalent to and should not be substituted by tipping commercial essential oil into food or capsules: solubility, concentration, solvent matrix, and quality standards differ fundamentally. Silexan is a prescription medicinal product in Germany.

Tincture: 1:5 in 40 percent ethanol from dried flowers; the traditional apothecary form for internal use.

Hydrosol (lavender water): the aqueous condensate separated from essential oil during steam distillation; contains trace quantities of volatile oil in aqueous suspension; used topically in cosmetics and as a facial toner; not concentrated enough for pharmacological effects of the essential oil.

Dried sachet: flowers loosely packed in muslin or linen, placed in drawers, linen closets, or under pillows; a traditional and household preparation continuous in use for sleep and moth-repellent purposes from at least the medieval period.

| dosing = '''Internal preparations'''

Infusion (dried flower): 1 to 2 g dried flowers per cup of hot water, steeped 10 to 15 minutes; taken 2 to 3 times daily and at bedtime for sleep. Traditional dose with no robust clinical trial evidence for this form; the Commission E approval covers this preparation based on traditional use.

Tincture (1:5 in 40 percent ethanol): 0.5 to 1 teaspoon (2.5 to 5 ml) diluted in a small amount of water, taken 2 to 3 times daily. Traditional dose with no clinical trial evidence independent of the Silexan data.

Silexan oral capsule: 80 mg once daily, the dose used in all published RCTs; some protocols have used 160 mg/day for more severe anxiety without identified additional harm. Take with food. Clinical benefit in GAD trials was apparent by week two and fully established by week four to six.

'''External preparations'''

Essential oil topical: 5 to 10 drops (0.25 to 0.5 ml) diluted in 1 tablespoon (15 ml) carrier oil (yielding approximately 2 to 3 percent); applied by massage to affected area. Aromatherapy diffusion: 3 to 5 drops in 15 ml water in a cold-air diffuser in the bedroom at night. Traditional sleep preparation: 3 to 5 drops essential oil on a cotton ball placed on the pillow, or a dried lavender sachet under the pillow.

'''Recreational dose ladder'''

Lavender carries no established recreational dose structure in the ethnopharmacological or self-dosing literature. The anxiolytic and sedative ceiling at therapeutic doses is modest: Silexan at 80 mg/day produces an effect non-inferior to lorazepam 0.5 mg/day but does not produce sedation sufficient to impair cognition or function in the RCT population. Dose escalation beyond 160 mg/day oral (twice the standard dose) has not been systematically studied and produces no documented psychoactive intensification; the pharmacology -- GABA-A allosteric modulation and VGCC inhibition without direct GABA-A agonism -- predicts a dose-effect plateau rather than progressive deepening of central depression. No recreational culture of lavender use analogous to kava, valerian, or cannabis has been documented in any ethnobotanical or contemporary context. The essential oil used as an inhalant produces transient relaxation but no psychoactive profile warranting a tiered dose ladder.

| pharmacokinetics = Linalool and linalyl acetate in Silexan are absorbed from the gastrointestinal tract following oral administration; linalyl acetate undergoes hydrolysis to linalool in the gut and by plasma esterases, such that linalool is the principal circulating species. Peak plasma concentrations are reached approximately 30 to 90 minutes after oral dosing.{{citation needed}} Linalool undergoes hepatic metabolism via cytochrome P450-mediated hydroxylation and glucuronidation; the metabolites are excreted renally. No significant accumulation has been reported at 80 mg/day dosing.

Following inhalation, linalool is absorbed via the pulmonary mucosa and by olfactory epithelium; plasma concentrations are substantially lower than after oral administration of an equivalent linalool dose, consistent with the smaller effect sizes observed in aromatherapy relative to oral-Silexan trials.

| interactions = Central nervous system depressants: theoretical additive sedation with benzodiazepines, alcohol, opioid analgesics, barbiturates, antihistamines, and sedating herbal medicines including valerian (Valeriana officinalis), kava (Piper methysticum), hops (Humulus lupulus), and passionflower (Passiflora incarnata). The clinical significance of this interaction at Silexan's standard 80 mg/day dose has not been formally evaluated; caution is appropriate when combining Silexan with benzodiazepines in patients transitioning from one agent to the other. The Woelk and Schlaefke (2010) trial documented successful lorazepam discontinuation in patients switched to Silexan,<ref name="woelk2010"/> suggesting that substitution is clinically feasible, but cross-tapering should be supervised.

Cytochrome P450: in vitro data at suprapharmacological concentrations suggest possible inhibition of CYP2C9 and CYP3A4 by lavender oil constituents. No pharmacokinetic interaction has been documented in clinical trials at 80 mg/day; the relevance of in vitro findings to standard clinical dosing is uncertain. No dose adjustment of co-administered medicines is presently supported by clinical evidence.

| interactionsummary = Additive CNS depression with sedatives, anxiolytics, alcohol, and sedating herbal medicines. No confirmed cytochrome P450 interaction at therapeutic dose.

| safety = Silexan at 80 mg/day has been well tolerated in all published RCTs, with no serious adverse events attributed to the study medicine. The most commonly reported adverse effects have been mild gastrointestinal symptoms (nausea, belching with lavender odor) and headache, each occurring at low incidence and resolving without intervention.

Prepubertal gynecomastia: Henley, Lipson, and Korach (2007) reported three cases of prepubertal boys who developed gynecomastia while using topical products containing lavender oil and tea tree oil; gynecomastia resolved in each case on discontinuation of the products. In vitro experiments demonstrated estrogenic and anti-androgenic activity of both lavender oil and tea tree oil at the tested concentrations.<ref name="henley2007">Henley DV, Lipson N, Korach KS, Bloch CA. "Prepubertal gynecomastia linked to lavender and tea tree oils." N Engl J Med. 2007;356(5):479-485. PMID 17267908.</ref> Subsequent epidemiological study has not confirmed a population-level signal; the three case reports represent a potential association rather than an established causal relationship. Conservative practice: avoid heavy chronic daily application of lavender oil-containing products to the skin of prepubertal boys.

Allergic contact dermatitis: linalool undergoes autooxidation in stored, poorly sealed, or heat-exposed essential oil, generating linalool hydroperoxide and other sensitizing oxidation products. Sensitization acquired through repeated exposure to oxidized lavender oil is permanent and subsequent exposures produce contact dermatitis. Properly stored, freshly purchased true lavender oil from a reputable supplier has low sensitization risk. This concern is among the more clinically relevant safety issues with topical lavender use; lavender is among the more common causes of fragrance-related contact sensitization in Europe.{{citation needed}}

Essential oil ingestion (non-Silexan): tipping lavender essential oil from a commercial aromatherapy bottle into food or beverages or swallowing it directly is not equivalent to Silexan and is not recommended. Case reports of oral essential oil ingestion -- in children accessing essential oil bottles -- have documented CNS depression and respiratory distress. Silexan is a specifically formulated pharmaceutical-grade oral preparation; the distinction between this and ad hoc oral consumption of essential oil is not cosmetic.

Pregnancy: Silexan trials have excluded pregnant participants; safety data for oral lavender oil preparations in pregnancy are absent. Ordinary aromatherapy use (inhalation at ambient concentrations, topical application in diluted carrier oil) is generally considered low risk but is not supported by trial data. High-dose oral preparations should be avoided in pregnancy in the absence of safety information.

| monitoring = No specific monitoring required for lavender flower infusion or tincture at traditional doses. Patients beginning Silexan 80 mg/day for generalized anxiety disorder: clinical assessment at two to four weeks to establish early response; continue through six weeks before assessing non-response. Patients with benzodiazepine dependence who are transitioning to Silexan should be supervised: cross-tapering under medical guidance is appropriate given the theoretical additive sedation risk during any overlap period.

| counseling = Patients beginning Silexan should understand that it is derived from lavender essential oil but is not equivalent to lavender aromatherapy: the clinical evidence for anxiety comes specifically from the oral capsule formulation at 80 mg/day, not from diffusers, massage oils, or pillow sprays. Benefit may take two to four weeks to become fully apparent; onset latency resembles that of SSRIs more closely than the immediate sedation of benzodiazepines.

The absence of dependence potential and withdrawal symptoms distinguishes Silexan from benzodiazepines. Patients anxious about benzodiazepine dependence or who have not tolerated them may find this distinction meaningful.

Patients using lavender essential oil products topically should use oils that are fresh, correctly stored (sealed, cool, and dark), and diluted in carrier oil for skin application; undiluted application to large skin areas over prolonged periods carries higher sensitization risk. Old or discolored essential oil should be discarded.

The prepubertal gynecomastia concern is worth mentioning to parents of boys who ask about lavender products; the evidence is from case reports rather than epidemiological studies, and the risk is not quantified, but the in vitro endocrine activity establishes a biologically plausible mechanism.

| regulatory = '''Germany and European Union'''

German Commission E (1990): lavender flower approved for mood disturbances with restlessness and sleep disturbances, and nervous stomach conditions; covers traditional oral preparations (infusion, tincture) based on traditional use rather than clinical trial evidence.

EMA HMPC: positive assessment of lavender flower as a traditional herbal medicinal product for mild anxiety and sleep disturbance; traditional use listing under the EU Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC). The EMA HMPC opinion does not cover Silexan, which was developed and approved as a distinct pharmaceutical medicinal product under a separate regulatory pathway.<ref name="ema-hmpc-lavender">European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Lavandula angustifolia P. Mill., flos. EMA/HMPC/734125/2010. First published: 13 June 2012. https://www.ema.europa.eu/en/medicines/herbal/lavandulae-flos.</ref>

Silexan (Lasea; Schwabe Pharmaceuticals): approved as a prescription medicinal product (not a traditional herbal product) in Germany and some other EU member states specifically for the treatment of generalized anxiety disorder, based on the RCT program described above. This is the most stringent regulatory status achieved by any essential-oil preparation in the EU regulatory framework.

'''United States'''

Lavender oil: GRAS (generally recognized as safe) status with the US FDA as a food flavoring additive; no approved therapeutic indication. Sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) without FDA evaluation of efficacy claims.

'''United Kingdom'''

MHRA traditional herbal registration: lavender preparations registered for traditional use for mild anxiety and sleep disturbance under the Traditional Herbal Registration scheme.

| history =
| effects =
| traditional_geography =
| anecdotes =
}}

== References ==
<references/>

[[Category:Plants]]
[[Category:Herbal medicines]]
[[Category:Medicines]]
[[Category:Nervine herbs]]
[[Category:Anxiolytic herbs]]
[[Category:Aromatics]]
[[Category:Western clinical herbs]]

Lavender

2026-05-26T18:01:09Z

Maintenance script: parser-claude: null edit to force re-parse after PlantMedTemplate fix

Template:PlantMedTemplate

2026-05-26T17:59:25Z

Maintenance script: parser-claude: move interactionsummary inside the Interactions H2 section; was rendering at top of page body. Bug routed via home-claude 2026-05-26 (Lavender, Lemon balm).

<noinclude>
== Usage ==

<pre>
{{PlantMedTemplate
| images = [[File:plant-photo-1.jpg|frameless|240px]] [[File:plant-photo-2.jpg|frameless|240px]]
| binomial = Genus species L.
| family = Family name
| common_names = common, vernacular, names
| native_range = geographic region
| cultivars = varieties / subspecies / chemovars
| parts_used = flowering tops, leaves, resin, seeds, root
| cultivation = brief context
| preparations_summary = one-line list of preparation forms
| constituents_summary = one-line summary of major constituents (linked)
| mechanism = one-line mechanism summary
| pregnancy = short flag
| legal = short status
| interactionsummary = pharmacogenomic + DDI summary chip
| intro = bold-lead history-first paragraph; reaches a person or place inside it
| traditional_uses = full History and traditional use H2 content (THE SPINE; 40-55% of page; prohibition history folds in here as the closing arc, no separate section)
| traditional_geography = optional geography subsection (woven into traditional_uses preferred)
| botany = Botany and identification H2 content
| constituents = full Active constituents H2 content
| preparations = full Preparations H2 content (cultural-historical level only; NO how-to)
| indications = problems treated (legacy parameter name; renders under Problems H2)
| dosing = titration / dosing
| effects = effects content
| pharmacokinetics = PK content (scoped-minimal on plant pages; PGx pass deepens later)
| pharmacodynamics = PD content (scoped-minimal on plant pages; PGx pass deepens later)
| interactions = usually <pharmaInteractions/>
| pregnancy_details = expanded
| monitoring = if applicable
| counseling = patient counseling
| anecdotes = anecdote content (Pendell quotes spread through traditional_uses ideally; one can sit here if it's about the experience)
| seealso = list of related pages
| references = usually <references/>
}}
</pre>

Sibling of [[Template:MedTemplate]], structured for whole-plant entities (botanical medicines) rather than single molecules. Use for Cannabis, Opium poppy, Coca, Peyote, San Pedro cactus, Psilocybin mushrooms, Salvia divinorum, Iboga, Khat, Datura, Mandrake, Henbane, Kava, Betel, Nutmeg, Tobacco, Coffee, Tea, Yerba mate, Guarana, etc. (sub-spec owed for preparations and animal sources like Ayahuasca and Bufo alvarius).

Section order is canonical per the plant-medicine-page spec (set 2026-05-18 by web-claude editorial directive): History and traditional use BEFORE Botany, prohibition folded INTO history as its closing arc rather than a separate section.

The indications parameter name is preserved for back-compat with MedTemplate even though the rendered heading is Problems.

[[Category:Templates]]
</noinclude><includeonly><table class="wikitable" style="float:right; clear:right; max-width:28em; margin:0 0 1em 1em; font-size:92%;">
<caption style="font-size:120%; padding:0.4em; font-weight:bold;">{{PAGENAME}}</caption>
{{#if:{{{images|}}}|<tr><td colspan="2" style="padding:0.8em; text-align:center;">{{{images}}}</td></tr>}}
<tr><th colspan="2" style="background:#2563eb; color:#fff; padding:0.4em; text-align:left;">Summary</th></tr>
{{#if:{{{binomial|}}}|<tr><th style="text-align:left; width:10em;">Binomial</th><td>''{{{binomial}}}''</td></tr>}}
{{#if:{{{family|}}}|<tr><th style="text-align:left;">Family</th><td>{{{family}}}</td></tr>}}
{{#if:{{{common_names|}}}|<tr><th style="text-align:left;">Common names</th><td>{{{common_names}}}</td></tr>}}
{{#if:{{{native_range|}}}|<tr><th style="text-align:left;">Native range</th><td>{{{native_range}}}</td></tr>}}
{{#if:{{{cultivars|}}}|<tr><th style="text-align:left;">Cultivars / varieties</th><td>{{{cultivars}}}</td></tr>}}
{{#if:{{{parts_used|}}}|<tr><th style="text-align:left;">Parts used</th><td>{{{parts_used}}}</td></tr>}}
{{#if:{{{cultivation|}}}|<tr><th style="text-align:left;">Cultivation</th><td>{{{cultivation}}}</td></tr>}}
<tr><th colspan="2" style="background:#16a34a; color:#fff; padding:0.4em; text-align:left;">Pharmacy</th></tr>
{{#if:{{{preparations_summary|}}}|<tr><th style="text-align:left;">Preparations</th><td>{{{preparations_summary}}}</td></tr>}}
{{#if:{{{pregnancy|}}}|<tr><th style="text-align:left;">Pregnancy</th><td>{{{pregnancy}}}</td></tr>}}
{{#if:{{{legal|}}}|<tr><th style="text-align:left;">Legal status</th><td>{{{legal}}}</td></tr>}}
<tr><th colspan="2" style="background:#7c3aed; color:#fff; padding:0.4em; text-align:left;">Pharmacology</th></tr>
{{#if:{{{constituents_summary|}}}|<tr><th style="text-align:left;">Active constituents</th><td>{{{constituents_summary}}}</td></tr>}}
{{#if:{{{mechanism|}}}|<tr><th style="text-align:left;">Mechanism (summary)</th><td>{{{mechanism}}}</td></tr>}}
</table>{{#if:{{{intro|}}}|
{{{intro}}}
}}{{#if:{{{traditional_uses|}}}|<h2 id="History">History and traditional use</h2>
{{{traditional_uses}}}
}}{{#if:{{{traditional_geography|}}}|<h3 id="Geography">Geography and peoples</h3>
{{{traditional_geography}}}
}}{{#if:{{{botany|}}}|<h2 id="Botany">Botany and identification</h2>
{{{botany}}}
}}{{#if:{{{constituents|}}}|<h2 id="Constituents">Active constituents</h2>
{{{constituents}}}
}}{{#if:{{{preparations|}}}|<h2 id="Preparations">Preparations</h2>
{{{preparations}}}
}}{{#if:{{{pharmacokinetics|}}}|<h2 id="Pharmacokinetics">Pharmacokinetics</h2>
{{{pharmacokinetics}}}
}}{{#if:{{{pharmacodynamics|}}}|<h2 id="Pharmacodynamics">Pharmacodynamics</h2>
{{{pharmacodynamics}}}
}}<h2 id="Experience">Experience</h2>
<pharmaExperience/>
<h2 id="Problems">Problems</h2>
{{#if:{{{indications|}}}|{{{indications}}}|<p style="opacity:0.7; font-style:italic;">No problems yet, be the first to suggest one.</p>}}

<span class="pcp-problem-suggest-wrap">[[Special:SuggestProblem/{{FULLPAGENAME}}|+ Add a problem]]</span><h2 id="Titration">Titration and dosing</h2>
{{#if:{{{dosing|}}}|{{{dosing}}}|<p style="opacity:0.7; font-style:italic;">No titration strategies yet, be the first to suggest one.</p>}}

<span class="pcp-titration-suggest-wrap">[[Special:SuggestTitration/{{FULLPAGENAME}}|+ Add a titration strategy]]</span>

<h2 id="Effects">Effects</h2>
{{#if:{{{effects|}}}|{{{effects}}}|<p style="opacity:0.7; font-style:italic;">No effects listed yet, be the first to suggest one.</p>}}

<span class="pcp-effect-suggest-wrap">[[Special:SuggestEffect/{{FULLPAGENAME}}|+ Add an effect]]</span>
{{#if:{{{interactions|}}}{{{interactionsummary|}}}|<h2 id="Interactions">Interactions</h2>
{{#if:{{{interactionsummary|}}}|<div class="pcp-pgx-summary">{{{interactionsummary}}}</div>
}}{{#if:{{{interactions|}}}|{{{interactions}}}
}}}}{{#if:{{{pregnancy_details|}}}|<h2 id="Pregnancy">Pregnancy and lactation</h2>
{{{pregnancy_details}}}
}}{{#if:{{{monitoring|}}}|<h2 id="Monitoring">Monitoring</h2>
{{{monitoring}}}
}}{{#if:{{{counseling|}}}|<h2 id="Counseling">Patient counseling</h2>
{{{counseling}}}
}}<h2 id="Anecdote">Relevant anecdote</h2>
{{#if:{{{anecdotes|}}}|{{{anecdotes}}}|<p style="opacity:0.7; font-style:italic;">No anecdotes yet, share a relevant one.</p>}}

<span class="pcp-anecdote-suggest-wrap">[[Special:SuggestAnecdote/{{FULLPAGENAME}}|+ Add an anecdote]]</span>
<h2 id="Literature">Relevant Literature</h2>
<pharmaLiterature/>
{{#if:{{{seealso|}}}|<h2 id="Seealso">See also</h2>
{{{seealso}}}
}}{{#if:{{{references|}}}|<h2 id="References">References</h2>
{{{references}}}
}}</includeonly>

Bromazolam

2026-05-16T02:42:47Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{MedTemplate
| generic = Bromazolam
| brand = (none — never marketed)
| structure = Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position).
| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
| mechanism = Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.
| uses = No approved medical indication. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
| starting_dose = No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
| preparations = Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.
| fda_max = N/A (never approved)
| routes = Oral, sublingual, intranasal; rectal and IV reported.
| onset = ~20–40 min PO; faster sublingual/intranasal.
| duration = 6–10 h subjective; full pharmacologic effect considerably longer.
| halflife = Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
| bioavailability = Not formally characterized in humans.
| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.
| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a med of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.
| pharmacodynamics = Non-selective positive allosteric modulator at the benzodiazepine site of GABA<sub>A</sub> receptors containing α1, α2, α3, or α5 subunits with a γ subunit. Like alprazolam, clinically displays anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle-relaxant effects with significant abuse liability. Respiratory depression at high doses is modest in isolation but markedly synergized by opioids, alcohol, and other CNS depressants — the dominant mechanism of bromazolam-associated mortality.
| indications = None approved. Has no recognized medical role.
| dosing = No therapeutic dosing. Harm-reduction note: because of inconsistent tablet purity and frequent fentanyl co-contamination, '''any''' illicit "benzo" tablet should be assumed to potentially contain bromazolam, fentanyl, or both.
| effects = Sedation, anxiolysis, anterograde amnesia, ataxia, slurred speech, disinhibition, prolonged blackouts. At high dose or in combination: severe sedation, respiratory depression, coma. Paradoxical agitation/aggression occasionally reported. Withdrawal mirrors other high-potency benzos: anxiety, insomnia, autonomic hyperactivity, seizures, delirium — and can be life-threatening, often more protracted than alprazolam withdrawal owing to the longer half-life.
| interactions = <pharmaInteractions/>

* '''Opioids''' (fentanyl, heroin, methadone, buprenorphine): profound additive respiratory depression — primary mechanism of bromazolam-associated overdose death.
* '''Alcohol, GHB, barbiturates, gabapentinoids''': additive CNS/respiratory depression.
* '''Xylazine''': frequently co-encountered in illicit opioid supply ("tranq dope"); compounds sedation and complicates resuscitation (xylazine is not reversed by naloxone).
* '''CYP3A4 inhibitors''' (azoles, macrolides, ritonavir, grapefruit): prolong/intensify effect.
* '''CYP3A4 inducers''' (rifampin, carbamazepine, phenytoin, St John's wort): may reduce levels.
* '''Flumazenil''' reverses GABA<sub>A</sub> effects but is rarely used in mixed-overdose / chronic-benzo contexts due to seizure risk.
| pregnancy_details = Avoid in pregnancy and lactation. Class data extrapolated from clinical benzodiazepines; designer status means no formal safety data.
| monitoring = In suspected overdose: airway, respiratory rate, oxygen saturation, mental status. Standard urine benzodiazepine immunoassay is '''insensitive''' to bromazolam — request specific LC-MS/MS confirmation. ECG and electrolytes if mixed overdose suspected.
| counseling = Patients should be counseled that illicit "Xanax bars" or designer benzodiazepine tablets are frequently bromazolam and/or fentanyl. Never combine with opioids or alcohol. Withdrawal requires medically supervised taper — do not stop abruptly after sustained use. Carry naloxone if any opioid co-use is plausible (naloxone does '''not''' reverse bromazolam itself but reverses concurrent opioid depression).
| anecdotes =
| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]
| references =
* DEA Diversion. ''Bromazolam.'' Drug & Chemical Evaluation Section, 2023.
* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.
* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.
* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated med supply.
}}

[[Category:Research Materials]]
[[Category:Benzodiazepines]]
[[Category:Triazolobenzodiazepines]]
[[Category:GABAA Positive Allosteric Modulators (General)]]
[[Category:GABAergics]]
[[Category:Anxiolytics & Sedative-Hypnotics]]

Nutmeg

2026-05-16T02:42:47Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{MedTemplate
| generic = Nutmeg
| brand = ''Myristica fragrans''. Mace (the fruit aril)
| classes = Plant Med, Empathogenica
| uses = <vote slug="culinary-use">Culinary spice</vote>
| starting_dose = 0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use
| preparations = Ground dried seed (nutmeg) or fruit aril (mace); occasionally infused
| routes = Oral
| onset = Slow — 2–6 h
| duration = 12–24 h or longer
| mechanism = Active oils are myristicin, elemicin, and safrole — phenethylamine precursors that may be aminated in vivo to MMDA, TMA, and MDA respectively (Shulgin's 'essential amphetamines' hypothesis).
| intro = Nutmeg is the dried seed kernel of ''Myristica fragrans'', a Moluccan tree of the Myristicaceae (same family as the South American DMT-source ''Virola''). At psychoactive doses (a sizable spoonful or more), produces a slow onset of empathogenic/dreamy effects lasting well into the next day, often with heavy nausea — [[Pendell]]'s "med-of-last-resort."
| seealso = [[MDMA]], [[MDA]], [[Cinnamon]]
| references = <references/>
}}

{{PendellsCorner
| quote = The drug-of-last-resort. Myself, I like nutmeg in eggnog.
| volume = Dynamis
| page = 199
}}

[[Category:Empathogenica]]
[[Category:Plant Medicines]]
[[Category:Medicines]]

Buprenorphine/Naloxone

2026-05-16T02:42:47Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{MedTemplate
| generic = Buprenorphine / Naloxone
| brand = Suboxone, Zubsolv, Bunavail, Cassipa
| classes = Opioid agonist therapy (OAT); Partial μ-agonist + abuse-deterrent
| uses = <vote slug="oud-treatment-use">Opioid use disorder (OUD) maintenance</vote>, <vote slug="opioid-withdrawal-use">Opioid withdrawal</vote>
| starting_dose = Induction: 2/0.5 to 4/1 mg SL once in moderate withdrawal; titrate to 12–16/3–4 mg/d by day 2–3
| preparations = SL film or tablet, 2/0.5 to 12/3 mg per dose
| fda_max = 24/6 mg/d (most labels)
| routes = Sublingual film or tablet (buccal for some)
| onset = 30–60 min (SL)
| duration = 24–36 h (driven by buprenorphine)
| halflife = 24–42 h (buprenorphine); 1–2 h (naloxone)
| bioavailability = Buprenorphine ~30% SL; naloxone <10% SL (intentional — inactive sublingually, matters only if injected)
| pregnancy = Category C (buprenorphine-only formulations preferred in pregnancy)
| legal = Schedule III in US; X-waiver no longer required (as of 2023)
| mechanism = Buprenorphine: high-affinity partial agonist at the μ-opioid receptor with ceiling effect on respiratory depression. Naloxone: abuse-deterrent — inactive SL but precipitates withdrawal if injected.
| intro = Buprenorphine/naloxone (most widely known as Suboxone) is one of the two pillars of med-assisted treatment for opioid use disorder. The partial-agonist nature of buprenorphine gives it a ceiling effect on respiratory depression — far safer than full agonists like methadone. The naloxone is essentially inert SL; it exists as an injection deterrent. See [[Buprenorphine]] for the pharmacology of the active component.
| indications =
| dosing =
| effects =
| pk_absorption = Buprenorphine ~30% SL; naloxone negligible.
| pk_distribution = Buprenorphine ~96% protein binding.
| pk_metabolism = Buprenorphine: CYP3A4 → norbuprenorphine (active). Naloxone: hepatic glucuronidation.
| pk_elimination = Fecal (buprenorphine and metabolites); renal (naloxone glucuronide).
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details = Prefer buprenorphine monoproduct (Subutex) in pregnancy when possible — more pregnancy data.
| monitoring = Withdrawal scale (COWS) during induction; LFTs at baseline + periodically; toxicology screens per program.
| counseling = '''Precipitated withdrawal''': do not induct until in moderate withdrawal (COWS ≥ 8–12). Hold under tongue until fully dissolved — do not chew or swallow. Combine with counseling and recovery support.
| anecdotes =
| seealso = [[Buprenorphine]], [[Methadone]], [[Naltrexone]], [[Naloxone]]
| references = <references/>
}}

[[Category:Medicines]]

About:Pharmacopedia.ext

2026-05-16T02:42:47Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{TOC right}}
= Pharmacopedia extension — specification =

'''Version:''' 0.7.10 · '''Requires:''' MediaWiki ≥ 1.45.0
'''Author:''' MDElliottMD · '''License:''' GPL-2.0-or-later
'''Source:''' <code>/var/www/mediawiki/extensions/Pharmacopedia/</code>

The Pharmacopedia extension turns a MediaWiki install into a structured, community-edited med reference. It adds parser tags, special pages, API modules, and a database schema that together support:

* Structured med pages via the <code>{{tlx|MedTemplate}}</code> template
* Per-user rating, voting, and reporting on effects, indications, titration strategies, anecdotes, and interactions
* Two-perspective data capture (personal vs. provider) wherever clinically meaningful
* Curated med-class categories used as interaction endpoints
* A verified-provider role with document-based verification

== High-level architecture ==

* '''Backend (PHP):''' <code>includes/</code> — one class per parser tag, store, special page, or API module. Auto-loaded under <code>MediaWiki\Extension\Pharmacopedia\</code>.
* '''Frontend (JS):''' <code>resources/ext.pharmacopedia.js</code> — single IIFE binding click handlers, modals, and inline AJAX submits.
* '''Styles (CSS):''' <code>resources/ext.pharmacopedia.css</code> — shared row layout, per-tag chrome, dark-theme-friendly colors.
* '''Schema:''' <code>sql/</code> — ten core tables plus four migration patches. Picked up via the <code>LoadExtensionSchemaUpdates</code> hook.

== Parser tags ==

All eight tags are registered via <code>Hooks::onParserFirstCallInit</code>:

{| class="wikitable"
! Tag !! Purpose !! Class
|-
| <code><vote></code> || Generic up/down binary vote on an arbitrary slug || <code>VoteTag</code>
|-
| <code><effect></code> || Therapeutic or adverse effect, dual patient/provider perspectives || <code>EffectTag</code>
|-
| <code><discuss></code> || Threaded comment widget || <code>CommentTag</code>
|-
| <code><effectsummary></code> || Roll-up aggregate header || <code>EffectSummaryTag</code>
|-
| <code><titration></code> || Titration strategy card with up/down vote || <code>TitrationTag</code>
|-
| <code><anecdote></code> || Personal or provider story with up/down vote || <code>AnecdoteTag</code>
|-
| <code><indication></code> || Condition the med is used for, 0–5 likert rating || <code>IndicationTag</code>
|-
| <code><pharmaInteractions/></code> || Self-closing; renders the Interactions section for the current page || <code>InteractionTag</code>
|}

All tags except <code><pharmaInteractions/></code> take a <code>slug</code> argument and (where relevant) a <code>title</code>, <code>label</code>, <code>author</code>, <code>ref</code>, or <code>perspective</code>.

=== Tag wikitext examples ===

<pre>
<indication slug="ssri-depression" title="Major depressive disorder"
author="MDElliottMD">Use cautiously in adolescents.</indication>

<effect slug="nausea" label="Nausea"/>

<effect ref="hyperkalemia"/> 

<titration slug="slow-start-elderly" title="Slow start (elderly)"
author="MDElliottMD">Begin at 10 mg q AM; titrate by 10 mg every 14 days.</titration>

<anecdote slug="qi8sg2" perspective="provider"
author="MDElliottMD">One patient developed serotonin syndrome at week 3...</anecdote>

<pharmaInteractions/>
</pre>

== The unified compact row layout ==

Indication, Effect, Interaction, Titration, and Anecdote all render through a shared row pattern:

<pre>
<div class="pcp-row pcp-row-{type} pcp-{type}" ...data-*>
<div class="pcp-row-head">
<span class="pcp-row-title">...</span>
<span class="pcp-row-aggs">...</span>
<span class="pcp-row-actions">
<button class="pcp-row-action pcp-row-action-toggle" data-target="rate">Rate</button>
[<button data-target="notes">Notes (N)</button>] # only for Interaction
[× delete button] # only for sysop/admin
</span>
</div>
[<div class="pcp-row-panel pcp-row-rate-panel" hidden>...</div>]
[<div class="pcp-row-panel pcp-row-notes-panel" hidden>...</div>]
[<div class="pcp-row-body">...wikitext body, always visible if present...</div>]
</div>
</pre>

* Rate / Notes panels are hidden by default; the shared <code>.pcp-row-action-toggle</code> JS handler reveals them inline on click.
* Bodies (page-specific descriptions for Indication / Effect / Titration / Anecdote) are always visible.
* The <code>×</code> admin delete button uses the established <code>.pcp-del-btn</code> pattern (or <code>.pcp-ix-del-row</code> for interactions).
* Each row sits in its own block-formatting context (<code>display: flow-root</code>) so its border-box respects floated infoboxes.

== Voting / rating semantics ==

{| class="wikitable"
! Element !! Scale !! Perspectives !! Storage
|-
| Vote tag || +1 / −1 binary || single || <code>pcp_votes</code>
|-
| Titration || +1 / −1 binary || single || <code>pcp_votes</code>
|-
| Anecdote || +1 / −1 binary || single (perspective is a metadata label, not a separate aggregate) || <code>pcp_votes</code>
|-
| Indication || 0–5 likert + "don't know" || single || <code>pcp_likert_reports</code>
|-
| Effect (patient) || experienced ∈ {yes, no, unsure} + valence −3..+3 || patient || <code>pcp_effect_reports</code> (perspective=1)
|-
| Effect (provider) || frequency ∈ {0, 5, 20, 33, 50, 66, 80, 95, −1 don't know} + valence −3..+3 || provider || <code>pcp_effect_reports</code> (perspective=2)
|-
| Interaction || experience 1–5 + outcome −3..+3 + optional free-text note || user + provider, separate aggregates || <code>pcp_interaction_reports</code>
|}

Server-side aggregates: <code>n</code>, mean of the rating field, and (where applicable) <code>severe = (vmean ≤ −2.5)</code>.

Aggregates are recomputed and returned by every report-submit API call so the row re-renders in place without a page reload.

== Effect bucketing ==

When a wiki <code><ul></code> contains only <code><effect></code> cards, JavaScript groups them into buckets by the provider frequency mean (<code>data-fmean</code>):

{| class="wikitable"
! Bucket !! fmean band !! Default state
|-
| '''Common''' || > 20 || expanded, always visible
|-
| '''Uncommon''' || > 5 and ≤ 20 || collapsed
|-
| '''Rare''' || ≤ 5, provider vmean > −2.5 || collapsed
|-
| '''Rare but Severe''' || ≤ 5 and vmean ≤ −2.5 || '''expanded by default''', red highlight
|-
| '''Not yet rated''' || no provider data (n=0) || collapsed, only renders if non-empty
|}

The vmean ≤ −2.5 threshold is also the trip-wire for the "severe" red treatment on interaction rows.

== Interactions feature ==

The Interactions section is rendered by placing <code><pharmaInteractions/></code> anywhere in the wikitext of a med article ('''NS_MAIN''') or a Category page ('''NS_CATEGORY''').

=== Entity model ===

An interaction is an undirected edge between two endpoints. Each endpoint has a '''type''' (<code>med</code> or <code>category</code>) and a '''slug''' (DB-key form of the page title).

Pairs are stored in canonical order: smaller <code>(type, slug)</code> tuple on the left. This collapses A↔B and B↔A into a single row.

=== Tables ===

<code>pcp_interactions</code>: one row per interaction edge.

pi_id auto-increment
pi_element_id FK -> pcp_votable_elements (reuse votes/comments infra)
pi_left_type 'med' | 'category'
pi_left_slug VARBINARY(255)
pi_right_type 'med' | 'category'
pi_right_slug VARBINARY(255)
pi_created_user_id INT
pi_created BINARY(14)
UNIQUE (pi_left_type, pi_left_slug, pi_right_type, pi_right_slug)

<code>pcp_interaction_reports</code>: one row per (interaction, user, perspective).

pir_element_id FK -> pcp_votable_elements
pir_user_id INT
pir_perspective 1 = user, 2 = provider
pir_experience TINYINT (1..5, nullable)
pir_valence TINYINT (-3..+3, nullable)
pir_note MEDIUMBLOB (nullable)
pir_created BINARY(14)
pir_updated BINARY(14)
UNIQUE (pir_element_id, pir_user_id, pir_perspective)

=== Rendering rules ===

* On a '''med''' page M, list:
** Direct edges: rows where M is one side.
** Transitive edges: rows where one side is a category C that M is itself a member of (via MW's <code>categorylinks</code>).
* '''Direct wins:''' if the same counterparty is reachable both directly and transitively, drop the transitive duplicate.
* On a '''Category''' page, list direct edges only (no transitive walk).
* Sort: pooled <code>valence_mean</code> ascending (most negative on top). Nulls sink. Tiebreakers: <code>n</code> desc, then alphabetic.
* Severe (any of pooled / user / provider vmean ≤ −2.5): red 4 px left border + red-tinted background + "severe" pill + counterparty title in red.

=== Add-interaction modal ===

Triggered by the <code>+ Add interaction</code> button at the bottom of the section. Two-stage UX:

# Search input → results split into '''Meds''' (teal chip) and '''Categories''' (amber chip).
# Click <code>Use</code> → confirm via <code>Add interaction</code> button → POST to <code>pharmacopediainteractionadd</code>.

Categories appear in the modal '''only if tagged with the marker category''' (default <code>Category:MedCategory</code>, configurable via <code>$wgPharmacopediaInteractionCategoryMarker</code>). The transitive walk during rendering, however, uses all of a page's categories regardless of marker — historic data isn't hidden by changing the marker policy.

=== Delete ===

Two a

Pharmacopedia:About

2026-05-16T02:42:47Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

Born in May 2026, Pharmacopedia started primarily as a one-man project of [https://markelliottmd.com MDElliottMD], who'd been dreaming of some place for the people who recommend and/or use meds of the mind to collaborate and create consensus-driven information, founded in a deep faith in the [https://en.wikipedia.org/wiki/Wisdom_of_the_crowd wisdom of the crowd].

First, I hope this to be a reasonable and reliable reference for prescribers of all sorts to find relevant and accurate information for their practice: available strengths, titration strategies, pill IDs, etc.

But almost moreso, I hope that this place can be a lively, collaborative place for a communal effort in understanding the bizarre world of meds and human brains. I hope that by pooling our collective anecdotes, we might actually make some data, of a sort.

The site empowers users (with 2-FA) to share their experience about almost every aspect of the site, in as fine a detail as I thought was tolerable. I hope that by pooling our estimates, we might find something like truth.

For now, I, [[User:MDElliottMD|MDElliottMD]], am the only person who can approve/publish page edits, though I hope to have a team of moderators some day.

I am not a software developer, but I am a top-tier expert in meds of the mind. I will keep the place as tidy as I can.

This project is not, in an way, driven by money or profit. The link above is as far as I will go to promote myself or my brand here. At the moment, I am happy to fund the project in its entirety. If that changes, I may some day ask for donations.

This project was entirely developed and partially populated by Claude (Opal 4.7), and is based on the [https://www.mediawiki.org/wiki/MediaWiki Mediawiki code base], bless their souls.

Much of the interface (voting, especially) here is run through an extension that I made with Claude: [[About:Pharmacopedia.ext|Pharmacopedia.ext]], which I'm happy to share with whomever wants it. Probably easiest to get ahold of me through my website above.

Thanks for coming by. Would be honored if you could help inform the hive mind.

-mark

Classes

2026-05-16T02:42:47Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

This page is a reference taxonomy of pharmacological '''classes''' used throughout Pharmacopedia. Click any class name to browse its members. Individual meds are listed on the [[List of CNS-active medicines]] page.

__TOC__

== Antidepressants ==

=== Selective Serotonin Reuptake Inhibitors (SSRIs) ===
Block presynaptic reuptake of serotonin via SERT. First-line for most depressive and anxiety disorders.

=== Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs) ===
Block reuptake of both serotonin and norepinephrine. Used in depression, anxiety, and neuropathic pain.

=== Norepinephrine–Dopamine Reuptake Inhibitors (NDRIs) ===
Block reuptake of norepinephrine and dopamine. Minimal serotonergic activity; lower sexual side-effect burden.

=== Norepinephrine Reuptake Inhibitors (NRIs) ===
Selective for norepinephrine reuptake. Used in depression and ADHD.

=== Tricyclic Antidepressants (TCAs) ===
Older class; block SERT and NET with broad receptor antagonism (H1, muscarinic, alpha-1). High side-effect burden; significant overdose risk.

=== Monoamine Oxidase Inhibitors (MAOIs) ===
Inhibit MAO-A and/or MAO-B, increasing monoamine levels. Require strict dietary and med interaction precautions. Subclasses:
* '''Irreversible non-selective MAOIs''' — inhibit both MAO-A and MAO-B permanently
* '''Reversible MAO-A inhibitors (RIMAs)''' — safer interaction profile; displaceable by tyramine
* '''Selective MAO-B inhibitors''' — used primarily in Parkinson's disease; antidepressant at higher doses

=== Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs) ===
Alpha-2 antagonists that increase norepinephrine and serotonin release; also potent H1 antagonists (sedating).

=== Serotonin Antagonist and Reuptake Inhibitors (SARIs) ===
Block SERT and antagonize 5-HT2A/2C receptors. Sedating; low sexual side-effect burden.

=== Melatonin Agonist / Serotonin Antagonist ===
Agonism at MT1/MT2 melatonin receptors and 5-HT2C antagonism; circadian-focused antidepressant mechanism.

=== Multimodal Serotonergic Agents ===
Act on multiple serotonin receptor subtypes simultaneously (SERT inhibition + receptor agonism/antagonism).

== Antipsychotics / Neuroleptics ==

=== First-Generation Antipsychotics (FGAs / Typicals) ===
Primarily D2 receptor antagonists. Effective for positive symptoms; high risk of extrapyramidal side effects and tardive dyskinesia. Subclasses by chemical structure:
* '''Phenothiazines''' — chlorpromazine, fluphenazine, perphenazine, thioridazine, trifluoperazine, prochlorperazine
* '''Butyrophenones''' — haloperidol, droperidol
* '''Thioxanthenes''' — thiothixene
* '''Dibenzoxazepines''' — loxapine
* '''Dihydroindolones''' — molindone
* '''Diphenylbutylpiperidines''' — pimozide

=== Second-Generation Antipsychotics (SGAs / Atypicals) ===
D2 and 5-HT2A antagonists (or partial agonists). Lower EPS risk; higher metabolic side-effect burden.

=== Third-Generation Antipsychotics ===
D2/D3 partial agonists with 5-HT1A partial agonism. Intended to stabilize rather than fully block dopamine signaling.

== Mood Stabilizers ==
Reduce episode frequency and severity in bipolar disorder. Mechanisms vary widely:
* Sodium channel blockers
* GABA enhancers
* Histone deacetylase inhibitors
* Unknown/multiple mechanisms (lithium)

== Anxiolytics & Sedative-Hypnotics ==

=== Benzodiazepines ===
Positive allosteric modulators at GABAA receptors (benzodiazepine site). Increase chloride channel opening frequency. Used for anxiety, seizures, muscle spasm, alcohol withdrawal, and procedural sedation. Dependence liability with chronic use.

=== Thienodiazepines ===
Structurally related to benzodiazepines with a thiophene ring substitution. Similar mechanism and effects.

=== Z-Drugs (Non-Benzodiazepine Hypnotics) ===
GABAA positive allosteric modulators with greater selectivity for alpha-1-containing receptors. Primarily hypnotic; lower anxiolytic/anticonvulsant activity than benzodiazepines.

=== Orexin Receptor Antagonists ===
Block orexin (hypocretin) signaling to promote sleep onset and maintenance. Lower dependence potential than GABAergic hypnotics.

=== Azapirones ===
5-HT1A partial agonists with D2 antagonism. Anxiolytic without sedation or dependence; slow onset of effect.

=== Barbiturates ===
Potentiate and directly activate GABAA receptors at higher concentrations. Older class; narrow therapeutic index; high overdose and dependence risk.

=== Beta Blockers (peripheral somatic anxiolytic) ===
β-adrenergic receptor antagonists. While primarily cardiovascular meds, they are widely used off-label as peripheral anxiolytics — blunting the somatic (tachycardia, tremor, sweating) manifestations of acute anxiety without sedation or dependence liability. Particularly useful for performance anxiety, akathisia, and essential tremor. [[Propranolol]] is the prototype. See [[:Category:Beta Blockers]].

== Stimulants & Wake-Promoting Agents ==

=== Amphetamines ===
Monoamine releasing agents; reverse transporter function to flood the synapse with dopamine, norepinephrine, and (to varying degrees) serotonin. Used for ADHD, narcolepsy, and obesity.

=== Methylphenidates (Phenidates) ===
Dopamine and norepinephrine reuptake inhibitors; structurally distinct from amphetamines. First-line for ADHD.

=== Eugeroics (Wakefulness-Promoting Agents) ===
Promote wakefulness through incompletely understood mechanisms involving dopamine reuptake inhibition and orexin pathway activation. Lower abuse potential than amphetamines.

=== Xanthines ===
Adenosine receptor antagonists. Mild CNS stimulation; widely consumed (caffeine). Theophylline also inhibits phosphodiesterase.

=== Alpha-2 Agonists (for ADHD) ===
Activate presynaptic and postsynaptic alpha-2A adrenergic receptors in prefrontal cortex. Non-stimulant; used for ADHD, tics, and opioid/nicotine withdrawal.

=== Norepinephrine Reuptake Inhibitors (ADHD) ===
Selective NET inhibitors approved for ADHD. Non-stimulant; full antidepressant-level NRI activity.

=== Histamine H3 Antagonists / Inverse Agonists ===
Block presynaptic H3 autoreceptors, increasing histamine (and other monoamine) release. Used for narcolepsy with cataplexy.

== Opioids ==

=== Mu-Opioid Receptor Agonists ===
Analgesia, euphoria, sedation, respiratory depression, and constipation via mu (μ) opioid receptors. The primary class for moderate-to-severe pain management. Subclasses:
* '''Natural opioids''' — derived directly from the opium poppy
* '''Semisynthetic opioids''' — modified natural opioids
* '''Synthetic opioids''' — fully synthetic; no plant-derived precursors

=== Partial Mu-Opioid Agonists ===
Ceiling effect on respiratory depression; used for addiction treatment and pain.

=== Mixed Agonist-Antagonists ===
Kappa agonists with mu partial agonism or antagonism. Analgesic but may precipitate withdrawal in opioid-dependent patients.

=== Kappa-Opioid Receptor Agonists ===
Dysphoria, hallucinations, sedation, analgesia. Endogenous stress response mediators; relevant to dissociative and psychedelic pharmacology.

=== Opioid Antagonists ===
Competitive blockade of opioid receptors. Used for overdose reversal and addiction treatment.

=== Opioid Receptor Modulator + NMDA Antagonists ===
Dual-mechanism opioids that add NMDA antagonism (methadone, levorphanol). Useful for complex pain; longer half-life.

== GABAergics ==

=== GABAB Receptor Agonists ===
Activate metabotropic GABAB receptors. Muscle relaxation, analgesia, euphoria/reinforcement at high doses. Includes baclofen and sodium oxybate (GHB).

=== GABAA Positive Allosteric Modulators (General) ===
Enhance chloride influx via GABAA receptors. Umbrella category covering benzodiazepines, barbiturates, Z-drugs, neurosteroids, and several other classes.

=== GABA Reuptake Inhibitors ===
Block GAT-1 transporter to raise synaptic GABA. Anticonvulsant application.

=== GABA-Transaminase Inhibitors ===
Irreversibly inhibit the enzyme that degrades GABA, raising brain GABA levels overall. Anticonvulsant.

=== GHB Receptor Agonists ===
Activate the endogenous GHB receptor in addition to GABAB. Sedative-hypnotic; used for narcolepsy and alcohol withdrawal.

== Anticonvulsants / Antiepileptics ==
Heterogeneous class united by seizure suppression. Mechanisms include:
* Sodium channel blockers
* Calcium channel blockers (T-type or N/P/Q-type)
* GABA enhancement (multiple mechanisms)
* Glutamate/AMPA antagonists
* SV2A ligands (synaptic vesicle protein)
* Carbonic anhydrase inhibitors

Many anticonvulsants are also used for pain, migraine prophylaxis, mood stabilization, or anxiety.

== Antiparkinsonian Meds ==

=== Dopamine Precursors ===
Levodopa, converted to dopamine in the brain, replenishes the depleted dopaminergic pathway in Parkinson's disease.

=== Dopamine Agonists ===
Directly stimulate D2/D3 receptors, bypassing presynaptic neurons. Also used for restless legs syndrome and hyperprolactinemia.

=== MAO-B Inhibitors ===
Reduce dopamine catabolism in the striatum by inhibiting the MAO-B isoform. Mild antiparkinsonian and neuroprotective effects.

=== COMT Inhibitors ===
Reduce peripheral and central metabolism of levodopa, extending its duration of action.

=== Anticholinergics (Antiparkinsonian) ===
Reduce the relative excess of cholinergic activity resulting from dopamine depletion in the striatum. Effective for tremor; significant cognitive side effects.

=== NMDA Antagonists (Antiparkinsonian) ===
Reduce glutamate-mediated excitotoxicity and may reduce dyskinesias. Amantadine also has dopamine-releasing effects.

== Anti-Dementia Meds ==

=== Acetylcholinesterase Inhibitors (AChEIs) ===
Prevent the breakdown of acetylcholine, increasing cholinergic transmission in the cortex and hippocampus. First-line for Alzheimer's and other dementias.

=== NMDA Receptor Antagonists ===
Block pathological NMDA receptor overactivation (excitotoxicity). Used adjunctively in moderate-to-severe Alzheimer's.

=== Anti-Amyloid Monoclonal Antibodies ===
Clear amyloid-beta plaques from the brain. Disease-modifying approach; newer class with contested clinical benefit.

== Anesthetics ==

=== General (IV) Anesthetics ===
Intravenous agents for induction and/or maintenance of anesthesia. Mechanisms vary:
* GABAA potentiators (propofol, etomidate, barbiturates)
* NMDA antagonists (ketamine)

=== Inhalational Anesthetics ===
Volatile agents for maintenance of anesthesia. Primarily GABAA potentiation and NMDA antagonism. Dose-dependent CNS depression.

=== Dissociative Anesthetics ===
NMDA antagonists producing analgesia, amnesia, and cataleptic state without loss of airway reflexes. See [[#Dissociatives]].

=== Local Anesthetics ===
Sodium channel blockers that block nerve conduction locally. CNS toxicity (including seizures) may occur with systemic absorption.

=== Alpha-2 Agonist Sedatives ===
Dexmedetomidine: highly selective alpha-2A agonist producing sedation that closely resembles natural sleep. Used for ICU sedation and procedural sedation.

== Muscle Relaxants (CNS-acting) ==
Centrally-acting agents that reduce skeletal muscle tone via spinal cord or supraspinal mechanisms. Distinct from peripherally-acting neuromuscular blocking agents.

== Antihistamines ==
H1 receptor antagonists. First-generation agents cross the blood-brain barrier and produce sedation, anticholinergic effects, and at high doses, delirium. Divided by generation:
* '''First-generation''' — lipophilic; CNS-penetrant; sedating; anticholinergic
* '''Second-generation''' — less CNS penetration; non-sedating

== Addiction Med ==
Meds used to treat substance use disorders. Mechanisms are specific to the target substance:
* Opioid agonist therapy (methadone, buprenorphine)
* Opioid antagonists (naltrexone, naloxone, nalmefene)
* Aversion agents (disulfiram)
* NMDA/GABA modulators for alcohol (acamprosate)
* Nicotinic partial agonists (varenicline)
* Alpha-2 agonists for withdrawal (clonidine, lofexidine)

== Migraine Meds ==

=== Triptans (5-HT1B/1D Agonists) ===
Selective serotonin agonists at 5-HT1B and 5-HT1D receptors. Cause vasoconstriction and inhibit trigeminal pain transmission. Acute treatment.

=== Gepants (CGRP Receptor Antagonists) ===
Block calcitonin gene-related peptide (CGRP) receptors. Effective for acute and preventive migraine treatment without vasoconstriction.

=== Ditans (5-HT1F Agonists) ===
Serotonin agonists selective for the 5-HT1F receptor. Inhibit trigeminal pain without vasoconstriction; CNS side effects (dizziness, sedation) are common.

=== Ergotamines ===
Ergot alkaloids; 5-HT1B/1D agonists with additional vasoconstrictor activity. Older class; significant side-effect burden.

== Psychedelics ==

=== Classical Psychedelics (Serotonergic) ===
Primary mechanism is agonism at 5-HT2A receptors in the cortex, producing profound alterations in perception, cognition, and sense of self. Subclasses by chemical scaffold:
* '''Tryptamines''' — indole alkaloids structurally related to serotonin
* '''Lysergamides''' — ergoline derivatives of lysergic acid
* '''Phenethylamines''' — related to the catecholamine scaffold (mescaline and analogues)
* '''2C-x series''' — 2,5-dimethoxyphenethylamines
* '''DOx series''' — amphetamine-based phenethylamines; very long duration
* '''NBOMe / NBOH series''' — N-benzyl derivatives; extremely potent; no oral activity

=== Empathogens / Entactogens ===
Primarily monoamine-releasing agents (especially serotonin) with partial 5-HT2A agonism. Produce emotional openness and prosocial effects. Core subclasses:
* '''MDxx''' — methylenedioxy-substituted amphetamines and cathinones
* '''Benzofurans''' — related scaffold; primarily serotonergic

=== Dissociatives ===
NMDA receptor antagonists producing dose-dependent detachment from self and environment. At sub-anesthetic doses: analgesia, euphoria, perceptual distortion. Subclasses:
* '''Arylcyclohexylamines''' — ketamine, PCP, and analogues; σ1 and dopaminergic activity
* '''Morphinans''' — dextromethorphan, dextrorphan; also sigma-1 and serotonergic
* '''Diarylethylamines''' — diphenidine and related
* '''Adamantanes''' — memantine
* '''Other''' — nitrous oxide, xenon

=== Deliriants ===
Produce a state of true delirium — confusion, disorientation, and realistic hallucinations indistinguishable from reality. Subclasses:
* '''Anticholinergics (muscarinic antagonists)''' — block muscarinic acetylcholine receptors; atropine, scopolamine, hyoscyamine, diphenhydramine
* '''Kainate / AMPA agonists''' — ibotenic acid
* '''GABAA agonists (at sedating doses)''' — muscimol
* '''Other''' — benzydamine, myristicin

=== κ-Opioid Agonists ===
Kappa receptor activation produces dysphoric, dissociative, and oneirogenic effects distinct from classical psychedelics and mu-opioid analgesia.

== Cannabinoids ==

=== Phytocannabinoids ===
Naturally occurring compounds in ''Cannabis sativa''. Act primarily at CB1 (CNS) and CB2 (immune) receptors.

=== Synthetic Cannabinoids ===
Fully synthetic full agonists at CB1/CB2. Often far more potent than THC; unpredictable toxicity profile.

=== Pharmaceutical Cannabinoids ===
Regulated preparations of naturally-derived or synthetic cannabinoids approved for specific indications.

== Nootropics ==

=== Racetams ===
Positive allosteric modulators at AMPA receptors; some also affect choline uptake or acetylcholine synthesis.

=== Eugeroics ===
See [[#Eugeroics (Wakefulness-Promoting Agents)]] above.

=== Peptide Nootropics ===
Short peptide sequences (e.g., Semax) with neurotrophic and neuroprotective activity.

=== Dietary Precursors and Cofactors ===
Amino acids, vitamins, and metabolites that support neurotransmitter synthesis or neuronal function.

== Research Materials ==
Compounds primarily of research interest, with limited or no human clinical approval. Many are analogues of approved meds or classical psychoactive substances. Use of the term '''material''' is preferred over "med" or "substance" in this context.

=== Lysergamides ===
LSD analogues and prodrugs, typically N-substituted at the amide position. Share the ergoline scaffold.

=== Novel Tryptamines ===
4-substituted and 5-substituted tryptamine analogues. Many are prodrugs of known psychedelics (e.g., 4-AcO-DMT → psilocin).

=== Novel Phenethylamines ===
Analogues of mescaline, 2C-x, and DOx compounds. Potency varies enormously; some (NBOMe series) are active at microgram doses.

=== Cathinones ===
Beta-keto amphetamine analogues. Stimulant and/or empathogenic; high abuse potential.

=== Pyrrolidinophenones ===
Cathinone-related stimulants with pyrrolidine ring substitution. Potent dopamine/norepinephrine reuptake inhibitors.

=== Novel Amphetamines ===
Fluorinated and other amphetamine analogues with modified pharmacokinetic or receptor profiles.

=== Novel Phenidates ===
Methylphenidate analogues with modified ester or ring substitutions.

=== Novel Dissociatives (Arylcyclohexylamines) ===
Ketamine and PCP analogues with various halogen, methoxy, or hydroxyl substitutions altering potency, duration, and receptor selectivity.

=== Novel / Designer Benzodiazepines ===
Benzodiazepine analogues including triazolo- and thienodiazepines. Structural modifications alter potency, duration, and subunit selectivity.

=== Beta-Carbolines ===
MAOI-active alkaloids found in plants used in ayahuasca preparations (harmine, harmaline, tetrahydroharmine). Also exhibit NMDA antagonism and 5-HT2A activity at higher doses.

== See also ==
* [[List of CNS-active medicines]]
* [[Main Page]]

[[Category:Reference]]
[[Category:Medicines]]

Dexmethylphenidate

2026-05-16T02:42:46Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{MedTemplate
| generic = Dexmethylphenidate
| brand = Focalin, Focalin XR
| structure = Methylphenidate.svg
| classes = Psychostimulant, CNS stimulant, NDRI
| mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET) — d-threo enantiomer of methylphenidate
| uses = <vote slug="inattention">Inattention</vote>, <vote slug="productivity">Productivity</vote>
| formula = C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>
| routes = Oral
| onset = 30–60 min
| duration = IR 4–6 h; XR 8–12 h
| halflife = 2.2 h (IR parent); ~3 h (XR parent)
| bioavailability = ~22–25%
| pregnancy = Category C
| legal = Schedule II
| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.
| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.
| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.
| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
* Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)
* Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that indication)
| dosing = '''Focalin IR:''' Start 2.5 mg PO twice daily (separate doses by at least 4 h). Titrate by 2.5–5 mg/week. Max 20 mg/day (adults and children).
'''Focalin XR:''' Start 5 mg PO once daily AM (children), 10 mg PO once daily AM (adults). Titrate weekly. Max 30 mg/day (children); 40 mg/day (adults).
'''Conversion from racemic methylphenidate:''' use approximately '''half''' the total daily dose (e.g., Ritalin 20 mg/day → Focalin 10 mg/day).
'''Renal/hepatic impairment:''' caution; reduce dose and monitor.
| effects =

==== Therapeutic ====
* <effect ref="attention">Improved attention, executive function, and working memory. Many patients report a cleaner subjective effect than racemic methylphenidate at equivalent therapeutic doses.</effect>
* <effect ref="reduced-impulsivity"/>
* <effect ref="wakefulness"/>

==== Common ====
* <effect ref="decreased-appetite">Often dose-limiting; may produce weight loss over time.</effect>
* <effect ref="insomnia">Especially with late-afternoon dosing.</effect>
* <effect ref="headache"/>
* <effect ref="abdominal-pain"/>
* <effect ref="irritability"/>
* <effect ref="dry-mouth"/>
* <effect ref="hr-bp-elevation">Usually mild but dose-dependent.</effect>
* <effect ref="weight-loss"/>

==== Cardiovascular ====
* <effect ref="palpitations"/>
* <effect ref="cardiac-event">Rare reports of sudden cardiac death in patients with structural heart disease (FDA warning).</effect>

==== Psychiatric ====
* <effect ref="anxiety"/>
* <effect ref="agitation"/>
* <effect ref="psychosis">Rare; higher risk in patients with bipolar predisposition.</effect>
* <effect ref="mania">Rare; higher risk in patients with bipolar predisposition.</effect>
* <effect ref="hallucinations">Visual or tactile; rare, more common at higher doses or in predisposed patients.</effect>

==== Other adverse ====
* <effect ref="tics">May emerge or worsen; comorbid Tourette syndrome is a traditional relative contraindication.</effect>
* <effect ref="dependence">Schedule II controlled substance; abuse liability similar to racemic methylphenidate per milligram of active material. Crushed/insufflated/IV misuse is the major risk pattern.</effect>
* <effect ref="tolerance">To therapeutic effects, with chronic high-dose use.</effect>
* <effect ref="growth-suppression">Modest reduction in growth velocity in chronically-treated children.</effect>
* <effect ref="priapism">Rare but documented; FDA warning, especially in adolescents.</effect>
* <effect ref="vasculopathy">Raynaud-like phenomenon, rare digital ischemia.</effect>
* <effect ref="seizure">Caution in epilepsy.</effect>
* <effect ref="withdrawal">Fatigue, rebound hyperactivity, dysphoria on dose offset.</effect>
| interactions = * '''MAOIs''' — hypertensive crisis risk; contraindicated within 14 days
* '''Tricyclic antidepressants''' — possible elevation of TCA levels; additive cardiovascular effects
* '''Warfarin''' — possible elevation of INR
* '''Phenytoin, phenobarbital, primidone''' — possible elevation of anticonvulsant levels
* '''Antihypertensives''' — pressor effect of dexmethylphenidate may partially antagonize
* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants) — additive cardiovascular effects
* '''Antipsychotics''' — mutual pharmacologic antagonism
* '''Alcohol''' — may mask effects; possible increased exposure via altered metabolism
* '''Caffeine''' — additive stimulant and anxiogenic effects

Like racemic methylphenidate, '''few CYP-mediated interactions''' due to CES1-dominated metabolism.
<pharmaInteractions/>
| pregnancy_details = Category C. Crosses the placenta. Reproductive data limited and largely extrapolated from racemic methylphenidate; overall not clearly teratogenic but cohort studies suggest a small increase in cardiac malformations. Third-trimester exposure can produce transient neonatal withdrawal. Risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in low amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
* Consider ECG if cardiac risk factors are present
* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
* Sleep quality and timing of last dose
* Periodically reassess continued need; consider med holidays in children
| counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
* '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''
* Eat regular meals despite appetite suppression; weigh periodically.
* Stay well-hydrated.
* Do not combine with significant alcohol or other stimulants.
* Do not share or sell — Schedule II controlled substance.
* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
* If switching from racemic methylphenidate, dose conversion is roughly half — confirm with prescriber.
* Plan for the "crash" when the dose wears off, especially with IR.
| anecdotes =
| seealso = [[Methylphenidate]], [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
| references =
}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>
'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated med interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>
Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2>
*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
*Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)
*Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that indication)<h2 id="Dosing">Dosing and titration</h2>
<span></span>

'''Focalin IR:''' Start 2.5 mg PO twice daily (separate doses by at least 4 h). Titrate by 2.5–5 mg/week. Max 20 mg/day (adults and children).
'''Focalin XR:''' Start 5 mg PO once daily AM (children), 10 mg PO once daily AM (adults). Titrate weekly. Max 30 mg/day (children); 40 mg/day (adults).
'''Conversion from racemic methylphenidate:''' use approximately '''half''' the total daily dose (e.g., Ritalin 20 mg/day → Focalin 10 mg/day).

<span></span>

'''Renal/hepatic impairment:''' caution; reduce dose and monitor.<h2 id="Effects">Effects</h2><span></span>
====Therapeutic====
*<effect ref="attention">Improved attention, executive function, and working memory. Many patients report a cleaner subjective effect than racemic methylphenidate at equivalent therapeutic doses.</effect>
*<effect ref="reduced-impulsivity"/>
*<effect ref="wakefulness"/>
<span></span>
====Common====
*<effect ref="decreased-appetite">Often dose-limiting; may produce weight loss over time.</effect>
*<effect ref="insomnia">Especially with late-afternoon dosing.</effect>
*<effect ref="headache"/>
*<effect ref="abdominal-pain"/>
*<effect ref="irritability"/>
*<effect ref="dry-mouth"/>
*<effect ref="hr-bp-elevation">Usually mild but dose-dependent.</effect>
*<effect ref="weight-loss"/>
<span></span>
====Cardiovascular====
*<effect ref="palpitations"/>
*<effect ref="cardiac-event">Rare reports of sudden cardiac death in patients with structural heart disease (FDA warning).</effect>
<span></span>
====Psychiatric====
*<effect ref="anxiety"/>
*<effect ref="agitation"/>
*<effect ref="psychosis">Rare; higher risk in patients with bipolar predisposition.</effect>
*<effect ref="mania">Rare; higher risk in patients with bipolar predisposition.</effect>
*<effect ref="hallucinations">Visual or tactile; rare, more common at higher doses or in predisposed patients.</effect>
<span></span>
====Other adverse====
*<effect ref="tics">May emerge or worsen; comorbid Tourette syndrome is a traditional relative contraindication.</effect>
*<effect ref="dependence">Schedule II controlled substance; abuse liability similar to racemic methylphenidate per milligram of active material. Crushed/insufflated/IV misuse is the major risk pattern.</effect>
*<effect ref="tolerance">To therapeutic effects, with chronic high-dose use.</effect>
*<effect ref="growth-suppression">Modest reduction in growth velocity in chronically-treated children.</effect>
*<effect ref="priapism">Rare but documented; FDA warning, especially in adolescents.</effect>
*<effect ref="vasculopathy">Raynaud-like phenomenon, rare digital ischemia.</effect>
*<effect ref="seizure">Caution in epilepsy.</effect>
*<effect ref="withdrawal">Fatigue, rebound hyperactivity, dysphoria on dose offset.</effect><h2 id="Contraindications">Contraindications</h2>
*Hypersensitivity to dexmethylphenidate or methylphenidate
*Concurrent MAOI use, or within 14 days of MAOI discontinuation
*Symptomatic cardiovascular disease, advanced atherosclerosis, moderate–severe hypertension, recent MI
*Hyperthyroidism
*Glaucoma
*Pheochromocytoma
*Severe anxiety, tension, or agitation
*'''Relative:''' Tourette syndrome / tic disorders, history of substance use disorder, bipolar disorder, psychotic disorders, structural cardiac abnormalities<h2 id="Interactions">Interactions</h2>
*'''MAOIs''' — hypertensive crisis risk; contraindicated within 14 days
*'''Tricyclic antidepressants''' — possible elevation of TCA levels; additive cardiovascular effects
*'''Warfarin''' — possible elevation of INR
*'''Phenytoin, phenobarbital, primidone''' — possible elevation of anticonvulsant levels
*'''Antihypertensives''' — pressor effect of dexmethylphenidate may partially antagonize
*'''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants) — additive cardiovascular effects
*'''Antipsychotics''' — mutual pharmacologic antagonism
*'''Alcohol''' — may mask effects; possible increased exposure via altered metabolism
*'''Caffeine''' — additive stimulant and anxiogenic effects

Like racemic methylphenidate, '''few CYP-mediated interactions''' due to CES1-dominated metabolism.<h2 id="Pregnancy">Pregnancy and lactation</h2>
Category C. Crosses the placenta. Reproductive data limited and largely extrapolated from racemic methylphenidate; overall not clearly teratogenic but cohort studies suggest a small increase in cardiac malformations. Third-trimester exposure can produce transient neonatal withdrawal. Risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in low amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.<h2 id="Monitoring">Monitoring</h2>
*Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
*Consider ECG if cardiac risk factors are present
*At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
*Sleep quality and timing of last dose
*Periodically reassess continued need; consider med holidays in children<h2 id="Counseling">Patient counseling</h2>
*Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
*'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''
*Eat regular meals despite appetite suppression; weigh periodically.
*Stay well-hydrated.
*Do not combine with significant alcohol or other stimulants.
*Do not share or sell — Schedule II controlled substance.
*Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
*If switching from racemic methylphenidate, dose conversion is roughly half — confirm with prescriber.
*<nowiki>Plan for the "crash" when the dose wears off, especially with IR.{{#if:</nowiki><h2 id="Anecdotes">Personal experience</h2>
<span></span>

''The following are personal accounts and not medical advice.''
<span></span><discuss slug="personal-experience" />

[[Category:Stimulants & Wake-Promoting Agents]]
[[Category:Methylphenidates (Phenidates)]]

Methylphenidate

2026-05-16T02:42:46Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

MediaWiki:Smw import schema

2026-05-16T02:42:46Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

Mixed amphetamine salts

2026-05-16T02:42:46Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{MedTemplate
| generic = Mixed amphetamine salts
| brand = Adderall, Adderall XR, Mydayis
| structure = Amphetamine-white.svg
| classes = Psychostimulant, Amphetamine
| uses = <vote slug="inattention">Inattention</vote>, <vote slug="narcolepsy">Narcolepsy</vote>, <vote slug="hyperactivity">Hyperactivity</vote>, <vote slug="impulsivity">Impulsivity</vote>, <vote slug="irritability">Irritability</vote>
| starting_dose = 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis
| preparations = IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg
| fda_max = XR = 40 or 60 mg/d; IR = 40 or 60 mg/d<ref name="carlat">S0</ref>
| routes = Oral
| onset = IR: 30–60 min; XR: 1–2 h to peak effect
| duration = IR 4–6 h; XR 10–12 h; Mydayis 14–16 h
| halflife = D-amphetamine ~10 h; L-amphetamine ~13 h (adults)
| bioavailability = ~75–90% (oral)
| pregnancy = Category C
| legal = Schedule II
| mechanism = TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport — net release of dopamine and norepinephrine
| intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate).
Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a med in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular meds in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world.
| indications = <indication ref="adhd" author="MDElliottMD"/>
<indication ref="narcolepsy" author="MDElliottMD"/>
<indication ref="trd-augment" author="MDElliottMD">
Off-label.
</indication>
<indication ref="shift-work" author="MDElliottMD">
Off-label.
</indication>
<indication ref="chronic-illness-cog" author="MDElliottMD">
Off-label.
</indication>

<indication ref="impulsivity" author="MDElliottMD"/>

<indication ref="distractibility" author="MDElliottMD">
Impoved sustained attention by decreasing distractibility
</indication>
| dosing = <titration slug="typical-adult" title="Typical Adult" author="MDElliottMD">
Start at 5 mg XR; may increase by 5 mg each day until the desired effect is reached, up to 30 mg XR to start, and up to 60 mg XR eventually if necessary, in 10 mg increments.

Occasionally can go higher if no notable effects (good or bad) at 60 mg — proceed with caution.

If not long enough acting: add a tail dose of Adderall IR at [XR dose]/2.
If too long acting (e.g. disrupting sleep): switch to IR entirely (again at half the XR dose).
</titration>
| effects =
* <effect ref="attention" author="MDElliottMD">Improved sustained attention, particularly on uninteresting things.</effect>
* <effect ref="reduced-impulsivity" author="MDElliottMD"/>
* <effect ref="wakefulness" author="MDElliottMD"/>
* <effect ref="motivation" author="MDElliottMD"/>
* <effect ref="euphoria" author="MDElliottMD"/>
* <effect ref="decreased-appetite" author="MDElliottMD"></effect>
* <effect ref="dry-mouth" author="MDElliottMD"/>
* <effect ref="hr-bp-elevation" author="MDElliottMD"/>
* <effect ref="bruxism" author="MDElliottMD"/>
* <effect ref="insomnia" author="MDElliottMD">(with proper am dosing)</effect>
* <effect ref="irritability" author="MDElliottMD"/>
* <effect ref="anxiety" author="MDElliottMD"/>
* <effect ref="headache" author="MDElliottMD"/>
* <effect ref="weight-loss" author="MDElliottMD"/>
* <effect ref="palpitations" author="MDElliottMD"/>
* <effect ref="stereotypies" author="MDElliottMD">Repetitive movements, e.g. skin picking, muscle twitches, tics</effect>
* <effect ref="cardiac-event" author="MDElliottMD"></effect>
* <effect ref="agitation" author="MDElliottMD"/>
* <effect ref="psychosis" author="MDElliottMD"></effect>
* <effect ref="mania" author="MDElliottMD"></effect>
* <effect ref="dependence" author="MDElliottMD"></effect>
* <effect ref="tolerance" author="MDElliottMD"></effect>
* <effect ref="growth-suppression" author="MDElliottMD">(well documented effect with chronic use in children)</effect>
* <effect ref="serotonin-syndrome" author="MDElliottMD">Especially in combination with MAOIs</effect>
* <effect ref="vasculopathy" author="MDElliottMD">Raynaud-like phenomenon, rare digital ischemia.</effect>
* <effect ref="seizure" author="MDElliottMD"></effect>
* <effect ref="hyperthermia" author="MDElliottMD">Risk in hot environments or with vigorous exercise.</effect>
* <effect ref="withdrawal" author="MDElliottMD">Low motivation, low mood, hypersomnia, increased appetite on abrupt discontinuation.</effect>
* <effect ref="urinary-retention" author="MDElliottMD">Difficult/slow urination</effect>

<effect ref="focus-intensification"/>

<effect ref="appetite-suppression"/>

<effect ref="alertness"/>

<effect ref="executive-functioning"/>
| pk_absorption = Excellent oral bioavailability — sources report ">75%" to "~90%". Food does not significantly affect total absorption but can delay peak concentration.
| pk_distribution = Volume of distribution ~4 L/kg; plasma protein binding less than 20%. Crosses the blood–brain barrier and placenta.
| pk_metabolism = Amphetamine is oxidized to 4-hydroxyamphetamine, α-hydroxyamphetamine, or norephedrine. Norephedrine and 4-hydroxyamphetamine are active metabolites and are further metabolized to 4-hydroxy-norephedrine. Deamination of α-hydroxyamphetamine yields phenylacetone, which is metabolized to benzoic acid and conjugated to its glucuronide and hippuric acid. '''CYP2D6''' is crucial for amphetamine metabolism; genetic polymorphism causes significant inter-patient variability in clearance. Amphetamine itself inhibits monoamine oxidase (MAO), and both CYP1A2 and CYP3A4 contribute to its metabolism.<ref>S1</ref>
| pk_elimination = Primarily renal — ~30–40% recovered as unchanged amphetamine, the rest as metabolites. Due to its pK<sub>a</sub> of 9.9, urinary elimination is highly pH-dependent: alkaline urine reduces ionization and decreases renal clearance, while acidic urine and high flow rates accelerate clearance via active tubular secretion. '''Half-life:''' D-enantiomer 9 h (children 6–12 y), 11 h (adolescents 13–17 y), 10 h (adults); L-enantiomer 11 h, 13–14 h, 13 h respectively.
| pharmacodynamics = Amphetamine purportedly works via several converging mechanisms at monoaminergic terminals:
* '''Trace amine-associated receptor 1 (TAAR1) agonism''' — activates TAAR1 in monoaminergic neurons, triggering PKA/PKC signaling that phosphorylates the dopamine and norepinephrine transporters (DAT, NET), causing them to internalize and reverse direction.
* '''VMAT2 substrate''' — enters the presynaptic terminal, displaces dopamine and norepinephrine from vesicles into the cytoplasm.
* '''Reverse transport via DAT/NET''' — the elevated cytoplasmic monoamine pool is then ejected into the synaptic cleft via the now-reversed transporters. '''This is the primary mechanism of action — release, not reuptake inhibition.'''
* '''Weak reuptake inhibition''' at DAT and NET (secondary to release).
* '''MAO inhibition''' at higher concentrations, slowing presynaptic catabolism of monoamines.
* '''Serotonergic effects''' at high or supratherapeutic doses (relevant to overdose and serotonin syndrome risk).

The net result is a robust increase in synaptic dopamine and norepinephrine in prefrontal cortex, striatum, and nucleus accumbens — underlying both therapeutic (attention, executive function, wakefulness) and reinforcing (euphoria, abuse liability) effects.
| interactions = Minimal in practice. Caution with other psychostimulants, including caffeine. metabolized by 2D6, so relevant caution applies.
<pharmaInteractions/>
| pregnancy_details = [https://www.ncbi.nlm.nih.gov/books/NBK501307/ Category C]. Crosses the placenta. Prenatal amphetamine exposure has been associated with low birth weight, premature delivery, and neonatal withdrawal (agitation, dysphoria, lassitude). Long-term neurodevelopmental outcomes from prescribed therapeutic exposure are less clear and likely modest, but illicit-dose exposure is associated with significant developmental impact. Decision should be individualized; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in clinically significant amounts — breastfeeding generally discouraged.
| monitoring = * Baseline: cardiovascular history, weight/height, mental health history (especially for psychosis/bipolar/substance use risk), (optional) blood pressure, (optional) heart rate,
* At each visit: efficacy, side effects, general well-being
* Periodically reassess continued need; consider med holidays to assess ongoing benefit
* Sleep quality (insomnia is dose-limiting)
| counseling = * Take first thing in the morning to minimize insomnia; avoid (late) afternoon dosing.
* '''Do not crush, chew, or split Adderall XR or Mydayis capsules''' — disrupts the controlled-release mechanism. (Capsules may be opened and sprinkled on applesauce if needed.)
* Take with or without food; high-acid beverages (orange juice, vitamin C) may reduce absorption.
* Stay well-hydrated, especially in heat or during exercise.
* Eat regular meals despite appetite suppression.
* Report any chest pain, palpitations, severe agitation, hallucinations, or signs of poor circulation in extremities.
* Sudden discontinuation can cause a fatigue/depression "crash" — plan for it.
* Take caution: make increase bowel motility and increase risk of expelled fecal content.
| anecdotes =
| seealso = [[Dextroamphetamine]], [[Lisdexamfetamine]], [[Methylphenidate]], [[Dexmethylphenidate]], [[Modafinil]], [[Atomoxetine]], [[Methamphetamine]]
| references =
}}

[[Category:Stimulants & Wake-Promoting Agents]]
[[Category:Amphetamines]]

Alprazolam

2026-05-16T02:42:46Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{MedTemplate
| generic = Alprazolam
| brand = Xanax, Xanax XR, Niravam, Frontin, Alprax, Helex
| structure = Alprazolam_structure.svg
| classes = Benzodiazepine, Anxiolytic
| mechanism = Positive allosteric modulator at GABA<sub>A</sub> receptor (benzodiazepine site)
| uses = Generalized anxiety disorder, panic disorder, anxiety with depression
| formula = C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub>
| routes = Oral, sublingual (ODT)
| onset = 15–30 minutes
| duration = 4–6 hours (IR); 11–17 hours (XR)
| halflife = ~11 hours (range 6–27 h; prolonged in elderly and hepatic impairment)
| bioavailability = ~80–100%
| pregnancy = Avoid
| legal = Schedule IV
| intro = '''Alprazolam''' is a high-potency, intermediate-acting triazolobenzodiazepine, FDA-approved for generalized anxiety disorder, panic disorder, and anxiety associated with depression. Its rapid onset, short-to-intermediate half-life, and high potency make it both clinically effective and uniquely problematic among benzodiazepines: alprazolam has consistently been associated with the highest rates of dependence, misuse, and difficult withdrawal in its class. For most chronic anxiety treatment, longer-acting agents (clonazepam, diazepam) or non-benzodiazepine alternatives (SSRIs, SNRIs, buspirone) are preferred.
| pharmacokinetics = Rapid and near-complete oral absorption; bioavailability ~80–100%. Peak plasma levels in 1–2 hours (IR) or ~9 hours (XR). Highly protein-bound (~80%). Metabolized hepatically by '''CYP3A4''' to α-hydroxyalprazolam and 4-hydroxyalprazolam — both pharmacologically active but present at low concentrations. Half-life ~11 hours in healthy adults; substantially prolonged in elderly patients, obesity, and hepatic impairment. The relatively short half-life relative to diazepam contributes to inter-dose rebound anxiety with TID dosing and to the severity of its discontinuation syndrome.
| pharmacodynamics = Binds to the benzodiazepine site on GABA<sub>A</sub> receptors, allosterically enhancing GABA-induced chloride channel opening (increased '''frequency''' of opening, not duration — distinguishing benzodiazepines from barbiturates). This hyperpolarizes the neuron, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal muscle relaxant effects. Compared to other benzodiazepines, alprazolam shows relatively greater anxiolytic and antipanic effect with somewhat less sedation per unit anxiolysis, attributed in part to its triazole ring. Some evidence of mild antidepressant activity at higher doses, the basis for its "anxiety with depression" indication.
| indications = * Generalized anxiety disorder
* Panic disorder (with or without agoraphobia)
* Anxiety associated with depression
* '''Not first-line''' for chronic anxiety — SSRIs, SNRIs, buspirone, or CBT typically preferred due to dependence risk
* Occasionally used short-term for procedural anxiety or situational anxiety
| dosing = '''GAD:''' Start 0.25–0.5 mg PO three times daily; titrate slowly. Max 4 mg/day.
'''Panic disorder:''' Start 0.5 mg PO three times daily; titrate by 1 mg/day every 3–4 days. Typical effective 1–10 mg/day (FDA labeling permits to 10 mg/day, but doses >4 mg substantially increase dependence and adverse effects).
'''Elderly/debilitated:''' Start 0.25 mg 2–3 times daily; titrate very cautiously.
'''Hepatic impairment:''' Reduce dose 50% or more.
'''Discontinuation:''' '''Always taper.''' Typical reduction 0.5 mg every 3 days at minimum; for long-term users, much slower (Ashton-style protocols reduce by ~10% of current dose every 1–2 weeks). Abrupt cessation can precipitate seizures.
| effects = ''Therapeutic:'' anxiolysis (rapid), reduced panic frequency and severity, calming, mild euphoria, improved sleep.
''Common adverse:'' '''drowsiness''', '''dizziness''', impaired coordination, fatigue, slurred speech, dry mouth, blurred vision, '''anterograde amnesia''', impaired psychomotor performance, decreased libido, changes in appetite.
| adverse = * '''Dependence and addiction''' — highest among commonly-prescribed benzodiazepines. Physical dependence can develop within weeks of regular use.
* '''Withdrawal syndrome''' — rebound anxiety, insomnia, tremor, sweating, perceptual disturbances, depersonalization, '''seizures''' with abrupt cessation. Often more severe and protracted than withdrawal from longer-acting benzodiazepines.
* '''Tolerance''' — anxiolytic and hypnotic tolerance develops with chronic use; tolerance to amnestic and motor effects is less complete.
* '''Respiratory depression''' — especially in combination with opioids ('''black box warning'''), alcohol, or other CNS depressants. Cause of many overdose deaths.
* '''Paradoxical reactions''' — agitation, disinhibition, aggression, particularly in elderly, children, or those with personality disorders.
* '''Cognitive impairment''' — both acute (memory, attention) and chronic with long-term use; partial reversibility uncertain.
* '''Falls and fractures''' in elderly.
* '''Anterograde amnesia''' — clinically significant; can be exploited for criminal purposes (med-facilitated assault).
* '''Misuse and diversion''' — Xanax has substantial street value and frequent recreational misuse.
* '''Suicide risk in overdose''' — especially when combined with alcohol or opioids.
* '''Rebound anxiety''' between doses with short-half-life IR formulation.
| interactions = * '''Opioids''' — additive respiratory depression and overdose risk ('''FDA black box warning'''); avoid when possible
* '''Alcohol''' — additive CNS depression and respiratory depression
* '''CYP3A4 inhibitors''' (ketoconazole, itraconazole, ritonavir, clarithromycin, nefazodone) — substantially increase alprazolam levels; some contraindicated
* '''CYP3A4 inducers''' (carbamazepine, phenytoin, rifampin, St. John's wort) — decrease levels; may reduce efficacy
* '''Other CNS depressants''' (Z-drugs, sedating antihistamines, gabapentinoids, sedating antidepressants) — additive
* '''Grapefruit juice''' — modest CYP3A4 inhibition; can raise alprazolam levels with regular consumption
* '''Fluoxetine, fluvoxamine''' — increase alprazolam levels via CYP3A4 inhibition
<pharmaInteractions/>
| pregnancy_details = Historically Category D. First-trimester benzodiazepine exposure has been associated with increased risk of cleft lip/palate in some studies, though absolute risk is small. Third-trimester or near-term use can produce '''floppy infant syndrome''' (hypotonia, hypothermia, feeding difficulty, respiratory depression) and neonatal withdrawal. Generally avoided in pregnancy unless benefits clearly outweigh risks; SSRIs are usually preferred for chronic anxiety. Excreted in breast milk — breastfeeding generally discouraged.
| monitoring = * Continued need for treatment — reassess at every visit; target shortest effective duration
* Signs of dependence, tolerance, dose escalation, or misuse
* Cognitive function, especially in long-term users and elderly
* Mood and suicidality
* Falls risk in elderly
* Respiratory status, especially in COPD/OSA or on opioids
* Liver function in long-term use
| counseling = * '''Take exactly as prescribed''' — do not increase dose without consulting prescriber.
* '''Do not combine with alcohol''' or other sedatives — combinations can be fatal.
* '''Do not stop abruptly''' — can cause seizures; must be tapered.
* Avoid driving or operating machinery until response is known.
* May cause memory gaps, especially with higher doses or alcohol.
* Long-term daily use carries a real risk of dependence — discuss alternatives if treatment will extend beyond a few weeks.
* Avoid grapefruit juice in large quantities.
* Keep secured — high risk of theft and diversion.
* If pregnant or planning pregnancy, discuss with prescriber.
| anecdotes =
| seealso = [[Lorazepam]], [[Diazepam]], [[Clonazepam]], [[Temazepam]], [[Midazolam]], [[Buspirone]], [[Hydroxyzine]], [[Pregabalin]]
| references =
}}
[[Category:Benzodiazepines]]
[[Category:GABAA Positive Allosteric Modulators (General)]]
[[Category:GABAergics]]
[[Category:Anxiolytics & Sedative-Hypnotics]]

Fluoxetine

2026-05-16T02:42:45Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

{{MedTemplate
| generic = Fluoxetine
| brand = Prozac
| structure = Fluoxwhite.svg
| classes = SSRI, Anxiolytic, Antidepressant
| uses = <vote slug="anxiety-use">Anxiety</vote>, <vote slug="premature-ejaculation-use">Premature ejaculation</vote>, <vote slug="low-mood-use">Low mood</vote>
| starting_dose = 10 mg
| preparations = 10 mg, 20 mg, 40 mg caps
| fda_max = 40 mg/d
| pill_id =
* '''10 mg:''' green/cream capsule, "PLIVA 647"
* '''20 mg:''' green/cream capsule, "PROZAC 20"
* '''40 mg:''' olive/cream capsule, "DISTA 3107"
* '''Oral solution:''' 20 mg / 5 mL, clear
| routes = Oral
| onset =
| duration = Very long
| halflife = 1–4 days (7–15 days for norfluoxetine)
| bioavailability = 70–90% (oral)
| pregnancy = Category C<ref name="lactmed">S0</ref>
| legal = Rx-only in US
| mechanism = TrkB/BDNF<ref name="trkb">S1</ref> <vote slug="ssri-claim">Fluoxetine is a selective serotonin reuptake inhibitor.</vote>
| intro = Fluoxetine was the first of a long line of SSRIs. It is notable for its extremely long half-life and relative lack of withdrawal syndrome. It can also be useful in helping taper and discontinue other SxRI meds.
| indications = <indication ref="depression" author="MDElliottMD"/>
<indication ref="anxiety-disorders" author="MDElliottMD">
Including generalized anxiety, panic, and social anxiety.
</indication>
<indication ref="panic" author="MDElliottMD"/>
<indication ref="social-anxiety" author="MDElliottMD"/>
<indication ref="ocd" author="MDElliottMD"/>
<indication ref="ptsd" author="MDElliottMD">
Potentially.
</indication>

<indication ref="premature-ejaculation"/>
| dosing = <titration slug="standard" author="MDElliottMD" title="Standard adult or child">
Start no higher than 10 mg for the first dose. May increase by 10 mg every 2–12 weeks, or remain at 10 mg if the response is adequate, up to a typical starting maximum of 40 mg. Absolute max: 80 mg.
</titration>

<titration slug="ocd" author="MDElliottMD" title="OCD">
Start at 10 mg daily; increase by 10–20 mg every 2–6 weeks, up to 80 mg. OCD typically requires elevated doses (60–80 mg).
</titration>
| effects =
* <effect ref="anxiolysis" author="MDElliottMD">Classically starting at 3–4 weeks and improving for another 8–12.</effect>
* <effect ref="delayed-ejaculation" author="MDElliottMD"/>
* <effect ref="mood-enhancement" author="MDElliottMD"/>
* <effect ref="nausea" author="MDElliottMD">Common, often improves over 1–2 weeks.</effect>
* <effect ref="decreased-libido" author="MDElliottMD"/>
* <effect ref="temporary-erectile-dysfunction" author="MDElliottMD"/>
* <effect ref="persistent-sexual-dysfunction" author="MDElliottMD">Historically [https://pmc.ncbi.nlm.nih.gov/articles/PMC11450419/ associated with SSRIs].</effect>

<effect ref="anorgasmia" author="MDElliottMD"/>
| pk_absorption = 70–90%<ref name="statpearls">S3</ref> oral bioavailability.
| pk_distribution = Fluoxetine has plasma protein binding of approximately 94.5%, bound to albumin and alpha-1 glycoprotein. Fluoxetine readily crosses the blood–brain barrier, with a brain-to-plasma ratio of 2.6:1 in humans. The volume of distribution (Vd) of fluoxetine and its metabolite ranges between 20 to 42 L/kg. Some studies report that fluoxetine has the maximum volume of distribution (Vd) of any SSRI (between 14 and 100 L/kg).<ref name="statpearls"/>
| pk_metabolism = Fluoxetine's active metabolite is norfluoxetine, produced when the cytochrome P450 enzyme (CYP2D6) acts on it. Prescribers must remember that fluoxetine has several med-med interactions due to its metabolism through the CYP2D6 isoenzyme. Additionally, norfluoxetine can have an inhibitory effect on CYP3A4. Fluoxetine has a half-life of 2 to 4 days, and its active metabolite norfluoxetine has a half-life of 7 to 9 days. Approximately 7% of individuals definitively exhibit poor metabolism of fluoxetine due to reduced activity of CYP2D6.<ref name="statpearls"/"
| pk_elimination =
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = None required
| counseling =
| anecdotes = <anecdote slug="2026-05-12" perspective="provider" author="MDElliottMD">
Fluoxetine is great for getting off other SxRIs! Especially venlafaxine and duloxetine.
</anecdote>
| seealso = [[Sertraline]], [[Duloxetine]]
| references = <references/>
}}

[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]
[[Category:Antidepressants]]
[[Category:Medicines]]

Template:MedInfo

2026-05-16T02:42:45Z

Maintenance script: Terminology: medicine → med (shorter form per user preference)

<includeonly>{| class="wikitable" style="float:right; clear:right; max-width:26em; margin:0 0 1em 1em; font-size:92%;"
|+ style="font-size:115%;" |'{{{PAGENAME}}}
! colspan="2" style="background:#eef;" | "Med Information"
|-
! style="width:9em; text-align:left;" | Generic name(s)
| {{{generic|—}}}
|-
! style="text-align:left;" | Brand name(s)
| {{{brand|—}}}
|-
! style="text-align:left;" | Classification(s)
| {{{class|—}}}
|-
! style="text-align:left;" | Common uses
| {{{uses|—}}}
|-
! style="text-align:left;" | Effects
| {{{effects|—}}}
|}{{#if:{{{titration|}}}|
== Titration strategies ==
{{{titration}}}
}}{{#if:{{{anecdotes|}}}|
== Personal anecdotes ==
''The following are personal accounts, not medical advice.''

{{{anecdotes}}}
}}[[Category:Medications]]</includeonly><noinclude>
== Usage ==
<pre>
{{MedInfo
| generic =
| brand =
| class =
| uses =
| effects =
| titration =
| anecdotes =
}}
</pre>

<templatedata>
{
"description": "Infobox + sections for a med entry. Short factual fields appear in a right-aligned infobox; longer prose fields render as full-width sections below.",
"params": {
"generic": { "label": "Generic name(s)", "description": "Comma-separated if more than one. Defaults to the page name.", "type": "string" },
"brand": { "label": "Brand name(s)", "description": "Comma-separated.", "type": "string" },
"class": { "label": "Classification(s)","description": "Med class(es), e.g. SSRI, NSAID.", "type": "string" },
"uses": { "label": "Common uses", "type": "string" },
"effects": { "label": "Effects", "description": "Therapeutic and side effects.", "type": "string" },
"titration": { "label": "Titration strategies", "description": "Wikitext; renders as a full-width section.", "type": "content" },
"anecdotes": { "label": "Personal anecdotes", "description": "Wikitext; renders as a full-width section. Auto-includes a 'not medical advice' disclaimer.", "type": "content" }
},
"format": "block"
}
</templatedata>

[[Category:Templates]]
</noinclude>

Bromazolam

2026-05-16T02:42:45Z

Maintenance script: Revert Bromazolam L38: 'Drug' is a proper noun in DEA citation

{{MedTemplate
| generic = Bromazolam
| brand = (none — never marketed)
| structure = Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position).
| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
| mechanism = Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.
| uses = No approved medical indication. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
| starting_dose = No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
| preparations = Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.
| fda_max = N/A (never approved)
| routes = Oral, sublingual, intranasal; rectal and IV reported.
| onset = ~20–40 min PO; faster sublingual/intranasal.
| duration = 6–10 h subjective; full pharmacologic effect considerably longer.
| halflife = Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
| bioavailability = Not formally characterized in humans.
| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.
| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a medicine of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.
| pharmacodynamics = Non-selective positive allosteric modulator at the benzodiazepine site of GABA<sub>A</sub> receptors containing α1, α2, α3, or α5 subunits with a γ subunit. Like alprazolam, clinically displays anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle-relaxant effects with significant abuse liability. Respiratory depression at high doses is modest in isolation but markedly synergized by opioids, alcohol, and other CNS depressants — the dominant mechanism of bromazolam-associated mortality.
| indications = None approved. Has no recognized medical role.
| dosing = No therapeutic dosing. Harm-reduction note: because of inconsistent tablet purity and frequent fentanyl co-contamination, '''any''' illicit "benzo" tablet should be assumed to potentially contain bromazolam, fentanyl, or both.
| effects = Sedation, anxiolysis, anterograde amnesia, ataxia, slurred speech, disinhibition, prolonged blackouts. At high dose or in combination: severe sedation, respiratory depression, coma. Paradoxical agitation/aggression occasionally reported. Withdrawal mirrors other high-potency benzos: anxiety, insomnia, autonomic hyperactivity, seizures, delirium — and can be life-threatening, often more protracted than alprazolam withdrawal owing to the longer half-life.
| interactions = <pharmaInteractions/>

* '''Opioids''' (fentanyl, heroin, methadone, buprenorphine): profound additive respiratory depression — primary mechanism of bromazolam-associated overdose death.
* '''Alcohol, GHB, barbiturates, gabapentinoids''': additive CNS/respiratory depression.
* '''Xylazine''': frequently co-encountered in illicit opioid supply ("tranq dope"); compounds sedation and complicates resuscitation (xylazine is not reversed by naloxone).
* '''CYP3A4 inhibitors''' (azoles, macrolides, ritonavir, grapefruit): prolong/intensify effect.
* '''CYP3A4 inducers''' (rifampin, carbamazepine, phenytoin, St John's wort): may reduce levels.
* '''Flumazenil''' reverses GABA<sub>A</sub> effects but is rarely used in mixed-overdose / chronic-benzo contexts due to seizure risk.
| pregnancy_details = Avoid in pregnancy and lactation. Class data extrapolated from clinical benzodiazepines; designer status means no formal safety data.
| monitoring = In suspected overdose: airway, respiratory rate, oxygen saturation, mental status. Standard urine benzodiazepine immunoassay is '''insensitive''' to bromazolam — request specific LC-MS/MS confirmation. ECG and electrolytes if mixed overdose suspected.
| counseling = Patients should be counseled that illicit "Xanax bars" or designer benzodiazepine tablets are frequently bromazolam and/or fentanyl. Never combine with opioids or alcohol. Withdrawal requires medically supervised taper — do not stop abruptly after sustained use. Carry naloxone if any opioid co-use is plausible (naloxone does '''not''' reverse bromazolam itself but reverses concurrent opioid depression).
| anecdotes =
| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]
| references =
* DEA Diversion. ''Bromazolam.'' Drug & Chemical Evaluation Section, 2023.
* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.
* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.
* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated medicine supply.
}}

[[Category:Research Materials]]
[[Category:Benzodiazepines]]
[[Category:Triazolobenzodiazepines]]
[[Category:GABAA Positive Allosteric Modulators (General)]]
[[Category:GABAergics]]
[[Category:Anxiolytics & Sedative-Hypnotics]]

Bromazolam

2026-05-16T02:30:58Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{MedTemplate
| generic = Bromazolam
| brand = (none — never marketed)
| structure = Triazolobenzodiazepine; 8-bromo analog of alprazolam (bromine in place of the chloro substituent at the 8-position).
| classes = Designer benzodiazepine, Triazolobenzodiazepine, Sedative-Hypnotic, Research material
| mechanism = Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects.
| uses = No approved medical indication. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies.
| starting_dose = No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
| preparations = Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists.
| fda_max = N/A (never approved)
| routes = Oral, sublingual, intranasal; rectal and IV reported.
| onset = ~20–40 min PO; faster sublingual/intranasal.
| duration = 6–10 h subjective; full pharmacologic effect considerably longer.
| halflife = Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect.
| bioavailability = Not formally characterized in humans.
| pregnancy = Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data — assume worst-case.
| legal = First synthesized by Upjohn in 1976; never marketed. Schedule I in several U.S. states (e.g., Virginia, Florida, Mississippi, Alabama); federally unscheduled in the U.S. as of mid-2020s but DEA has listed it as a medicine of concern. Class C in the UK (generic benzodiazepine controls). Controlled in Sweden, Germany (NpSG), Switzerland, and Canada.
| intro = '''Bromazolam''' is a triazolobenzodiazepine first synthesized by Upjohn in 1976 and never developed clinically. It emerged on the research-chemical market around 2016 and, beginning around 2021–2022, became one of the most commonly encountered designer benzodiazepines in North America — notably as an adulterant in the illicit opioid supply alongside fentanyl and, often, xylazine. Pharmacologically and structurally it is the bromine analog of alprazolam, with comparable potency and a similar (or somewhat longer) duration of action.
| pharmacokinetics = Lipophilic; orally bioavailable; hepatic metabolism (CYP3A4 predominantly) with hydroxylated metabolites. Half-life appears longer than alprazolam, with case reports of detection in blood/urine for days after a single exposure. Standard benzodiazepine immunoassay screens frequently '''miss''' bromazolam — confirmatory LC-MS/MS is required for reliable detection.
| pharmacodynamics = Non-selective positive allosteric modulator at the benzodiazepine site of GABA<sub>A</sub> receptors containing α1, α2, α3, or α5 subunits with a γ subunit. Like alprazolam, clinically displays anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle-relaxant effects with significant abuse liability. Respiratory depression at high doses is modest in isolation but markedly synergized by opioids, alcohol, and other CNS depressants — the dominant mechanism of bromazolam-associated mortality.
| indications = None approved. Has no recognized medical role.
| dosing = No therapeutic dosing. Harm-reduction note: because of inconsistent tablet purity and frequent fentanyl co-contamination, '''any''' illicit "benzo" tablet should be assumed to potentially contain bromazolam, fentanyl, or both.
| effects = Sedation, anxiolysis, anterograde amnesia, ataxia, slurred speech, disinhibition, prolonged blackouts. At high dose or in combination: severe sedation, respiratory depression, coma. Paradoxical agitation/aggression occasionally reported. Withdrawal mirrors other high-potency benzos: anxiety, insomnia, autonomic hyperactivity, seizures, delirium — and can be life-threatening, often more protracted than alprazolam withdrawal owing to the longer half-life.
| interactions = <pharmaInteractions/>

* '''Opioids''' (fentanyl, heroin, methadone, buprenorphine): profound additive respiratory depression — primary mechanism of bromazolam-associated overdose death.
* '''Alcohol, GHB, barbiturates, gabapentinoids''': additive CNS/respiratory depression.
* '''Xylazine''': frequently co-encountered in illicit opioid supply ("tranq dope"); compounds sedation and complicates resuscitation (xylazine is not reversed by naloxone).
* '''CYP3A4 inhibitors''' (azoles, macrolides, ritonavir, grapefruit): prolong/intensify effect.
* '''CYP3A4 inducers''' (rifampin, carbamazepine, phenytoin, St John's wort): may reduce levels.
* '''Flumazenil''' reverses GABA<sub>A</sub> effects but is rarely used in mixed-overdose / chronic-benzo contexts due to seizure risk.
| pregnancy_details = Avoid in pregnancy and lactation. Class data extrapolated from clinical benzodiazepines; designer status means no formal safety data.
| monitoring = In suspected overdose: airway, respiratory rate, oxygen saturation, mental status. Standard urine benzodiazepine immunoassay is '''insensitive''' to bromazolam — request specific LC-MS/MS confirmation. ECG and electrolytes if mixed overdose suspected.
| counseling = Patients should be counseled that illicit "Xanax bars" or designer benzodiazepine tablets are frequently bromazolam and/or fentanyl. Never combine with opioids or alcohol. Withdrawal requires medically supervised taper — do not stop abruptly after sustained use. Carry naloxone if any opioid co-use is plausible (naloxone does '''not''' reverse bromazolam itself but reverses concurrent opioid depression).
| anecdotes =
| seealso = [[Alprazolam]], [[Clonazolam]], [[Flualprazolam]], [[Etizolam]], [[Flumazenil]], [[Fentanyl]], [[Xylazine]], [[Naloxone]]
| references =
* DEA Diversion. ''Bromazolam.'' Medicine & Chemical Evaluation Section, 2023.
* Papsun DM, et al. Forensic toxicology of bromazolam. ''J Anal Toxicol'' 2022.
* CFSRE / NPS Discovery. Bromazolam emergence reports, 2021–2024.
* Health Canada / CCENDU bulletins on designer benzodiazepines in the unregulated medicine supply.
}}

[[Category:Research Materials]]
[[Category:Benzodiazepines]]
[[Category:Triazolobenzodiazepines]]
[[Category:GABAA Positive Allosteric Modulators (General)]]
[[Category:GABAergics]]
[[Category:Anxiolytics & Sedative-Hypnotics]]

Nutmeg

2026-05-16T02:30:58Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{MedTemplate
| generic = Nutmeg
| brand = ''Myristica fragrans''. Mace (the fruit aril)
| classes = Plant Medicine, Empathogenica
| uses = <vote slug="culinary-use">Culinary spice</vote>
| starting_dose = 0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use
| preparations = Ground dried seed (nutmeg) or fruit aril (mace); occasionally infused
| routes = Oral
| onset = Slow — 2–6 h
| duration = 12–24 h or longer
| mechanism = Active oils are myristicin, elemicin, and safrole — phenethylamine precursors that may be aminated in vivo to MMDA, TMA, and MDA respectively (Shulgin's 'essential amphetamines' hypothesis).
| intro = Nutmeg is the dried seed kernel of ''Myristica fragrans'', a Moluccan tree of the Myristicaceae (same family as the South American DMT-source ''Virola''). At psychoactive doses (a sizable spoonful or more), produces a slow onset of empathogenic/dreamy effects lasting well into the next day, often with heavy nausea — [[Pendell]]'s "medicine-of-last-resort."
| seealso = [[MDMA]], [[MDA]], [[Cinnamon]]
| references = <references/>
}}

{{PendellsCorner
| quote = The drug-of-last-resort. Myself, I like nutmeg in eggnog.
| volume = Dynamis
| page = 199
}}

[[Category:Empathogenica]]
[[Category:Plant Medicines]]
[[Category:Medicines]]

Buprenorphine/Naloxone

2026-05-16T02:30:58Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{MedTemplate
| generic = Buprenorphine / Naloxone
| brand = Suboxone, Zubsolv, Bunavail, Cassipa
| classes = Opioid agonist therapy (OAT); Partial μ-agonist + abuse-deterrent
| uses = <vote slug="oud-treatment-use">Opioid use disorder (OUD) maintenance</vote>, <vote slug="opioid-withdrawal-use">Opioid withdrawal</vote>
| starting_dose = Induction: 2/0.5 to 4/1 mg SL once in moderate withdrawal; titrate to 12–16/3–4 mg/d by day 2–3
| preparations = SL film or tablet, 2/0.5 to 12/3 mg per dose
| fda_max = 24/6 mg/d (most labels)
| routes = Sublingual film or tablet (buccal for some)
| onset = 30–60 min (SL)
| duration = 24–36 h (driven by buprenorphine)
| halflife = 24–42 h (buprenorphine); 1–2 h (naloxone)
| bioavailability = Buprenorphine ~30% SL; naloxone <10% SL (intentional — inactive sublingually, matters only if injected)
| pregnancy = Category C (buprenorphine-only formulations preferred in pregnancy)
| legal = Schedule III in US; X-waiver no longer required (as of 2023)
| mechanism = Buprenorphine: high-affinity partial agonist at the μ-opioid receptor with ceiling effect on respiratory depression. Naloxone: abuse-deterrent — inactive SL but precipitates withdrawal if injected.
| intro = Buprenorphine/naloxone (most widely known as Suboxone) is one of the two pillars of medicine-assisted treatment for opioid use disorder. The partial-agonist nature of buprenorphine gives it a ceiling effect on respiratory depression — far safer than full agonists like methadone. The naloxone is essentially inert SL; it exists as an injection deterrent. See [[Buprenorphine]] for the pharmacology of the active component.
| indications =
| dosing =
| effects =
| pk_absorption = Buprenorphine ~30% SL; naloxone negligible.
| pk_distribution = Buprenorphine ~96% protein binding.
| pk_metabolism = Buprenorphine: CYP3A4 → norbuprenorphine (active). Naloxone: hepatic glucuronidation.
| pk_elimination = Fecal (buprenorphine and metabolites); renal (naloxone glucuronide).
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details = Prefer buprenorphine monoproduct (Subutex) in pregnancy when possible — more pregnancy data.
| monitoring = Withdrawal scale (COWS) during induction; LFTs at baseline + periodically; toxicology screens per program.
| counseling = '''Precipitated withdrawal''': do not induct until in moderate withdrawal (COWS ≥ 8–12). Hold under tongue until fully dissolved — do not chew or swallow. Combine with counseling and recovery support.
| anecdotes =
| seealso = [[Buprenorphine]], [[Methadone]], [[Naltrexone]], [[Naloxone]]
| references = <references/>
}}

[[Category:Medicines]]

About:Pharmacopedia.ext

2026-05-16T02:30:57Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{TOC right}}
= Pharmacopedia extension — specification =

'''Version:''' 0.7.10 · '''Requires:''' MediaWiki ≥ 1.45.0
'''Author:''' MDElliottMD · '''License:''' GPL-2.0-or-later
'''Source:''' <code>/var/www/mediawiki/extensions/Pharmacopedia/</code>

The Pharmacopedia extension turns a MediaWiki install into a structured, community-edited medicine reference. It adds parser tags, special pages, API modules, and a database schema that together support:

* Structured medicine pages via the <code>{{tlx|MedTemplate}}</code> template
* Per-user rating, voting, and reporting on effects, indications, titration strategies, anecdotes, and interactions
* Two-perspective data capture (personal vs. provider) wherever clinically meaningful
* Curated medicine-class categories used as interaction endpoints
* A verified-provider role with document-based verification

== High-level architecture ==

* '''Backend (PHP):''' <code>includes/</code> — one class per parser tag, store, special page, or API module. Auto-loaded under <code>MediaWiki\Extension\Pharmacopedia\</code>.
* '''Frontend (JS):''' <code>resources/ext.pharmacopedia.js</code> — single IIFE binding click handlers, modals, and inline AJAX submits.
* '''Styles (CSS):''' <code>resources/ext.pharmacopedia.css</code> — shared row layout, per-tag chrome, dark-theme-friendly colors.
* '''Schema:''' <code>sql/</code> — ten core tables plus four migration patches. Picked up via the <code>LoadExtensionSchemaUpdates</code> hook.

== Parser tags ==

All eight tags are registered via <code>Hooks::onParserFirstCallInit</code>:

{| class="wikitable"
! Tag !! Purpose !! Class
|-
| <code><vote></code> || Generic up/down binary vote on an arbitrary slug || <code>VoteTag</code>
|-
| <code><effect></code> || Therapeutic or adverse effect, dual patient/provider perspectives || <code>EffectTag</code>
|-
| <code><discuss></code> || Threaded comment widget || <code>CommentTag</code>
|-
| <code><effectsummary></code> || Roll-up aggregate header || <code>EffectSummaryTag</code>
|-
| <code><titration></code> || Titration strategy card with up/down vote || <code>TitrationTag</code>
|-
| <code><anecdote></code> || Personal or provider story with up/down vote || <code>AnecdoteTag</code>
|-
| <code><indication></code> || Condition the medicine is used for, 0–5 likert rating || <code>IndicationTag</code>
|-
| <code><pharmaInteractions/></code> || Self-closing; renders the Interactions section for the current page || <code>InteractionTag</code>
|}

All tags except <code><pharmaInteractions/></code> take a <code>slug</code> argument and (where relevant) a <code>title</code>, <code>label</code>, <code>author</code>, <code>ref</code>, or <code>perspective</code>.

=== Tag wikitext examples ===

<pre>
<indication slug="ssri-depression" title="Major depressive disorder"
author="MDElliottMD">Use cautiously in adolescents.</indication>

<effect slug="nausea" label="Nausea"/>

<effect ref="hyperkalemia"/> 

<titration slug="slow-start-elderly" title="Slow start (elderly)"
author="MDElliottMD">Begin at 10 mg q AM; titrate by 10 mg every 14 days.</titration>

<anecdote slug="qi8sg2" perspective="provider"
author="MDElliottMD">One patient developed serotonin syndrome at week 3...</anecdote>

<pharmaInteractions/>
</pre>

== The unified compact row layout ==

Indication, Effect, Interaction, Titration, and Anecdote all render through a shared row pattern:

<pre>
<div class="pcp-row pcp-row-{type} pcp-{type}" ...data-*>
<div class="pcp-row-head">
<span class="pcp-row-title">...</span>
<span class="pcp-row-aggs">...</span>
<span class="pcp-row-actions">
<button class="pcp-row-action pcp-row-action-toggle" data-target="rate">Rate</button>
[<button data-target="notes">Notes (N)</button>] # only for Interaction
[× delete button] # only for sysop/admin
</span>
</div>
[<div class="pcp-row-panel pcp-row-rate-panel" hidden>...</div>]
[<div class="pcp-row-panel pcp-row-notes-panel" hidden>...</div>]
[<div class="pcp-row-body">...wikitext body, always visible if present...</div>]
</div>
</pre>

* Rate / Notes panels are hidden by default; the shared <code>.pcp-row-action-toggle</code> JS handler reveals them inline on click.
* Bodies (page-specific descriptions for Indication / Effect / Titration / Anecdote) are always visible.
* The <code>×</code> admin delete button uses the established <code>.pcp-del-btn</code> pattern (or <code>.pcp-ix-del-row</code> for interactions).
* Each row sits in its own block-formatting context (<code>display: flow-root</code>) so its border-box respects floated infoboxes.

== Voting / rating semantics ==

{| class="wikitable"
! Element !! Scale !! Perspectives !! Storage
|-
| Vote tag || +1 / −1 binary || single || <code>pcp_votes</code>
|-
| Titration || +1 / −1 binary || single || <code>pcp_votes</code>
|-
| Anecdote || +1 / −1 binary || single (perspective is a metadata label, not a separate aggregate) || <code>pcp_votes</code>
|-
| Indication || 0–5 likert + "don't know" || single || <code>pcp_likert_reports</code>
|-
| Effect (patient) || experienced ∈ {yes, no, unsure} + valence −3..+3 || patient || <code>pcp_effect_reports</code> (perspective=1)
|-
| Effect (provider) || frequency ∈ {0, 5, 20, 33, 50, 66, 80, 95, −1 don't know} + valence −3..+3 || provider || <code>pcp_effect_reports</code> (perspective=2)
|-
| Interaction || experience 1–5 + outcome −3..+3 + optional free-text note || user + provider, separate aggregates || <code>pcp_interaction_reports</code>
|}

Server-side aggregates: <code>n</code>, mean of the rating field, and (where applicable) <code>severe = (vmean ≤ −2.5)</code>.

Aggregates are recomputed and returned by every report-submit API call so the row re-renders in place without a page reload.

== Effect bucketing ==

When a wiki <code><ul></code> contains only <code><effect></code> cards, JavaScript groups them into buckets by the provider frequency mean (<code>data-fmean</code>):

{| class="wikitable"
! Bucket !! fmean band !! Default state
|-
| '''Common''' || > 20 || expanded, always visible
|-
| '''Uncommon''' || > 5 and ≤ 20 || collapsed
|-
| '''Rare''' || ≤ 5, provider vmean > −2.5 || collapsed
|-
| '''Rare but Severe''' || ≤ 5 and vmean ≤ −2.5 || '''expanded by default''', red highlight
|-
| '''Not yet rated''' || no provider data (n=0) || collapsed, only renders if non-empty
|}

The vmean ≤ −2.5 threshold is also the trip-wire for the "severe" red treatment on interaction rows.

== Interactions feature ==

The Interactions section is rendered by placing <code><pharmaInteractions/></code> anywhere in the wikitext of a medicine article ('''NS_MAIN''') or a Category page ('''NS_CATEGORY''').

=== Entity model ===

An interaction is an undirected edge between two endpoints. Each endpoint has a '''type''' (<code>medicine</code> or <code>category</code>) and a '''slug''' (DB-key form of the page title).

Pairs are stored in canonical order: smaller <code>(type, slug)</code> tuple on the left. This collapses A↔B and B↔A into a single row.

=== Tables ===

<code>pcp_interactions</code>: one row per interaction edge.

pi_id auto-increment
pi_element_id FK -> pcp_votable_elements (reuse votes/comments infra)
pi_left_type 'medicine' | 'category'
pi_left_slug VARBINARY(255)
pi_right_type 'medicine' | 'category'
pi_right_slug VARBINARY(255)
pi_created_user_id INT
pi_created BINARY(14)
UNIQUE (pi_left_type, pi_left_slug, pi_right_type, pi_right_slug)

<code>pcp_interaction_reports</code>: one row per (interaction, user, perspective).

pir_element_id FK -> pcp_votable_elements
pir_user_id INT
pir_perspective 1 = user, 2 = provider
pir_experience TINYINT (1..5, nullable)
pir_valence TINYINT (-3..+3, nullable)
pir_note MEDIUMBLOB (nullable)
pir_created BINARY(14)
pir_updated BINARY(14)
UNIQUE (pir_element_id, pir_user_id, pir_perspective)

=== Rendering rules ===

* On a '''medicine''' page M, list:
** Direct edges: rows where M is one side.
** Transitive edges: rows where one side is a category C that M is itself a member of (via MW's <code>categorylinks</code>).
* '''Direct wins:''' if the same counterparty is reachable both directly and transitively, drop the transitive duplicate.
* On a '''Category''' page, list direct edges only (no transitive walk).
* Sort: pooled <code>valence_mean</code> ascending (most negative on top). Nulls sink. Tiebreakers: <code>n</code> desc, then alphabetic.
* Severe (any of pooled / user / provider vmean ≤ −2.5): red 4 px left border + red-tinted background + "severe" pill + counterparty title in red.

=== Add-interaction modal ===

Triggered by the <code>+ Add interaction</code> button at the bottom of the section. Two-stage UX:

# Search input → results split into '''Medicines''' (teal chip) and '''Categories''' (amber chip).
# Click <code>Use</code> → confirm via <code>Add interaction</code> button → POST to <code>pharmacopediainteractionadd</code>.

Categories appear in the modal '''only if tagged with the marker category''' (default <code>Category:MedCategory</code>, configurable via <code>$wgPharmacopediaInteractionCategoryMarker</code>). The transitive walk during rendering, however, uses all of a page's categories regardless of marker — historic data isn't hidden by changing the marker policy.

=== Delete ===

Two a

Pharmacopedia:About

2026-05-16T02:30:57Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

Born in May 2026, Pharmacopedia started primarily as a one-man project of [https://markelliottmd.com MDElliottMD], who'd been dreaming of some place for the people who recommend and/or use medicines of the mind to collaborate and create consensus-driven information, founded in a deep faith in the [https://en.wikipedia.org/wiki/Wisdom_of_the_crowd wisdom of the crowd].

First, I hope this to be a reasonable and reliable reference for prescribers of all sorts to find relevant and accurate information for their practice: available strengths, titration strategies, pill IDs, etc.

But almost moreso, I hope that this place can be a lively, collaborative place for a communal effort in understanding the bizarre world of medicines and human brains. I hope that by pooling our collective anecdotes, we might actually make some data, of a sort.

The site empowers users (with 2-FA) to share their experience about almost every aspect of the site, in as fine a detail as I thought was tolerable. I hope that by pooling our estimates, we might find something like truth.

For now, I, [[User:MDElliottMD|MDElliottMD]], am the only person who can approve/publish page edits, though I hope to have a team of moderators some day.

I am not a software developer, but I am a top-tier expert in medicines of the mind. I will keep the place as tidy as I can.

This project is not, in an way, driven by money or profit. The link above is as far as I will go to promote myself or my brand here. At the moment, I am happy to fund the project in its entirety. If that changes, I may some day ask for donations.

This project was entirely developed and partially populated by Claude (Opal 4.7), and is based on the [https://www.mediawiki.org/wiki/MediaWiki Mediawiki code base], bless their souls.

Much of the interface (voting, especially) here is run through an extension that I made with Claude: [[About:Pharmacopedia.ext|Pharmacopedia.ext]], which I'm happy to share with whomever wants it. Probably easiest to get ahold of me through my website above.

Thanks for coming by. Would be honored if you could help inform the hive mind.

-mark

Classes

2026-05-16T02:30:57Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

This page is a reference taxonomy of pharmacological '''classes''' used throughout Pharmacopedia. Click any class name to browse its members. Individual medicines are listed on the [[List of CNS-active medicines]] page.

__TOC__

== Antidepressants ==

=== Selective Serotonin Reuptake Inhibitors (SSRIs) ===
Block presynaptic reuptake of serotonin via SERT. First-line for most depressive and anxiety disorders.

=== Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs) ===
Block reuptake of both serotonin and norepinephrine. Used in depression, anxiety, and neuropathic pain.

=== Norepinephrine–Dopamine Reuptake Inhibitors (NDRIs) ===
Block reuptake of norepinephrine and dopamine. Minimal serotonergic activity; lower sexual side-effect burden.

=== Norepinephrine Reuptake Inhibitors (NRIs) ===
Selective for norepinephrine reuptake. Used in depression and ADHD.

=== Tricyclic Antidepressants (TCAs) ===
Older class; block SERT and NET with broad receptor antagonism (H1, muscarinic, alpha-1). High side-effect burden; significant overdose risk.

=== Monoamine Oxidase Inhibitors (MAOIs) ===
Inhibit MAO-A and/or MAO-B, increasing monoamine levels. Require strict dietary and medicine interaction precautions. Subclasses:
* '''Irreversible non-selective MAOIs''' — inhibit both MAO-A and MAO-B permanently
* '''Reversible MAO-A inhibitors (RIMAs)''' — safer interaction profile; displaceable by tyramine
* '''Selective MAO-B inhibitors''' — used primarily in Parkinson's disease; antidepressant at higher doses

=== Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs) ===
Alpha-2 antagonists that increase norepinephrine and serotonin release; also potent H1 antagonists (sedating).

=== Serotonin Antagonist and Reuptake Inhibitors (SARIs) ===
Block SERT and antagonize 5-HT2A/2C receptors. Sedating; low sexual side-effect burden.

=== Melatonin Agonist / Serotonin Antagonist ===
Agonism at MT1/MT2 melatonin receptors and 5-HT2C antagonism; circadian-focused antidepressant mechanism.

=== Multimodal Serotonergic Agents ===
Act on multiple serotonin receptor subtypes simultaneously (SERT inhibition + receptor agonism/antagonism).

== Antipsychotics / Neuroleptics ==

=== First-Generation Antipsychotics (FGAs / Typicals) ===
Primarily D2 receptor antagonists. Effective for positive symptoms; high risk of extrapyramidal side effects and tardive dyskinesia. Subclasses by chemical structure:
* '''Phenothiazines''' — chlorpromazine, fluphenazine, perphenazine, thioridazine, trifluoperazine, prochlorperazine
* '''Butyrophenones''' — haloperidol, droperidol
* '''Thioxanthenes''' — thiothixene
* '''Dibenzoxazepines''' — loxapine
* '''Dihydroindolones''' — molindone
* '''Diphenylbutylpiperidines''' — pimozide

=== Second-Generation Antipsychotics (SGAs / Atypicals) ===
D2 and 5-HT2A antagonists (or partial agonists). Lower EPS risk; higher metabolic side-effect burden.

=== Third-Generation Antipsychotics ===
D2/D3 partial agonists with 5-HT1A partial agonism. Intended to stabilize rather than fully block dopamine signaling.

== Mood Stabilizers ==
Reduce episode frequency and severity in bipolar disorder. Mechanisms vary widely:
* Sodium channel blockers
* GABA enhancers
* Histone deacetylase inhibitors
* Unknown/multiple mechanisms (lithium)

== Anxiolytics & Sedative-Hypnotics ==

=== Benzodiazepines ===
Positive allosteric modulators at GABAA receptors (benzodiazepine site). Increase chloride channel opening frequency. Used for anxiety, seizures, muscle spasm, alcohol withdrawal, and procedural sedation. Dependence liability with chronic use.

=== Thienodiazepines ===
Structurally related to benzodiazepines with a thiophene ring substitution. Similar mechanism and effects.

=== Z-Drugs (Non-Benzodiazepine Hypnotics) ===
GABAA positive allosteric modulators with greater selectivity for alpha-1-containing receptors. Primarily hypnotic; lower anxiolytic/anticonvulsant activity than benzodiazepines.

=== Orexin Receptor Antagonists ===
Block orexin (hypocretin) signaling to promote sleep onset and maintenance. Lower dependence potential than GABAergic hypnotics.

=== Azapirones ===
5-HT1A partial agonists with D2 antagonism. Anxiolytic without sedation or dependence; slow onset of effect.

=== Barbiturates ===
Potentiate and directly activate GABAA receptors at higher concentrations. Older class; narrow therapeutic index; high overdose and dependence risk.

=== Beta Blockers (peripheral somatic anxiolytic) ===
β-adrenergic receptor antagonists. While primarily cardiovascular medicines, they are widely used off-label as peripheral anxiolytics — blunting the somatic (tachycardia, tremor, sweating) manifestations of acute anxiety without sedation or dependence liability. Particularly useful for performance anxiety, akathisia, and essential tremor. [[Propranolol]] is the prototype. See [[:Category:Beta Blockers]].

== Stimulants & Wake-Promoting Agents ==

=== Amphetamines ===
Monoamine releasing agents; reverse transporter function to flood the synapse with dopamine, norepinephrine, and (to varying degrees) serotonin. Used for ADHD, narcolepsy, and obesity.

=== Methylphenidates (Phenidates) ===
Dopamine and norepinephrine reuptake inhibitors; structurally distinct from amphetamines. First-line for ADHD.

=== Eugeroics (Wakefulness-Promoting Agents) ===
Promote wakefulness through incompletely understood mechanisms involving dopamine reuptake inhibition and orexin pathway activation. Lower abuse potential than amphetamines.

=== Xanthines ===
Adenosine receptor antagonists. Mild CNS stimulation; widely consumed (caffeine). Theophylline also inhibits phosphodiesterase.

=== Alpha-2 Agonists (for ADHD) ===
Activate presynaptic and postsynaptic alpha-2A adrenergic receptors in prefrontal cortex. Non-stimulant; used for ADHD, tics, and opioid/nicotine withdrawal.

=== Norepinephrine Reuptake Inhibitors (ADHD) ===
Selective NET inhibitors approved for ADHD. Non-stimulant; full antidepressant-level NRI activity.

=== Histamine H3 Antagonists / Inverse Agonists ===
Block presynaptic H3 autoreceptors, increasing histamine (and other monoamine) release. Used for narcolepsy with cataplexy.

== Opioids ==

=== Mu-Opioid Receptor Agonists ===
Analgesia, euphoria, sedation, respiratory depression, and constipation via mu (μ) opioid receptors. The primary class for moderate-to-severe pain management. Subclasses:
* '''Natural opioids''' — derived directly from the opium poppy
* '''Semisynthetic opioids''' — modified natural opioids
* '''Synthetic opioids''' — fully synthetic; no plant-derived precursors

=== Partial Mu-Opioid Agonists ===
Ceiling effect on respiratory depression; used for addiction treatment and pain.

=== Mixed Agonist-Antagonists ===
Kappa agonists with mu partial agonism or antagonism. Analgesic but may precipitate withdrawal in opioid-dependent patients.

=== Kappa-Opioid Receptor Agonists ===
Dysphoria, hallucinations, sedation, analgesia. Endogenous stress response mediators; relevant to dissociative and psychedelic pharmacology.

=== Opioid Antagonists ===
Competitive blockade of opioid receptors. Used for overdose reversal and addiction treatment.

=== Opioid Receptor Modulator + NMDA Antagonists ===
Dual-mechanism opioids that add NMDA antagonism (methadone, levorphanol). Useful for complex pain; longer half-life.

== GABAergics ==

=== GABAB Receptor Agonists ===
Activate metabotropic GABAB receptors. Muscle relaxation, analgesia, euphoria/reinforcement at high doses. Includes baclofen and sodium oxybate (GHB).

=== GABAA Positive Allosteric Modulators (General) ===
Enhance chloride influx via GABAA receptors. Umbrella category covering benzodiazepines, barbiturates, Z-drugs, neurosteroids, and several other classes.

=== GABA Reuptake Inhibitors ===
Block GAT-1 transporter to raise synaptic GABA. Anticonvulsant application.

=== GABA-Transaminase Inhibitors ===
Irreversibly inhibit the enzyme that degrades GABA, raising brain GABA levels overall. Anticonvulsant.

=== GHB Receptor Agonists ===
Activate the endogenous GHB receptor in addition to GABAB. Sedative-hypnotic; used for narcolepsy and alcohol withdrawal.

== Anticonvulsants / Antiepileptics ==
Heterogeneous class united by seizure suppression. Mechanisms include:
* Sodium channel blockers
* Calcium channel blockers (T-type or N/P/Q-type)
* GABA enhancement (multiple mechanisms)
* Glutamate/AMPA antagonists
* SV2A ligands (synaptic vesicle protein)
* Carbonic anhydrase inhibitors

Many anticonvulsants are also used for pain, migraine prophylaxis, mood stabilization, or anxiety.

== Antiparkinsonian Medicines ==

=== Dopamine Precursors ===
Levodopa, converted to dopamine in the brain, replenishes the depleted dopaminergic pathway in Parkinson's disease.

=== Dopamine Agonists ===
Directly stimulate D2/D3 receptors, bypassing presynaptic neurons. Also used for restless legs syndrome and hyperprolactinemia.

=== MAO-B Inhibitors ===
Reduce dopamine catabolism in the striatum by inhibiting the MAO-B isoform. Mild antiparkinsonian and neuroprotective effects.

=== COMT Inhibitors ===
Reduce peripheral and central metabolism of levodopa, extending its duration of action.

=== Anticholinergics (Antiparkinsonian) ===
Reduce the relative excess of cholinergic activity resulting from dopamine depletion in the striatum. Effective for tremor; significant cognitive side effects.

=== NMDA Antagonists (Antiparkinsonian) ===
Reduce glutamate-mediated excitotoxicity and may reduce dyskinesias. Amantadine also has dopamine-releasing effects.

== Anti-Dementia Medicines ==

=== Acetylcholinesterase Inhibitors (AChEIs) ===
Prevent the breakdown of acetylcholine, increasing cholinergic transmission in the cortex and hippocampus. First-line for Alzheimer's and other dementias.

=== NMDA Receptor Antagonists ===
Block pathological NMDA receptor overactivation (excitotoxicity). Used adjunctively in moderate-to-severe Alzheimer's.

=== Anti-Amyloid Monoclonal Antibodies ===
Clear amyloid-beta plaques from the brain. Disease-modifying approach; newer class with contested clinical benefit.

== Anesthetics ==

=== General (IV) Anesthetics ===
Intravenous agents for induction and/or maintenance of anesthesia. Mechanisms vary:
* GABAA potentiators (propofol, etomidate, barbiturates)
* NMDA antagonists (ketamine)

=== Inhalational Anesthetics ===
Volatile agents for maintenance of anesthesia. Primarily GABAA potentiation and NMDA antagonism. Dose-dependent CNS depression.

=== Dissociative Anesthetics ===
NMDA antagonists producing analgesia, amnesia, and cataleptic state without loss of airway reflexes. See [[#Dissociatives]].

=== Local Anesthetics ===
Sodium channel blockers that block nerve conduction locally. CNS toxicity (including seizures) may occur with systemic absorption.

=== Alpha-2 Agonist Sedatives ===
Dexmedetomidine: highly selective alpha-2A agonist producing sedation that closely resembles natural sleep. Used for ICU sedation and procedural sedation.

== Muscle Relaxants (CNS-acting) ==
Centrally-acting agents that reduce skeletal muscle tone via spinal cord or supraspinal mechanisms. Distinct from peripherally-acting neuromuscular blocking agents.

== Antihistamines ==
H1 receptor antagonists. First-generation agents cross the blood-brain barrier and produce sedation, anticholinergic effects, and at high doses, delirium. Divided by generation:
* '''First-generation''' — lipophilic; CNS-penetrant; sedating; anticholinergic
* '''Second-generation''' — less CNS penetration; non-sedating

== Addiction Medicine ==
Medicines used to treat substance use disorders. Mechanisms are specific to the target substance:
* Opioid agonist therapy (methadone, buprenorphine)
* Opioid antagonists (naltrexone, naloxone, nalmefene)
* Aversion agents (disulfiram)
* NMDA/GABA modulators for alcohol (acamprosate)
* Nicotinic partial agonists (varenicline)
* Alpha-2 agonists for withdrawal (clonidine, lofexidine)

== Migraine Medicines ==

=== Triptans (5-HT1B/1D Agonists) ===
Selective serotonin agonists at 5-HT1B and 5-HT1D receptors. Cause vasoconstriction and inhibit trigeminal pain transmission. Acute treatment.

=== Gepants (CGRP Receptor Antagonists) ===
Block calcitonin gene-related peptide (CGRP) receptors. Effective for acute and preventive migraine treatment without vasoconstriction.

=== Ditans (5-HT1F Agonists) ===
Serotonin agonists selective for the 5-HT1F receptor. Inhibit trigeminal pain without vasoconstriction; CNS side effects (dizziness, sedation) are common.

=== Ergotamines ===
Ergot alkaloids; 5-HT1B/1D agonists with additional vasoconstrictor activity. Older class; significant side-effect burden.

== Psychedelics ==

=== Classical Psychedelics (Serotonergic) ===
Primary mechanism is agonism at 5-HT2A receptors in the cortex, producing profound alterations in perception, cognition, and sense of self. Subclasses by chemical scaffold:
* '''Tryptamines''' — indole alkaloids structurally related to serotonin
* '''Lysergamides''' — ergoline derivatives of lysergic acid
* '''Phenethylamines''' — related to the catecholamine scaffold (mescaline and analogues)
* '''2C-x series''' — 2,5-dimethoxyphenethylamines
* '''DOx series''' — amphetamine-based phenethylamines; very long duration
* '''NBOMe / NBOH series''' — N-benzyl derivatives; extremely potent; no oral activity

=== Empathogens / Entactogens ===
Primarily monoamine-releasing agents (especially serotonin) with partial 5-HT2A agonism. Produce emotional openness and prosocial effects. Core subclasses:
* '''MDxx''' — methylenedioxy-substituted amphetamines and cathinones
* '''Benzofurans''' — related scaffold; primarily serotonergic

=== Dissociatives ===
NMDA receptor antagonists producing dose-dependent detachment from self and environment. At sub-anesthetic doses: analgesia, euphoria, perceptual distortion. Subclasses:
* '''Arylcyclohexylamines''' — ketamine, PCP, and analogues; σ1 and dopaminergic activity
* '''Morphinans''' — dextromethorphan, dextrorphan; also sigma-1 and serotonergic
* '''Diarylethylamines''' — diphenidine and related
* '''Adamantanes''' — memantine
* '''Other''' — nitrous oxide, xenon

=== Deliriants ===
Produce a state of true delirium — confusion, disorientation, and realistic hallucinations indistinguishable from reality. Subclasses:
* '''Anticholinergics (muscarinic antagonists)''' — block muscarinic acetylcholine receptors; atropine, scopolamine, hyoscyamine, diphenhydramine
* '''Kainate / AMPA agonists''' — ibotenic acid
* '''GABAA agonists (at sedating doses)''' — muscimol
* '''Other''' — benzydamine, myristicin

=== κ-Opioid Agonists ===
Kappa receptor activation produces dysphoric, dissociative, and oneirogenic effects distinct from classical psychedelics and mu-opioid analgesia.

== Cannabinoids ==

=== Phytocannabinoids ===
Naturally occurring compounds in ''Cannabis sativa''. Act primarily at CB1 (CNS) and CB2 (immune) receptors.

=== Synthetic Cannabinoids ===
Fully synthetic full agonists at CB1/CB2. Often far more potent than THC; unpredictable toxicity profile.

=== Pharmaceutical Cannabinoids ===
Regulated preparations of naturally-derived or synthetic cannabinoids approved for specific indications.

== Nootropics ==

=== Racetams ===
Positive allosteric modulators at AMPA receptors; some also affect choline uptake or acetylcholine synthesis.

=== Eugeroics ===
See [[#Eugeroics (Wakefulness-Promoting Agents)]] above.

=== Peptide Nootropics ===
Short peptide sequences (e.g., Semax) with neurotrophic and neuroprotective activity.

=== Dietary Precursors and Cofactors ===
Amino acids, vitamins, and metabolites that support neurotransmitter synthesis or neuronal function.

== Research Materials ==
Compounds primarily of research interest, with limited or no human clinical approval. Many are analogues of approved medicines or classical psychoactive substances. Use of the term '''material''' is preferred over "medicine" or "substance" in this context.

=== Lysergamides ===
LSD analogues and prodrugs, typically N-substituted at the amide position. Share the ergoline scaffold.

=== Novel Tryptamines ===
4-substituted and 5-substituted tryptamine analogues. Many are prodrugs of known psychedelics (e.g., 4-AcO-DMT → psilocin).

=== Novel Phenethylamines ===
Analogues of mescaline, 2C-x, and DOx compounds. Potency varies enormously; some (NBOMe series) are active at microgram doses.

=== Cathinones ===
Beta-keto amphetamine analogues. Stimulant and/or empathogenic; high abuse potential.

=== Pyrrolidinophenones ===
Cathinone-related stimulants with pyrrolidine ring substitution. Potent dopamine/norepinephrine reuptake inhibitors.

=== Novel Amphetamines ===
Fluorinated and other amphetamine analogues with modified pharmacokinetic or receptor profiles.

=== Novel Phenidates ===
Methylphenidate analogues with modified ester or ring substitutions.

=== Novel Dissociatives (Arylcyclohexylamines) ===
Ketamine and PCP analogues with various halogen, methoxy, or hydroxyl substitutions altering potency, duration, and receptor selectivity.

=== Novel / Designer Benzodiazepines ===
Benzodiazepine analogues including triazolo- and thienodiazepines. Structural modifications alter potency, duration, and subunit selectivity.

=== Beta-Carbolines ===
MAOI-active alkaloids found in plants used in ayahuasca preparations (harmine, harmaline, tetrahydroharmine). Also exhibit NMDA antagonism and 5-HT2A activity at higher doses.

== See also ==
* [[List of CNS-active medicines]]
* [[Main Page]]

[[Category:Reference]]
[[Category:Medicines]]

Dexmethylphenidate

2026-05-16T02:30:55Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{MedTemplate
| generic = Dexmethylphenidate
| brand = Focalin, Focalin XR
| structure = Methylphenidate.svg
| classes = Psychostimulant, CNS stimulant, NDRI
| mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET) — d-threo enantiomer of methylphenidate
| uses = <vote slug="inattention">Inattention</vote>, <vote slug="productivity">Productivity</vote>
| formula = C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>
| routes = Oral
| onset = 30–60 min
| duration = IR 4–6 h; XR 8–12 h
| halflife = 2.2 h (IR parent); ~3 h (XR parent)
| bioavailability = ~22–25%
| pregnancy = Category C
| legal = Schedule II
| intro = '''Dexmethylphenidate''' — marketed as '''Focalin''' and '''Focalin XR''' — is the isolated d-threo enantiomer of [[Methylphenidate|methylphenidate]]. Racemic methylphenidate contains both d- and l-threo enantiomers in equal amounts, but essentially all pharmacologic activity resides in the d-isomer; the l-isomer is rapidly cleared on first-pass and contributes little beyond a possible minor role in peripheral side effects. By delivering only the active enantiomer, Focalin achieves equivalent therapeutic effect at approximately half the milligram dose of racemic methylphenidate, with some patients reporting a cleaner subjective profile (less jitteriness, more focused effect). Its clinical indications, mechanism, contraindications, and adverse-effect profile are otherwise nearly identical to racemic methylphenidate.
| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated medicine interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.
| pharmacodynamics = Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.
| indications = * Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
* Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)
* Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that indication)
| dosing = '''Focalin IR:''' Start 2.5 mg PO twice daily (separate doses by at least 4 h). Titrate by 2.5–5 mg/week. Max 20 mg/day (adults and children).
'''Focalin XR:''' Start 5 mg PO once daily AM (children), 10 mg PO once daily AM (adults). Titrate weekly. Max 30 mg/day (children); 40 mg/day (adults).
'''Conversion from racemic methylphenidate:''' use approximately '''half''' the total daily dose (e.g., Ritalin 20 mg/day → Focalin 10 mg/day).
'''Renal/hepatic impairment:''' caution; reduce dose and monitor.
| effects =

==== Therapeutic ====
* <effect ref="attention">Improved attention, executive function, and working memory. Many patients report a cleaner subjective effect than racemic methylphenidate at equivalent therapeutic doses.</effect>
* <effect ref="reduced-impulsivity"/>
* <effect ref="wakefulness"/>

==== Common ====
* <effect ref="decreased-appetite">Often dose-limiting; may produce weight loss over time.</effect>
* <effect ref="insomnia">Especially with late-afternoon dosing.</effect>
* <effect ref="headache"/>
* <effect ref="abdominal-pain"/>
* <effect ref="irritability"/>
* <effect ref="dry-mouth"/>
* <effect ref="hr-bp-elevation">Usually mild but dose-dependent.</effect>
* <effect ref="weight-loss"/>

==== Cardiovascular ====
* <effect ref="palpitations"/>
* <effect ref="cardiac-event">Rare reports of sudden cardiac death in patients with structural heart disease (FDA warning).</effect>

==== Psychiatric ====
* <effect ref="anxiety"/>
* <effect ref="agitation"/>
* <effect ref="psychosis">Rare; higher risk in patients with bipolar predisposition.</effect>
* <effect ref="mania">Rare; higher risk in patients with bipolar predisposition.</effect>
* <effect ref="hallucinations">Visual or tactile; rare, more common at higher doses or in predisposed patients.</effect>

==== Other adverse ====
* <effect ref="tics">May emerge or worsen; comorbid Tourette syndrome is a traditional relative contraindication.</effect>
* <effect ref="dependence">Schedule II controlled substance; abuse liability similar to racemic methylphenidate per milligram of active material. Crushed/insufflated/IV misuse is the major risk pattern.</effect>
* <effect ref="tolerance">To therapeutic effects, with chronic high-dose use.</effect>
* <effect ref="growth-suppression">Modest reduction in growth velocity in chronically-treated children.</effect>
* <effect ref="priapism">Rare but documented; FDA warning, especially in adolescents.</effect>
* <effect ref="vasculopathy">Raynaud-like phenomenon, rare digital ischemia.</effect>
* <effect ref="seizure">Caution in epilepsy.</effect>
* <effect ref="withdrawal">Fatigue, rebound hyperactivity, dysphoria on dose offset.</effect>
| interactions = * '''MAOIs''' — hypertensive crisis risk; contraindicated within 14 days
* '''Tricyclic antidepressants''' — possible elevation of TCA levels; additive cardiovascular effects
* '''Warfarin''' — possible elevation of INR
* '''Phenytoin, phenobarbital, primidone''' — possible elevation of anticonvulsant levels
* '''Antihypertensives''' — pressor effect of dexmethylphenidate may partially antagonize
* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants) — additive cardiovascular effects
* '''Antipsychotics''' — mutual pharmacologic antagonism
* '''Alcohol''' — may mask effects; possible increased exposure via altered metabolism
* '''Caffeine''' — additive stimulant and anxiogenic effects

Like racemic methylphenidate, '''few CYP-mediated interactions''' due to CES1-dominated metabolism.
<pharmaInteractions/>
| pregnancy_details = Category C. Crosses the placenta. Reproductive data limited and largely extrapolated from racemic methylphenidate; overall not clearly teratogenic but cohort studies suggest a small increase in cardiac malformations. Third-trimester exposure can produce transient neonatal withdrawal. Risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in low amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
* Consider ECG if cardiac risk factors are present
* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
* Sleep quality and timing of last dose
* Periodically reassess continued need; consider medicine holidays in children
| counseling = * Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
* '''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''
* Eat regular meals despite appetite suppression; weigh periodically.
* Stay well-hydrated.
* Do not combine with significant alcohol or other stimulants.
* Do not share or sell — Schedule II controlled substance.
* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
* If switching from racemic methylphenidate, dose conversion is roughly half — confirm with prescriber.
* Plan for the "crash" when the dose wears off, especially with IR.
| anecdotes =
| seealso = [[Methylphenidate]], [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
| references =
}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><span></span>
'''Absorption:''' Rapid oral absorption; peak plasma in ~1–1.5 h (IR) or ~6.5 h (XR, which has a biphasic release profile with an initial peak around 1.5 h and a second peak ~6.5 h). Bioavailability ~22–25% due to extensive first-pass metabolism. '''Distribution:''' Volume of distribution similar to racemic methylphenidate (~13 L/kg); plasma protein binding ~15%. '''Metabolism:''' Like the racemate, dexmethylphenidate is metabolized primarily by '''carboxylesterase 1 (CES1)''' to ritalinic acid (inactive). This non-CYP metabolic pathway means dexmethylphenidate, like its racemate, has '''few clinically significant CYP-mediated medicine interactions'''. '''Elimination:''' Predominantly renal as ritalinic acid; parent half-life 2.2 h (IR) and ~3 h (XR parent). Multi-dose-daily IR dosing or once-daily XR is required for sustained therapeutic effect.<h2 id="Pharmacodynamics">Pharmacodynamics</h2>
Mechanistically identical to racemic methylphenidate at the molecular level — competitive inhibition of the dopamine and norepinephrine transporters (DAT, NET), increasing synaptic catecholamine concentrations without acting as a transporter substrate (i.e., no reverse transport or vesicular displacement; '''reuptake inhibition only'''). The functional difference is purely stereochemical: dexmethylphenidate provides the same effective amount of pharmacologically active material at half the milligram dose. Minimal effect on serotonin; no MAO inhibition; no significant binding at 5-HT, histamine, or muscarinic receptors.<h2 id="Indications">Indications</h2>
*Attention-deficit hyperactivity disorder (children ≥6 y, adolescents, and adults)
*Off-label: same off-label uses as racemic methylphenidate (treatment-resistant depression augmentation, cancer/HIV/MS fatigue)
*Not FDA-approved for narcolepsy (use racemic methylphenidate or an amphetamine for that indication)<h2 id="Dosing">Dosing and titration</h2>
<span></span>

'''Focalin IR:''' Start 2.5 mg PO twice daily (separate doses by at least 4 h). Titrate by 2.5–5 mg/week. Max 20 mg/day (adults and children).
'''Focalin XR:''' Start 5 mg PO once daily AM (children), 10 mg PO once daily AM (adults). Titrate weekly. Max 30 mg/day (children); 40 mg/day (adults).
'''Conversion from racemic methylphenidate:''' use approximately '''half''' the total daily dose (e.g., Ritalin 20 mg/day → Focalin 10 mg/day).

<span></span>

'''Renal/hepatic impairment:''' caution; reduce dose and monitor.<h2 id="Effects">Effects</h2><span></span>
====Therapeutic====
*<effect ref="attention">Improved attention, executive function, and working memory. Many patients report a cleaner subjective effect than racemic methylphenidate at equivalent therapeutic doses.</effect>
*<effect ref="reduced-impulsivity"/>
*<effect ref="wakefulness"/>
<span></span>
====Common====
*<effect ref="decreased-appetite">Often dose-limiting; may produce weight loss over time.</effect>
*<effect ref="insomnia">Especially with late-afternoon dosing.</effect>
*<effect ref="headache"/>
*<effect ref="abdominal-pain"/>
*<effect ref="irritability"/>
*<effect ref="dry-mouth"/>
*<effect ref="hr-bp-elevation">Usually mild but dose-dependent.</effect>
*<effect ref="weight-loss"/>
<span></span>
====Cardiovascular====
*<effect ref="palpitations"/>
*<effect ref="cardiac-event">Rare reports of sudden cardiac death in patients with structural heart disease (FDA warning).</effect>
<span></span>
====Psychiatric====
*<effect ref="anxiety"/>
*<effect ref="agitation"/>
*<effect ref="psychosis">Rare; higher risk in patients with bipolar predisposition.</effect>
*<effect ref="mania">Rare; higher risk in patients with bipolar predisposition.</effect>
*<effect ref="hallucinations">Visual or tactile; rare, more common at higher doses or in predisposed patients.</effect>
<span></span>
====Other adverse====
*<effect ref="tics">May emerge or worsen; comorbid Tourette syndrome is a traditional relative contraindication.</effect>
*<effect ref="dependence">Schedule II controlled substance; abuse liability similar to racemic methylphenidate per milligram of active material. Crushed/insufflated/IV misuse is the major risk pattern.</effect>
*<effect ref="tolerance">To therapeutic effects, with chronic high-dose use.</effect>
*<effect ref="growth-suppression">Modest reduction in growth velocity in chronically-treated children.</effect>
*<effect ref="priapism">Rare but documented; FDA warning, especially in adolescents.</effect>
*<effect ref="vasculopathy">Raynaud-like phenomenon, rare digital ischemia.</effect>
*<effect ref="seizure">Caution in epilepsy.</effect>
*<effect ref="withdrawal">Fatigue, rebound hyperactivity, dysphoria on dose offset.</effect><h2 id="Contraindications">Contraindications</h2>
*Hypersensitivity to dexmethylphenidate or methylphenidate
*Concurrent MAOI use, or within 14 days of MAOI discontinuation
*Symptomatic cardiovascular disease, advanced atherosclerosis, moderate–severe hypertension, recent MI
*Hyperthyroidism
*Glaucoma
*Pheochromocytoma
*Severe anxiety, tension, or agitation
*'''Relative:''' Tourette syndrome / tic disorders, history of substance use disorder, bipolar disorder, psychotic disorders, structural cardiac abnormalities<h2 id="Interactions">Interactions</h2>
*'''MAOIs''' — hypertensive crisis risk; contraindicated within 14 days
*'''Tricyclic antidepressants''' — possible elevation of TCA levels; additive cardiovascular effects
*'''Warfarin''' — possible elevation of INR
*'''Phenytoin, phenobarbital, primidone''' — possible elevation of anticonvulsant levels
*'''Antihypertensives''' — pressor effect of dexmethylphenidate may partially antagonize
*'''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants) — additive cardiovascular effects
*'''Antipsychotics''' — mutual pharmacologic antagonism
*'''Alcohol''' — may mask effects; possible increased exposure via altered metabolism
*'''Caffeine''' — additive stimulant and anxiogenic effects

Like racemic methylphenidate, '''few CYP-mediated interactions''' due to CES1-dominated metabolism.<h2 id="Pregnancy">Pregnancy and lactation</h2>
Category C. Crosses the placenta. Reproductive data limited and largely extrapolated from racemic methylphenidate; overall not clearly teratogenic but cohort studies suggest a small increase in cardiac malformations. Third-trimester exposure can produce transient neonatal withdrawal. Risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in low amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.<h2 id="Monitoring">Monitoring</h2>
*Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
*Consider ECG if cardiac risk factors are present
*At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
*Sleep quality and timing of last dose
*Periodically reassess continued need; consider medicine holidays in children<h2 id="Counseling">Patient counseling</h2>
*Take in the morning (XR) or twice daily 4+ hours apart (IR); avoid late-afternoon dosing to minimize insomnia.
*'''Focalin XR capsules:''' may be swallowed whole or opened and sprinkled on applesauce; '''do not crush or chew the beads inside.'''
*Eat regular meals despite appetite suppression; weigh periodically.
*Stay well-hydrated.
*Do not combine with significant alcohol or other stimulants.
*Do not share or sell — Schedule II controlled substance.
*Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
*If switching from racemic methylphenidate, dose conversion is roughly half — confirm with prescriber.
*<nowiki>Plan for the "crash" when the dose wears off, especially with IR.{{#if:</nowiki><h2 id="Anecdotes">Personal experience</h2>
<span></span>

''The following are personal accounts and not medical advice.''
<span></span><discuss slug="personal-experience" />

[[Category:Stimulants & Wake-Promoting Agents]]
[[Category:Methylphenidates (Phenidates)]]

Methylphenidate

2026-05-16T02:30:55Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

MediaWiki:Smw import schema

2026-05-16T02:30:55Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

Mixed amphetamine salts

2026-05-16T02:30:55Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{MedTemplate
| generic = Mixed amphetamine salts
| brand = Adderall, Adderall XR, Mydayis
| structure = Amphetamine-white.svg
| classes = Psychostimulant, Amphetamine
| uses = <vote slug="inattention">Inattention</vote>, <vote slug="narcolepsy">Narcolepsy</vote>, <vote slug="hyperactivity">Hyperactivity</vote>, <vote slug="impulsivity">Impulsivity</vote>, <vote slug="irritability">Irritability</vote>
| starting_dose = 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis
| preparations = IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg
| fda_max = XR = 40 or 60 mg/d; IR = 40 or 60 mg/d<ref name="carlat">S0</ref>
| routes = Oral
| onset = IR: 30–60 min; XR: 1–2 h to peak effect
| duration = IR 4–6 h; XR 10–12 h; Mydayis 14–16 h
| halflife = D-amphetamine ~10 h; L-amphetamine ~13 h (adults)
| bioavailability = ~75–90% (oral)
| pregnancy = Category C
| legal = Schedule II
| mechanism = TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport — net release of dopamine and norepinephrine
| intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate).
Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a medicine in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular medicines in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world.
| indications = <indication ref="adhd" author="MDElliottMD"/>
<indication ref="narcolepsy" author="MDElliottMD"/>
<indication ref="trd-augment" author="MDElliottMD">
Off-label.
</indication>
<indication ref="shift-work" author="MDElliottMD">
Off-label.
</indication>
<indication ref="chronic-illness-cog" author="MDElliottMD">
Off-label.
</indication>

<indication ref="impulsivity" author="MDElliottMD"/>

<indication ref="distractibility" author="MDElliottMD">
Impoved sustained attention by decreasing distractibility
</indication>
| dosing = <titration slug="typical-adult" title="Typical Adult" author="MDElliottMD">
Start at 5 mg XR; may increase by 5 mg each day until the desired effect is reached, up to 30 mg XR to start, and up to 60 mg XR eventually if necessary, in 10 mg increments.

Occasionally can go higher if no notable effects (good or bad) at 60 mg — proceed with caution.

If not long enough acting: add a tail dose of Adderall IR at [XR dose]/2.
If too long acting (e.g. disrupting sleep): switch to IR entirely (again at half the XR dose).
</titration>
| effects =
* <effect ref="attention" author="MDElliottMD">Improved sustained attention, particularly on uninteresting things.</effect>
* <effect ref="reduced-impulsivity" author="MDElliottMD"/>
* <effect ref="wakefulness" author="MDElliottMD"/>
* <effect ref="motivation" author="MDElliottMD"/>
* <effect ref="euphoria" author="MDElliottMD"/>
* <effect ref="decreased-appetite" author="MDElliottMD"></effect>
* <effect ref="dry-mouth" author="MDElliottMD"/>
* <effect ref="hr-bp-elevation" author="MDElliottMD"/>
* <effect ref="bruxism" author="MDElliottMD"/>
* <effect ref="insomnia" author="MDElliottMD">(with proper am dosing)</effect>
* <effect ref="irritability" author="MDElliottMD"/>
* <effect ref="anxiety" author="MDElliottMD"/>
* <effect ref="headache" author="MDElliottMD"/>
* <effect ref="weight-loss" author="MDElliottMD"/>
* <effect ref="palpitations" author="MDElliottMD"/>
* <effect ref="stereotypies" author="MDElliottMD">Repetitive movements, e.g. skin picking, muscle twitches, tics</effect>
* <effect ref="cardiac-event" author="MDElliottMD"></effect>
* <effect ref="agitation" author="MDElliottMD"/>
* <effect ref="psychosis" author="MDElliottMD"></effect>
* <effect ref="mania" author="MDElliottMD"></effect>
* <effect ref="dependence" author="MDElliottMD"></effect>
* <effect ref="tolerance" author="MDElliottMD"></effect>
* <effect ref="growth-suppression" author="MDElliottMD">(well documented effect with chronic use in children)</effect>
* <effect ref="serotonin-syndrome" author="MDElliottMD">Especially in combination with MAOIs</effect>
* <effect ref="vasculopathy" author="MDElliottMD">Raynaud-like phenomenon, rare digital ischemia.</effect>
* <effect ref="seizure" author="MDElliottMD"></effect>
* <effect ref="hyperthermia" author="MDElliottMD">Risk in hot environments or with vigorous exercise.</effect>
* <effect ref="withdrawal" author="MDElliottMD">Low motivation, low mood, hypersomnia, increased appetite on abrupt discontinuation.</effect>
* <effect ref="urinary-retention" author="MDElliottMD">Difficult/slow urination</effect>

<effect ref="focus-intensification"/>

<effect ref="appetite-suppression"/>

<effect ref="alertness"/>

<effect ref="executive-functioning"/>
| pk_absorption = Excellent oral bioavailability — sources report ">75%" to "~90%". Food does not significantly affect total absorption but can delay peak concentration.
| pk_distribution = Volume of distribution ~4 L/kg; plasma protein binding less than 20%. Crosses the blood–brain barrier and placenta.
| pk_metabolism = Amphetamine is oxidized to 4-hydroxyamphetamine, α-hydroxyamphetamine, or norephedrine. Norephedrine and 4-hydroxyamphetamine are active metabolites and are further metabolized to 4-hydroxy-norephedrine. Deamination of α-hydroxyamphetamine yields phenylacetone, which is metabolized to benzoic acid and conjugated to its glucuronide and hippuric acid. '''CYP2D6''' is crucial for amphetamine metabolism; genetic polymorphism causes significant inter-patient variability in clearance. Amphetamine itself inhibits monoamine oxidase (MAO), and both CYP1A2 and CYP3A4 contribute to its metabolism.<ref>S1</ref>
| pk_elimination = Primarily renal — ~30–40% recovered as unchanged amphetamine, the rest as metabolites. Due to its pK<sub>a</sub> of 9.9, urinary elimination is highly pH-dependent: alkaline urine reduces ionization and decreases renal clearance, while acidic urine and high flow rates accelerate clearance via active tubular secretion. '''Half-life:''' D-enantiomer 9 h (children 6–12 y), 11 h (adolescents 13–17 y), 10 h (adults); L-enantiomer 11 h, 13–14 h, 13 h respectively.
| pharmacodynamics = Amphetamine purportedly works via several converging mechanisms at monoaminergic terminals:
* '''Trace amine-associated receptor 1 (TAAR1) agonism''' — activates TAAR1 in monoaminergic neurons, triggering PKA/PKC signaling that phosphorylates the dopamine and norepinephrine transporters (DAT, NET), causing them to internalize and reverse direction.
* '''VMAT2 substrate''' — enters the presynaptic terminal, displaces dopamine and norepinephrine from vesicles into the cytoplasm.
* '''Reverse transport via DAT/NET''' — the elevated cytoplasmic monoamine pool is then ejected into the synaptic cleft via the now-reversed transporters. '''This is the primary mechanism of action — release, not reuptake inhibition.'''
* '''Weak reuptake inhibition''' at DAT and NET (secondary to release).
* '''MAO inhibition''' at higher concentrations, slowing presynaptic catabolism of monoamines.
* '''Serotonergic effects''' at high or supratherapeutic doses (relevant to overdose and serotonin syndrome risk).

The net result is a robust increase in synaptic dopamine and norepinephrine in prefrontal cortex, striatum, and nucleus accumbens — underlying both therapeutic (attention, executive function, wakefulness) and reinforcing (euphoria, abuse liability) effects.
| interactions = Minimal in practice. Caution with other psychostimulants, including caffeine. metabolized by 2D6, so relevant caution applies.
<pharmaInteractions/>
| pregnancy_details = [https://www.ncbi.nlm.nih.gov/books/NBK501307/ Category C]. Crosses the placenta. Prenatal amphetamine exposure has been associated with low birth weight, premature delivery, and neonatal withdrawal (agitation, dysphoria, lassitude). Long-term neurodevelopmental outcomes from prescribed therapeutic exposure are less clear and likely modest, but illicit-dose exposure is associated with significant developmental impact. Decision should be individualized; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in clinically significant amounts — breastfeeding generally discouraged.
| monitoring = * Baseline: cardiovascular history, weight/height, mental health history (especially for psychosis/bipolar/substance use risk), (optional) blood pressure, (optional) heart rate,
* At each visit: efficacy, side effects, general well-being
* Periodically reassess continued need; consider medicine holidays to assess ongoing benefit
* Sleep quality (insomnia is dose-limiting)
| counseling = * Take first thing in the morning to minimize insomnia; avoid (late) afternoon dosing.
* '''Do not crush, chew, or split Adderall XR or Mydayis capsules''' — disrupts the controlled-release mechanism. (Capsules may be opened and sprinkled on applesauce if needed.)
* Take with or without food; high-acid beverages (orange juice, vitamin C) may reduce absorption.
* Stay well-hydrated, especially in heat or during exercise.
* Eat regular meals despite appetite suppression.
* Report any chest pain, palpitations, severe agitation, hallucinations, or signs of poor circulation in extremities.
* Sudden discontinuation can cause a fatigue/depression "crash" — plan for it.
* Take caution: make increase bowel motility and increase risk of expelled fecal content.
| anecdotes =
| seealso = [[Dextroamphetamine]], [[Lisdexamfetamine]], [[Methylphenidate]], [[Dexmethylphenidate]], [[Modafinil]], [[Atomoxetine]], [[Methamphetamine]]
| references =
}}

[[Category:Stimulants & Wake-Promoting Agents]]
[[Category:Amphetamines]]

Alprazolam

2026-05-16T02:30:54Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{MedTemplate
| generic = Alprazolam
| brand = Xanax, Xanax XR, Niravam, Frontin, Alprax, Helex
| structure = Alprazolam_structure.svg
| classes = Benzodiazepine, Anxiolytic
| mechanism = Positive allosteric modulator at GABA<sub>A</sub> receptor (benzodiazepine site)
| uses = Generalized anxiety disorder, panic disorder, anxiety with depression
| formula = C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub>
| routes = Oral, sublingual (ODT)
| onset = 15–30 minutes
| duration = 4–6 hours (IR); 11–17 hours (XR)
| halflife = ~11 hours (range 6–27 h; prolonged in elderly and hepatic impairment)
| bioavailability = ~80–100%
| pregnancy = Avoid
| legal = Schedule IV
| intro = '''Alprazolam''' is a high-potency, intermediate-acting triazolobenzodiazepine, FDA-approved for generalized anxiety disorder, panic disorder, and anxiety associated with depression. Its rapid onset, short-to-intermediate half-life, and high potency make it both clinically effective and uniquely problematic among benzodiazepines: alprazolam has consistently been associated with the highest rates of dependence, misuse, and difficult withdrawal in its class. For most chronic anxiety treatment, longer-acting agents (clonazepam, diazepam) or non-benzodiazepine alternatives (SSRIs, SNRIs, buspirone) are preferred.
| pharmacokinetics = Rapid and near-complete oral absorption; bioavailability ~80–100%. Peak plasma levels in 1–2 hours (IR) or ~9 hours (XR). Highly protein-bound (~80%). Metabolized hepatically by '''CYP3A4''' to α-hydroxyalprazolam and 4-hydroxyalprazolam — both pharmacologically active but present at low concentrations. Half-life ~11 hours in healthy adults; substantially prolonged in elderly patients, obesity, and hepatic impairment. The relatively short half-life relative to diazepam contributes to inter-dose rebound anxiety with TID dosing and to the severity of its discontinuation syndrome.
| pharmacodynamics = Binds to the benzodiazepine site on GABA<sub>A</sub> receptors, allosterically enhancing GABA-induced chloride channel opening (increased '''frequency''' of opening, not duration — distinguishing benzodiazepines from barbiturates). This hyperpolarizes the neuron, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal muscle relaxant effects. Compared to other benzodiazepines, alprazolam shows relatively greater anxiolytic and antipanic effect with somewhat less sedation per unit anxiolysis, attributed in part to its triazole ring. Some evidence of mild antidepressant activity at higher doses, the basis for its "anxiety with depression" indication.
| indications = * Generalized anxiety disorder
* Panic disorder (with or without agoraphobia)
* Anxiety associated with depression
* '''Not first-line''' for chronic anxiety — SSRIs, SNRIs, buspirone, or CBT typically preferred due to dependence risk
* Occasionally used short-term for procedural anxiety or situational anxiety
| dosing = '''GAD:''' Start 0.25–0.5 mg PO three times daily; titrate slowly. Max 4 mg/day.
'''Panic disorder:''' Start 0.5 mg PO three times daily; titrate by 1 mg/day every 3–4 days. Typical effective 1–10 mg/day (FDA labeling permits to 10 mg/day, but doses >4 mg substantially increase dependence and adverse effects).
'''Elderly/debilitated:''' Start 0.25 mg 2–3 times daily; titrate very cautiously.
'''Hepatic impairment:''' Reduce dose 50% or more.
'''Discontinuation:''' '''Always taper.''' Typical reduction 0.5 mg every 3 days at minimum; for long-term users, much slower (Ashton-style protocols reduce by ~10% of current dose every 1–2 weeks). Abrupt cessation can precipitate seizures.
| effects = ''Therapeutic:'' anxiolysis (rapid), reduced panic frequency and severity, calming, mild euphoria, improved sleep.
''Common adverse:'' '''drowsiness''', '''dizziness''', impaired coordination, fatigue, slurred speech, dry mouth, blurred vision, '''anterograde amnesia''', impaired psychomotor performance, decreased libido, changes in appetite.
| adverse = * '''Dependence and addiction''' — highest among commonly-prescribed benzodiazepines. Physical dependence can develop within weeks of regular use.
* '''Withdrawal syndrome''' — rebound anxiety, insomnia, tremor, sweating, perceptual disturbances, depersonalization, '''seizures''' with abrupt cessation. Often more severe and protracted than withdrawal from longer-acting benzodiazepines.
* '''Tolerance''' — anxiolytic and hypnotic tolerance develops with chronic use; tolerance to amnestic and motor effects is less complete.
* '''Respiratory depression''' — especially in combination with opioids ('''black box warning'''), alcohol, or other CNS depressants. Cause of many overdose deaths.
* '''Paradoxical reactions''' — agitation, disinhibition, aggression, particularly in elderly, children, or those with personality disorders.
* '''Cognitive impairment''' — both acute (memory, attention) and chronic with long-term use; partial reversibility uncertain.
* '''Falls and fractures''' in elderly.
* '''Anterograde amnesia''' — clinically significant; can be exploited for criminal purposes (medicine-facilitated assault).
* '''Misuse and diversion''' — Xanax has substantial street value and frequent recreational misuse.
* '''Suicide risk in overdose''' — especially when combined with alcohol or opioids.
* '''Rebound anxiety''' between doses with short-half-life IR formulation.
| interactions = * '''Opioids''' — additive respiratory depression and overdose risk ('''FDA black box warning'''); avoid when possible
* '''Alcohol''' — additive CNS depression and respiratory depression
* '''CYP3A4 inhibitors''' (ketoconazole, itraconazole, ritonavir, clarithromycin, nefazodone) — substantially increase alprazolam levels; some contraindicated
* '''CYP3A4 inducers''' (carbamazepine, phenytoin, rifampin, St. John's wort) — decrease levels; may reduce efficacy
* '''Other CNS depressants''' (Z-drugs, sedating antihistamines, gabapentinoids, sedating antidepressants) — additive
* '''Grapefruit juice''' — modest CYP3A4 inhibition; can raise alprazolam levels with regular consumption
* '''Fluoxetine, fluvoxamine''' — increase alprazolam levels via CYP3A4 inhibition
<pharmaInteractions/>
| pregnancy_details = Historically Category D. First-trimester benzodiazepine exposure has been associated with increased risk of cleft lip/palate in some studies, though absolute risk is small. Third-trimester or near-term use can produce '''floppy infant syndrome''' (hypotonia, hypothermia, feeding difficulty, respiratory depression) and neonatal withdrawal. Generally avoided in pregnancy unless benefits clearly outweigh risks; SSRIs are usually preferred for chronic anxiety. Excreted in breast milk — breastfeeding generally discouraged.
| monitoring = * Continued need for treatment — reassess at every visit; target shortest effective duration
* Signs of dependence, tolerance, dose escalation, or misuse
* Cognitive function, especially in long-term users and elderly
* Mood and suicidality
* Falls risk in elderly
* Respiratory status, especially in COPD/OSA or on opioids
* Liver function in long-term use
| counseling = * '''Take exactly as prescribed''' — do not increase dose without consulting prescriber.
* '''Do not combine with alcohol''' or other sedatives — combinations can be fatal.
* '''Do not stop abruptly''' — can cause seizures; must be tapered.
* Avoid driving or operating machinery until response is known.
* May cause memory gaps, especially with higher doses or alcohol.
* Long-term daily use carries a real risk of dependence — discuss alternatives if treatment will extend beyond a few weeks.
* Avoid grapefruit juice in large quantities.
* Keep secured — high risk of theft and diversion.
* If pregnant or planning pregnancy, discuss with prescriber.
| anecdotes =
| seealso = [[Lorazepam]], [[Diazepam]], [[Clonazepam]], [[Temazepam]], [[Midazolam]], [[Buspirone]], [[Hydroxyzine]], [[Pregabalin]]
| references =
}}
[[Category:Benzodiazepines]]
[[Category:GABAA Positive Allosteric Modulators (General)]]
[[Category:GABAergics]]
[[Category:Anxiolytics & Sedative-Hypnotics]]

Fluoxetine

2026-05-16T02:30:54Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

{{MedTemplate
| generic = Fluoxetine
| brand = Prozac
| structure = Fluoxwhite.svg
| classes = SSRI, Anxiolytic, Antidepressant
| uses = <vote slug="anxiety-use">Anxiety</vote>, <vote slug="premature-ejaculation-use">Premature ejaculation</vote>, <vote slug="low-mood-use">Low mood</vote>
| starting_dose = 10 mg
| preparations = 10 mg, 20 mg, 40 mg caps
| fda_max = 40 mg/d
| pill_id =
* '''10 mg:''' green/cream capsule, "PLIVA 647"
* '''20 mg:''' green/cream capsule, "PROZAC 20"
* '''40 mg:''' olive/cream capsule, "DISTA 3107"
* '''Oral solution:''' 20 mg / 5 mL, clear
| routes = Oral
| onset =
| duration = Very long
| halflife = 1–4 days (7–15 days for norfluoxetine)
| bioavailability = 70–90% (oral)
| pregnancy = Category C<ref name="lactmed">S0</ref>
| legal = Rx-only in US
| mechanism = TrkB/BDNF<ref name="trkb">S1</ref> <vote slug="ssri-claim">Fluoxetine is a selective serotonin reuptake inhibitor.</vote>
| intro = Fluoxetine was the first of a long line of SSRIs. It is notable for its extremely long half-life and relative lack of withdrawal syndrome. It can also be useful in helping taper and discontinue other SxRI medicines.
| indications = <indication ref="depression" author="MDElliottMD"/>
<indication ref="anxiety-disorders" author="MDElliottMD">
Including generalized anxiety, panic, and social anxiety.
</indication>
<indication ref="panic" author="MDElliottMD"/>
<indication ref="social-anxiety" author="MDElliottMD"/>
<indication ref="ocd" author="MDElliottMD"/>
<indication ref="ptsd" author="MDElliottMD">
Potentially.
</indication>

<indication ref="premature-ejaculation"/>
| dosing = <titration slug="standard" author="MDElliottMD" title="Standard adult or child">
Start no higher than 10 mg for the first dose. May increase by 10 mg every 2–12 weeks, or remain at 10 mg if the response is adequate, up to a typical starting maximum of 40 mg. Absolute max: 80 mg.
</titration>

<titration slug="ocd" author="MDElliottMD" title="OCD">
Start at 10 mg daily; increase by 10–20 mg every 2–6 weeks, up to 80 mg. OCD typically requires elevated doses (60–80 mg).
</titration>
| effects =
* <effect ref="anxiolysis" author="MDElliottMD">Classically starting at 3–4 weeks and improving for another 8–12.</effect>
* <effect ref="delayed-ejaculation" author="MDElliottMD"/>
* <effect ref="mood-enhancement" author="MDElliottMD"/>
* <effect ref="nausea" author="MDElliottMD">Common, often improves over 1–2 weeks.</effect>
* <effect ref="decreased-libido" author="MDElliottMD"/>
* <effect ref="temporary-erectile-dysfunction" author="MDElliottMD"/>
* <effect ref="persistent-sexual-dysfunction" author="MDElliottMD">Historically [https://pmc.ncbi.nlm.nih.gov/articles/PMC11450419/ associated with SSRIs].</effect>

<effect ref="anorgasmia" author="MDElliottMD"/>
| pk_absorption = 70–90%<ref name="statpearls">S3</ref> oral bioavailability.
| pk_distribution = Fluoxetine has plasma protein binding of approximately 94.5%, bound to albumin and alpha-1 glycoprotein. Fluoxetine readily crosses the blood–brain barrier, with a brain-to-plasma ratio of 2.6:1 in humans. The volume of distribution (Vd) of fluoxetine and its metabolite ranges between 20 to 42 L/kg. Some studies report that fluoxetine has the maximum volume of distribution (Vd) of any SSRI (between 14 and 100 L/kg).<ref name="statpearls"/>
| pk_metabolism = Fluoxetine's active metabolite is norfluoxetine, produced when the cytochrome P450 enzyme (CYP2D6) acts on it. Prescribers must remember that fluoxetine has several medicine-medicine interactions due to its metabolism through the CYP2D6 isoenzyme. Additionally, norfluoxetine can have an inhibitory effect on CYP3A4. Fluoxetine has a half-life of 2 to 4 days, and its active metabolite norfluoxetine has a half-life of 7 to 9 days. Approximately 7% of individuals definitively exhibit poor metabolism of fluoxetine due to reduced activity of CYP2D6.<ref name="statpearls"/"
| pk_elimination =
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = None required
| counseling =
| anecdotes = <anecdote slug="2026-05-12" perspective="provider" author="MDElliottMD">
Fluoxetine is great for getting off other SxRIs! Especially venlafaxine and duloxetine.
</anecdote>
| seealso = [[Sertraline]], [[Duloxetine]]
| references = <references/>
}}

[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]
[[Category:Antidepressants]]
[[Category:Medicines]]

Template:MedInfo

2026-05-16T02:30:54Z

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

<includeonly>{| class="wikitable" style="float:right; clear:right; max-width:26em; margin:0 0 1em 1em; font-size:92%;"
|+ style="font-size:115%;" |'{{{PAGENAME}}}
! colspan="2" style="background:#eef;" | "Medicine Information"
|-
! style="width:9em; text-align:left;" | Generic name(s)
| {{{generic|—}}}
|-
! style="text-align:left;" | Brand name(s)
| {{{brand|—}}}
|-
! style="text-align:left;" | Classification(s)
| {{{class|—}}}
|-
! style="text-align:left;" | Common uses
| {{{uses|—}}}
|-
! style="text-align:left;" | Effects
| {{{effects|—}}}
|}{{#if:{{{titration|}}}|
== Titration strategies ==
{{{titration}}}
}}{{#if:{{{anecdotes|}}}|
== Personal anecdotes ==
''The following are personal accounts, not medical advice.''

{{{anecdotes}}}
}}[[Category:Medications]]</includeonly><noinclude>
== Usage ==
<pre>
{{MedInfo
| generic =
| brand =
| class =
| uses =
| effects =
| titration =
| anecdotes =
}}
</pre>

<templatedata>
{
"description": "Infobox + sections for a medicine entry. Short factual fields appear in a right-aligned infobox; longer prose fields render as full-width sections below.",
"params": {
"generic": { "label": "Generic name(s)", "description": "Comma-separated if more than one. Defaults to the page name.", "type": "string" },
"brand": { "label": "Brand name(s)", "description": "Comma-separated.", "type": "string" },
"class": { "label": "Classification(s)","description": "Medicine class(es), e.g. SSRI, NSAID.", "type": "string" },
"uses": { "label": "Common uses", "type": "string" },
"effects": { "label": "Effects", "description": "Therapeutic and side effects.", "type": "string" },
"titration": { "label": "Titration strategies", "description": "Wikitext; renders as a full-width section.", "type": "content" },
"anecdotes": { "label": "Personal anecdotes", "description": "Wikitext; renders as a full-width section. Auto-includes a 'not medical advice' disclaimer.", "type": "content" }
},
"format": "block"
}
</templatedata>

[[Category:Templates]]
</noinclude>

Vilazodone

2026-05-16T02:27:27Z

Maintenance script: Terminology sweep: drug/medication → medicine

{{MedTemplate
| brand = Viibryd
| classes = Serotonin partial agonist reuptake inhibitor (SPARI)
| mechanism = Combines SERT inhibition (typical SSRI mechanism) with 5HT1A receptor partial agonism. The 5HT1A partial agonism is proposed to: (1) provide intrinsic 5HT1A agonist activity beyond what SERT inhibition produces, and (2) accelerate downregulation of 5HT1A autoreceptors, potentially shortening the typical 4-6 week onset for SSRI effect.
| uses = Major depressive disorder in adults (FDA-approved 2011)
| starting_dose = 10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food)
| preparations = 10 mg, 20 mg, 40 mg tablets
| fda_max = 40 mg/d
| routes = Oral
| onset = 4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism)
| duration = Daily dosing
| halflife = ~25 hours
| bioavailability = ~72% (with food); much lower fasting (~36%)
| pregnancy = Limited data; weigh benefits/risks
| legal = Rx
| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation.

In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The medicine carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference).
| pharmacodynamics= SERT inhibition (Ki ~0.1 nM); 5HT1A partial agonist (Ki ~0.2 nM). Minimal NET, DAT, or non-5HT1A serotonin receptor activity.
| effects = Nausea, diarrhea, headache, somnolence, insomnia, vomiting. Sexual dysfunction (variably reported as similar to or less than SSRIs). SSRI discontinuation syndrome possible. Class warning for suicidal thoughts in pediatric/young adult patients.
| interactions = <pharmaInteractions/>
}}

[[Category:Antidepressants]]
[[Category:Multimodal Serotonergic Agents]]
[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]
[[Category:Serotonin Partial Agonist Reuptake Inhibitors (SPARIs)]]
[[Category:Serotonin Reuptake Inhibitors]]

Daridorexant

2026-05-16T02:27:27Z

Maintenance script: Terminology sweep: drug/medication → medicine

{{MedTemplate
| brand = Quviviq
| classes = Dual orexin receptor antagonist (DORA)
| mechanism = Selective antagonist at both orexin (OX1R, OX2R) receptors. Orexin/hypocretin from lateral hypothalamus is a key wake-promoting neuropeptide; antagonizing its receptors reduces arousal and promotes sleep. Unlike GABAergic hypnotics (benzos, Z-medicines), DORAs do not enhance inhibitory tone — they reduce excitatory tone. Less effect on sleep architecture and possibly lower next-day impairment.
| uses = Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022)
| starting_dose = 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate
| preparations = 25 mg, 50 mg tablets
| fda_max = 50 mg/d
| routes = Oral
| onset = ~30 min
| duration = ~7-8 hours
| halflife = ~8 hours (shorter than suvorexant and lemborexant)
| bioavailability = ~62%
| pregnancy = Limited data; avoid
| legal = Rx, Schedule IV (US)
| intro = '''Daridorexant''' (brand name Quviviq) is a dual orexin receptor antagonist (DORA) FDA-approved in January 2022 for insomnia. Among the three approved DORAs, daridorexant has the shortest half-life (~8 hours vs lemborexant ~17-19 h and suvorexant ~12 h), which may reduce next-day residual sedation. Mechanism: orexin/hypocretin neurons in the lateral hypothalamus drive arousal; blocking both OX1R and OX2R reduces wake-promoting signaling. The result is sleep that resembles normal physiologic sleep more closely than GABAergic hypnotics (less REM suppression, fewer abnormal sleep behaviors).

DORAs may be particularly useful when sleep maintenance (rather than just sleep onset) is the problem, since they reduce arousal across the night without enhancing GABA-mediated inhibition.
| pharmacodynamics= Selective dual antagonist at OX1R (Ki ~0.5 nM) and OX2R (Ki ~0.9 nM). No significant binding at other receptors. Minimal effect on REM/NREM sleep architecture.
| effects = Headache, somnolence (next-day), fatigue, dizziness, nausea. Sleep paralysis, hallucinations near sleep onset reported. Complex sleep behaviors (sleep-driving, etc.) — class warning. Lower next-day impairment than benzos/Z-medicines in trials.
| interactions = <pharmaInteractions/>
}}

[[Category:Hypnotics]]
[[Category:Orexin Antagonists]]
[[Category:Anxiolytics & Sedative-Hypnotics]]
[[Category:GABAergics]]

Pitolisant

2026-05-16T02:27:26Z

Maintenance script: Terminology sweep: drug/medication → medicine

{{MedTemplate
| brand = Wakix
| classes = Histamine H3 receptor inverse agonist / antagonist, wake-promoting agent
| mechanism = Selective inverse agonist (or antagonist depending on assay) at presynaptic histamine H3 autoreceptors. H3 receptors normally inhibit histamine release; blocking them disinhibits histamine release from tuberomammillary nucleus, promoting wakefulness. Also enhances acetylcholine, norepinephrine, dopamine release (downstream of histamine signaling).
| uses = Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019)
| starting_dose = Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed.
| preparations = 4.45 mg, 17.8 mg tablets
| fda_max = 35.6 mg/d
| routes = Oral
| onset = Wake-promoting effect over weeks of titration
| duration = Daily morning dosing
| halflife = ~20 hours
| bioavailability = Not formally established; oral once-daily adequate
| pregnancy = Limited data; pitolisant may reduce hormonal contraceptive efficacy
| legal = Rx — '''not a controlled substance''' (unique among wake-promoting agents)
| intro = '''Pitolisant''' (brand name Wakix) is a selective histamine H3 receptor inverse agonist FDA-approved in August 2019 for excessive daytime sleepiness and cataplexy in narcolepsy. Notable for being '''not a controlled substance''' — unique among approved wake-promoting medicines, all of which have abuse potential and DEA scheduling (modafinil IV, methylphenidate II, amphetamine II, solriamfetol IV, sodium oxybate III).

Mechanism: H3 autoreceptors on histamine neurons in the tuberomammillary nucleus normally inhibit histamine release. Pitolisant blocks (or inverse-agonizes) these autoreceptors, disinhibiting histamine release and promoting wakefulness. Downstream effects on acetylcholine, norepinephrine, and dopamine pathways may also contribute. Slow titration required.
| pharmacodynamics= High-affinity inverse agonist at human H3 receptor. Minimal binding at H1, H2, H4, monoamine transporters, or other monoamine receptors.
| effects = Headache, insomnia, anxiety, nausea, abdominal pain, decreased appetite, sleep disturbances. QT prolongation possible (caution with other QT-prolonging medicines). Can reduce hormonal contraceptive efficacy.
| interactions = <pharmaInteractions/>
}}

[[Category:Stimulants & Wake-Promoting Agents]]
[[Category:Eugeroics (Wakefulness-Promoting Agents)]]
[[Category:Psychostimulants]]
[[Category:Histamine H3 Antagonists / Inverse Agonists]]
[[Category:Wake-Promoting Agents]]
[[Category:Histamine Modulators]]

Brexpiprazole

2026-05-16T02:27:26Z

Maintenance script: Terminology sweep: drug/medication → medicine

{{MedTemplate
| brand = Rexulti
| classes = Atypical antipsychotic, D2/5HT1A partial agonist with stronger α1A, 5HT2A, 5HT1A activity than aripiprazole
| mechanism = Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole — proposed to reduce akathisia and enhance affective/cognitive effects.
| uses = Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023 — first agent specifically approved for this indication). Investigational for PTSD (combined with sertraline).
| starting_dose = Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily.
| preparations = 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets
| fda_max = 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct)
| routes = Oral
| onset = Weeks for psychosis/depression; AD agitation benefit emerges over weeks
| duration = Daily dosing
| halflife = ~91 hours
| bioavailability = ~95%
| pregnancy = Limited data; National Pregnancy Registry available
| legal = Rx
| intro = '''Brexpiprazole''' (brand name Rexulti) is a 'pip' D2/5HT1A partial agonist FDA-approved for schizophrenia (2015), adjunctive treatment of major depressive disorder (2015), and — in a landmark 2023 approval — '''agitation associated with Alzheimer dementia'''. It is the first FDA-approved medicine specifically for AD agitation. Compared to its 'pip' cousin aripiprazole, brexpiprazole has relatively stronger 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism — proposed to reduce akathisia and enhance affective/cognitive efficacy.

The AD agitation approval carries the antipsychotic class black-box warning for increased mortality in elderly dementia patients; FDA approval rested on demonstrating a favorable risk-benefit ratio in this population specifically for the indication.
| pharmacodynamics= D2 partial agonist (lower intrinsic activity than aripiprazole). 5HT1A partial agonist. 5HT2A, 5HT2B, 5HT7, α1A, α1B, α2C antagonist. H1 antagonism. Notable: lower D2 intrinsic activity and stronger 5HT2A antagonism may underlie reduced akathisia compared with aripiprazole.
| effects = Weight gain (especially long-term), akathisia (reduced compared to aripiprazole), restlessness, headache, somnolence, increased fasting glucose. Class warning: increased mortality in elderly dementia-related psychosis. AD agitation indication acknowledges this risk with specific benefit-risk analysis.
| interactions = <pharmaInteractions/>
}}

[[Category:Antipsychotics / Neuroleptics]]
[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]]
[[Category:Neuroleptics]]
[[Category:Third-Generation Antipsychotics]]
[[Category:Atypical Antipsychotics]]
[[Category:Antipsychotics]]
[[Category:Dopamine Partial Agonists]]
[[Category:Psychotic Disorders]]
[[Category:Adjunctive Antidepressants]]

Esketamine

2026-05-16T02:27:26Z

Maintenance script: Terminology sweep: drug/medication → medicine

{{MedTemplate
| brand = Spravato
| classes = NMDA receptor antagonist (uncompetitive), dissociative
| mechanism = The S-enantiomer of racemic ketamine. Uncompetitive NMDA receptor antagonist (binds open channel). Proposed antidepressant mechanism: NMDA blockade on GABA interneurons disinhibits glutamate burst → AMPA receptor activation → BDNF/VEGF release → mTOR-mediated synaptogenesis and dendritic spine formation within hours. Also binds sigma-1, opioid receptors (controversial μ-opioid contribution to antidepressant effect debated).
| uses = Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020).
| starting_dose = Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site.
| preparations = 28 mg/device (each dose uses 2 devices)
| fda_max = 84 mg per session
| routes = Intranasal (under direct medical supervision)
| onset = Within hours of first administration
| duration = Acute effect ~24 hours; cumulative effect builds with repeated dosing
| halflife = ~7-12 hours
| bioavailability = ~48% intranasal
| pregnancy = Avoid; may cause fetal harm
| legal = Rx, Schedule III (US). REMS program required.
| intro = '''Esketamine''' (brand name Spravato) is the S-enantiomer of ketamine, FDA-approved as an intranasal medicine for treatment-resistant depression (March 2019) and for major depression with acute suicidal ideation or behavior (August 2020). The S-enantiomer has approximately 4-fold higher NMDA receptor affinity than the R-enantiomer; Spravato delivers it via a nasal spray under direct medical supervision in a REMS-certified setting due to risks of dissociation, sedation, and abuse.

Mechanism: uncompetitive NMDA receptor antagonism on GABA interneurons disinhibits glutamatergic output, leading to AMPA receptor activation, BDNF/VEGF release, and rapid synaptogenesis through mTOR pathway activation. Antidepressant onset within hours is striking compared to monoaminergic antidepressants (4-6 weeks). Patients must be monitored ≥2 hours after dose due to dissociation, sedation, and blood pressure elevation.
| pharmacodynamics= Uncompetitive NMDA receptor antagonist with channel-trapping action. Sigma-1 receptor binding. Possible weak μ-opioid agonism (mechanism contribution debated; naltrexone-blockade studies have given conflicting results).
| effects = Dissociation, sedation, dizziness, nausea, vertigo, blood pressure elevation, anxiety, sedation. Long-term risks include abuse/dependence, cognitive effects.
| interactions = <pharmaInteractions/>
}}

[[Category:Anesthetics]]
[[Category:Arylcyclohexylamines]]
[[Category:Dissociative Anesthetics]]
[[Category:General (IV) Anesthetics]]
[[Category:NMDA Receptor Antagonists]]
[[Category:Antidepressants]]
[[Category:Dissociatives]]

Pimavanserin

2026-05-16T02:27:26Z

Maintenance script: Terminology sweep: drug/medication → medicine

{{MedTemplate
| brand = Nuplazid
| classes = Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)
| mechanism = Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity — unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline.
| uses = Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression.
| starting_dose = 34 mg PO once daily
| preparations = 10 mg, 34 mg capsules/tablets
| fda_max = 34 mg/d
| routes = Oral
| onset = Benefit over weeks of dosing
| duration = Daily dosing
| halflife = ~57 hours (parent), ~200 h (active metabolite)
| bioavailability = Not characterized; oral dosing once daily
| pregnancy = Limited data; avoid
| legal = Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics)
| intro = '''Pimavanserin''' (brand name Nuplazid) is the only FDA-approved medicine for the treatment of hallucinations and delusions in Parkinson's disease psychosis (approved April 2016). Unlike every other approved antipsychotic, it has '''no D2 dopamine receptor activity''' — a critical feature in Parkinson's, where conventional D2 antagonists worsen motor symptoms. Mechanism: selective 5HT2A inverse agonism with weaker 5HT2C inverse agonism. Carries the class black-box warning for increased mortality when used in elderly dementia-related psychosis, though it has been studied in that population and is investigational for dementia psychosis. Also studied as augmentation for major depression with positive preliminary results.
| pharmacodynamics= Selective 5HT2A inverse agonist (Ki ~0.4 nM). Weaker 5HT2C inverse agonism. No significant binding at D2, muscarinic, adrenergic, or histaminergic receptors. The lack of D2 activity preserves dopaminergic function (essential in PD) while reducing the 5HT2A-mediated psychotic symptoms.
| effects = Peripheral edema, confusion, nausea, constipation, gait disturbance, hallucinations (paradoxically reported), QT prolongation (avoid combination with other QT-prolonging medicines).
| interactions = <pharmaInteractions/>
}}

[[Category:Atypical Antipsychotics]]
[[Category:Antipsychotics]]
[[Category:Psychotic Disorders]]

Brexanolone

2026-05-16T02:27:26Z

Maintenance script: Terminology sweep: drug/medication → medicine

{{MedTemplate
| brand = Zulresso
| classes = Neuroactive steroid, GABA-A positive allosteric modulator
| mechanism = Allopregnanolone (the body's own neurosteroid metabolite of progesterone) delivered IV. Positive allosteric modulator at both benzodiazepine-sensitive and benzodiazepine-insensitive GABA-A receptors. Hypothesized to act primarily at the benzodiazepine-insensitive site, which differentiates it from benzodiazepines (which lack antidepressant efficacy)
| uses = Postpartum depression (PPD) in adults
| starting_dose = Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h
| preparations = 100 mg/20 mL vial, single-use
| fda_max = Single 60-hour course
| routes = Intravenous (continuous infusion in a REMS-certified facility)
| onset = Antidepressant effect within hours of infusion start; sustained at 30 days
| duration = Single infusion course
| halflife = ~9 hours (terminal)
| bioavailability = 100% (IV)
| pregnancy = Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered
| legal = Rx; REMS program required (excessive sedation/loss of consciousness during infusion)
| intro = '''Brexanolone''' (brand name Zulresso) is a cyclodextrin-based IV formulation of '''allopregnanolone''', the body's own neuroactive steroid produced as a metabolite of progesterone. FDA-approved in March 2019 as the first medicine specifically for postpartum depression (PPD). Administered as a single 60-hour continuous infusion in a REMS-certified inpatient setting due to risk of excessive sedation. The medicine's rationale rests on the observation that allopregnanolone levels fall precipitously after delivery; rapidly restoring those levels via infusion produces a rapid antidepressant response that persists for 30+ days in trials.
| pharmacodynamics= Positive allosteric modulator at GABA-A receptors at a distinct '''neuroactive steroid binding site''' (separate from benzodiazepine and barbiturate sites). Modulates both '''synaptic''' (phasic, mostly benzo-sensitive α1/α2/α3/α5-containing) and '''extrasynaptic''' (tonic, mostly benzo-insensitive δ-containing) GABA-A receptors. The benzodiazepine-insensitive δ-containing extrasynaptic receptors are hypothesized to be the key target for antidepressant effect, since benzodiazepines themselves do not have antidepressant efficacy.
| effects = Sedation (very common), loss of consciousness (REMS warning), syncope, dry mouth, flushing. Suicidal thoughts have been observed.
| interactions = <pharmaInteractions/>
}}

[[Category:Neuroactive Steroids]]
[[Category:GABAA Positive Allosteric Modulators (General)]]
[[Category:GABAergics]]
[[Category:Antidepressants]]

Vilazodone

2026-05-16T02:03:47Z

Maintenance script: Expand Vilazodone with Stahl-sourced detail (with skepticism)

{{MedTemplate
| brand = Viibryd
| classes = Serotonin partial agonist reuptake inhibitor (SPARI)
| mechanism = Combines SERT inhibition (typical SSRI mechanism) with 5HT1A receptor partial agonism. The 5HT1A partial agonism is proposed to: (1) provide intrinsic 5HT1A agonist activity beyond what SERT inhibition produces, and (2) accelerate downregulation of 5HT1A autoreceptors, potentially shortening the typical 4-6 week onset for SSRI effect.
| uses = Major depressive disorder in adults (FDA-approved 2011)
| starting_dose = 10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food)
| preparations = 10 mg, 20 mg, 40 mg tablets
| fda_max = 40 mg/d
| routes = Oral
| onset = 4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism)
| duration = Daily dosing
| halflife = ~25 hours
| bioavailability = ~72% (with food); much lower fasting (~36%)
| pregnancy = Limited data; weigh benefits/risks
| legal = Rx
| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation.

In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The drug carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference).
| pharmacodynamics= SERT inhibition (Ki ~0.1 nM); 5HT1A partial agonist (Ki ~0.2 nM). Minimal NET, DAT, or non-5HT1A serotonin receptor activity.
| effects = Nausea, diarrhea, headache, somnolence, insomnia, vomiting. Sexual dysfunction (variably reported as similar to or less than SSRIs). SSRI discontinuation syndrome possible. Class warning for suicidal thoughts in pediatric/young adult patients.
| interactions = <pharmaInteractions/>
}}

[[Category:Antidepressants]]
[[Category:Multimodal Serotonergic Agents]]
[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]
[[Category:Serotonin Partial Agonist Reuptake Inhibitors (SPARIs)]]
[[Category:Serotonin Reuptake Inhibitors]]

Donanemab

2026-05-16T02:03:47Z

Maintenance script: Expand Donanemab with Stahl-sourced detail (with skepticism)

{{MedTemplate
| brand = Kisunla
| classes = Anti-amyloid beta (Aβ) monoclonal antibody, targets pyroglutamated Aβ in plaques
| mechanism = Humanized IgG1 monoclonal antibody specifically targeting '''N-terminally truncated, pyroglutamated Aβ''' (an early modified form found primarily in established plaques). Designed for rapid plaque clearance. Patients can stop treatment once amyloid is cleared on PET (unique among approved anti-amyloid mAbs).
| uses = Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024
| starting_dose = 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance
| preparations = 350 mg/20 mL vial for IV infusion
| fda_max = 1400 mg q4w
| routes = IV infusion every 4 weeks
| onset = Amyloid PET clearance within months; cognitive benefit over 18 months
| duration = Treatment can be discontinued upon achieving amyloid clearance
| halflife = ~12.1 days
| bioavailability = 100% (IV)
| pregnancy = Limited data
| legal = Rx; ARIA monitoring required
| intro = '''Donanemab''' (brand name Kisunla) is a humanized monoclonal antibody targeting N-terminally truncated, pyroglutamated Aβ — an Aβ form found predominantly in established plaques. FDA-approved in July 2024 for Alzheimer disease (MCI/mild AD). Unique among approved anti-amyloid mAbs: patients can '''discontinue treatment once amyloid PET shows plaque clearance''', typically within 12-18 months. This stop-criterion (a finite course rather than indefinite biweekly infusions like lecanemab) is donanemab's main clinical advantage.

Pivotal trial (TRAILBLAZER-ALZ 2): ~35% slowing of cognitive decline on integrated Alzheimer Disease Rating Scale (iADRS) over 18 months. The trial enriched for tau-positive patients. As with other anti-amyloid mAbs, ARIA is the principal safety concern, with higher rates than lecanemab (especially ARIA-E in ~25% of treated patients).
| pharmacodynamics= Humanized IgG1 targeting pyroglutamated Aβ (Aβ3-42(pE)). Aggressive plaque clearance via microglial phagocytosis.
| effects = ARIA-E (~24-27% in trials), ARIA-H. Some symptomatic ARIA cases including deaths reported. Infusion reactions. Headache. APOE ε4 carriers at higher ARIA risk.
| interactions = <pharmaInteractions/>
}}

[[Category:Anti-Dementia Medicines]]
[[Category:Anti-dementia]]
[[Category:Anti-Amyloid Monoclonal Antibodies]]
[[Category:Anti-Amyloid Antibodies]]
[[Category:Alzheimer Disease Medicines]]

Lecanemab

2026-05-16T02:03:47Z

Maintenance script: Expand Lecanemab with Stahl-sourced detail (with skepticism)

{{MedTemplate
| brand = Leqembi
| classes = Anti-amyloid beta (Aβ) monoclonal antibody, targets protofibrils
| mechanism = Humanized IgG1 monoclonal antibody with higher affinity for '''soluble Aβ protofibrils''' than for monomeric Aβ or insoluble plaques. The protofibril-targeting rationale: soluble oligomers and protofibrils are hypothesized to be the most neurotoxic Aβ species. Promotes microglial clearance and reduces protofibril burden.
| uses = Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023
| starting_dose = 10 mg/kg IV every 2 weeks
| preparations = 200 mg/2 mL, 500 mg/5 mL vials for IV infusion
| fda_max = 10 mg/kg q2w
| routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting
| onset = Slowing of cognitive decline over 18 months (modest effect — ~27% relative slowing)
| duration = Ongoing dosing
| halflife = ~5-7 days
| bioavailability = 100% (IV)
| pregnancy = Limited data
| legal = Rx; REMS-like program for ARIA monitoring
| intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB.

The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes — boxed warning recommends genotyping before treatment). Several deaths from ARIA-related cerebral edema/hemorrhage have been reported, particularly in patients on concurrent anticoagulants.

The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree.
| pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement.
| effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages) — both often asymptomatic but can be serious. Infusion reactions. Headache. Boxed warning: APOE ε4 homozygotes at higher ARIA risk (~33% vs ~13% in non-carriers); genotype testing recommended before initiating.
| interactions = <pharmaInteractions/>
}}

[[Category:Anti-Dementia Medicines]]
[[Category:Anti-dementia]]
[[Category:Anti-Amyloid Monoclonal Antibodies]]
[[Category:Anti-Amyloid Antibodies]]
[[Category:Alzheimer Disease Medicines]]

Aducanumab

2026-05-16T02:03:46Z

Maintenance script: Expand Aducanumab with Stahl-sourced detail (with skepticism)

{{MedTemplate
| brand = Aduhelm
| classes = Anti-amyloid beta (Aβ) monoclonal antibody
| mechanism = Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ) — soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy.
| uses = Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD.
| starting_dose = Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w
| preparations = Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion
| fda_max = Withdrawn 2024
| routes = IV infusion every 4 weeks
| onset = PET Aβ reduction over months
| duration = Withdrawn
| halflife = ~25 days
| bioavailability = 100% (IV)
| pregnancy = Discontinued/withdrawn
| legal = Withdrawn from US market January 2024
| intro = '''Aducanumab''' (brand name Aduhelm) was an anti-amyloid-β monoclonal antibody granted FDA '''accelerated approval''' in June 2021 for Alzheimer disease — the first new AD therapy in nearly two decades. The approval was deeply controversial: three FDA advisory committee members resigned in protest, the agency overrode its own scientific advisors' recommendation, and the clinical evidence for cognitive benefit was conflicting (one phase 3 trial positive, one negative, with post-hoc analyses driving approval). Medicare ultimately limited coverage to clinical trials, severely restricting use.

'''Biogen withdrew aducanumab from the market in January 2024''', citing commercial reasons. The episode is widely cited as a cautionary tale about evidence standards and the persistent dominance of the amyloid cascade hypothesis even as direct evidence for clinical benefit remained weak.
| pharmacodynamics= IgG1 monoclonal antibody binding aggregated Aβ (oligomers and fibrils) at the N-terminus. Promotes microglial Aβ clearance via Fc-receptor binding.
| effects = ARIA — '''amyloid-related imaging abnormalities''' (cerebral edema or microhemorrhages on MRI), often asymptomatic but can be severe. Headache, falls, confusion. APOE ε4 carriers at substantially elevated ARIA risk.
| interactions = <pharmaInteractions/>
}}

[[Category:Anti-Dementia Medicines]]
[[Category:Anti-dementia]]
[[Category:Anti-Amyloid Monoclonal Antibodies]]
[[Category:Anti-Amyloid Antibodies]]
[[Category:Alzheimer Disease Medicines]]
[[Category:Withdrawn Medicines]]

Suvorexant

2026-05-16T02:03:46Z

Maintenance script: Expand Suvorexant with Stahl-sourced detail (with skepticism)

{{MedTemplate
| brand = Belsomra
| classes = Dual orexin receptor antagonist (DORA) — the first approved
| mechanism = Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant.
| uses = Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease.
| starting_dose = 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned)
| preparations = 5 mg, 10 mg, 15 mg, 20 mg tablets
| fda_max = 20 mg/d
| routes = Oral
| onset = ~30 min
| duration = ~7-8 hours
| halflife = ~12 hours
| bioavailability = ~82%
| pregnancy = Limited data; avoid
| legal = Rx, Schedule IV (US)
| intro = '''Suvorexant''' (brand name Belsomra) is the first FDA-approved dual orexin receptor antagonist (DORA), approved August 2014 for insomnia. Suvorexant established the DORA class as a treatment paradigm — reducing arousal via orexin blockade rather than enhancing GABA-mediated inhibition. Subsequent DORAs (lemborexant 2019, daridorexant 2022) have been positioned as iterative improvements with different pharmacokinetics.

Suvorexant has been studied in mild-moderate Alzheimer disease with positive results; trials have suggested potential for reducing sleep-disordered breathing exacerbations and possibly delaying cognitive decline (though the cognitive claim remains controversial).
| pharmacodynamics= Competitive antagonist at OX1R (Ki ~0.55 nM) and OX2R (Ki ~0.35 nM). Receptor dissociation slower than lemborexant or daridorexant.
| effects = Next-day somnolence (more common than with daridorexant due to longer half-life), headache, abnormal dreams, dry mouth, fatigue. Sleep paralysis and hallucinations near sleep onset. Complex sleep behaviors class warning.
| interactions = <pharmaInteractions/>
}}

[[Category:Anxiolytics & Sedative-Hypnotics]]
[[Category:Orexin Receptor Antagonists]]
[[Category:Sedative-Hypnotics]]
[[Category:Hypnotics]]
[[Category:Orexin Antagonists]]

Lemborexant

2026-05-16T02:03:46Z

Maintenance script: Expand Lemborexant with Stahl-sourced detail (with skepticism)

{{MedTemplate
| brand = Dayvigo
| classes = Dual orexin receptor antagonist (DORA)
| mechanism = Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance.
| uses = Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019)
| starting_dose = 5 mg PO at bedtime; may increase to 10 mg if inadequate
| preparations = 5 mg, 10 mg tablets
| fda_max = 10 mg/d
| routes = Oral
| onset = ~30 min
| duration = ~7-8 hours
| halflife = ~17-19 hours (longer than daridorexant)
| bioavailability = ~44%
| pregnancy = Limited data; avoid
| legal = Rx, Schedule IV (US)
| intro = '''Lemborexant''' (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) FDA-approved in December 2019 for insomnia in adults. Among DORAs, lemborexant has faster receptor association/dissociation kinetics than suvorexant — which is hypothesized to facilitate sleep onset while still maintaining adequate duration of antagonism for sleep maintenance. The 17-19 hour half-life can produce some next-day residual sedation in sensitive individuals.

DORAs broadly produce sleep that more closely resembles physiologic sleep architecture than GABAergic hypnotics, with reduced REM suppression. Side effect profile favorable compared to benzodiazepines, but sleep paralysis, sleep-related hallucinations, and complex sleep behaviors have been reported.
| pharmacodynamics= Competitive antagonism at OX1R (Ki ~6 nM) and OX2R (Ki ~3 nM). No clinically significant activity at other receptors.
| effects = Somnolence (next-day), headache, nightmares, abnormal dreams, sleep paralysis, hallucinations near sleep onset. Complex sleep behaviors class warning.
| interactions = <pharmaInteractions/>
}}

[[Category:Anxiolytics & Sedative-Hypnotics]]
[[Category:Orexin Receptor Antagonists]]
[[Category:Sedative-Hypnotics]]
[[Category:Hypnotics]]
[[Category:Orexin Antagonists]]

Daridorexant

2026-05-16T02:03:46Z

Maintenance script: Expand Daridorexant with Stahl-sourced detail (with skepticism)

{{MedTemplate
| brand = Quviviq
| classes = Dual orexin receptor antagonist (DORA)
| mechanism = Selective antagonist at both orexin (OX1R, OX2R) receptors. Orexin/hypocretin from lateral hypothalamus is a key wake-promoting neuropeptide; antagonizing its receptors reduces arousal and promotes sleep. Unlike GABAergic hypnotics (benzos, Z-drugs), DORAs do not enhance inhibitory tone — they reduce excitatory tone. Less effect on sleep architecture and possibly lower next-day impairment.
| uses = Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022)
| starting_dose = 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate
| preparations = 25 mg, 50 mg tablets
| fda_max = 50 mg/d
| routes = Oral
| onset = ~30 min
| duration = ~7-8 hours
| halflife = ~8 hours (shorter than suvorexant and lemborexant)
| bioavailability = ~62%
| pregnancy = Limited data; avoid
| legal = Rx, Schedule IV (US)
| intro = '''Daridorexant''' (brand name Quviviq) is a dual orexin receptor antagonist (DORA) FDA-approved in January 2022 for insomnia. Among the three approved DORAs, daridorexant has the shortest half-life (~8 hours vs lemborexant ~17-19 h and suvorexant ~12 h), which may reduce next-day residual sedation. Mechanism: orexin/hypocretin neurons in the lateral hypothalamus drive arousal; blocking both OX1R and OX2R reduces wake-promoting signaling. The result is sleep that resembles normal physiologic sleep more closely than GABAergic hypnotics (less REM suppression, fewer abnormal sleep behaviors).

DORAs may be particularly useful when sleep maintenance (rather than just sleep onset) is the problem, since they reduce arousal across the night without enhancing GABA-mediated inhibition.
| pharmacodynamics= Selective dual antagonist at OX1R (Ki ~0.5 nM) and OX2R (Ki ~0.9 nM). No significant binding at other receptors. Minimal effect on REM/NREM sleep architecture.
| effects = Headache, somnolence (next-day), fatigue, dizziness, nausea. Sleep paralysis, hallucinations near sleep onset reported. Complex sleep behaviors (sleep-driving, etc.) — class warning. Lower next-day impairment than benzos/Z-drugs in trials.
| interactions = <pharmaInteractions/>
}}

[[Category:Hypnotics]]
[[Category:Orexin Antagonists]]
[[Category:Anxiolytics & Sedative-Hypnotics]]
[[Category:GABAergics]]